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Abstract 
In mono-infected individuals, the HLA-B27 allele is strongly associated with 
spontaneous clearance of HCV in association with a strong CD8+ response 
targeted against a single epitope within the HCV RNA-dependent RNA 
polymerase (NS5B). We studied variation across the whole HCV genome and T 
cell responses over time in a rare cohort of HLA-B27+ patients with acute HCV 
and HIV co-infection, the majority of whom progressed to chronicity.  
 We used next generation sequencing to detect changes within and outwith 
the immuno-dominant HLA-B27 restricted HCV-specific CD8+ T cell epitope 
NS5B2841-2849 (ARMILMTHF) during evolving progression of early HCV infection. 
Within the Acute HCV UK cohort, 10 patients carried the HLA B27 allele. Of 
these, 3/8 patients (37.5%) with HIV infection and 2/2 (100%) without HIV 
spontaneously cleared HCV (p=0.44). Sequential samples from nine HLA-B27+ 
patients (2 with monoinfection and 7 with HIV co-infection) were available for 
analysis (four spontaneous clearers and five evolving progressors). Mutations 
identified using NGS were assessed using a replicon genotype 1a system to 
evaluate viral fitness. Multiple mutations within the HLA-B27 restricted NS5B2841-
2849 epitope were associated with progression to chroncity whereas patients who 
cleared the HCV infection spontaneously had no or only one mutation at this site 
(p=0.03). A triple NS5B2841-2849 mutant observed during progression to chronicity 
was associated with restored replication when compared to wild-type virus while 
single or double mutants were significantly associated with impaired replication 
(p=0.0495). 
 T cell responses measured in these patients using ELISpot and flow 
cytometry.  HLA-B27+ patients had significantly higher IFN-γ responses than 
patients who were HLA-B27- (p=0.0014). Those who progressed to chronicity had 
lower IFN-γ responses than those who cleared HCV (p=0.0011). Mono-infected 
patients had higher IFN-γ responses compared to co-infected patients 
(p=0.0015). 
 HIV co-infection is associated with a lower likelihood of spontaneous 
clearance of HCV in HLA B27+ patients and this is associated with impaired T cell 
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function in this group.  
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PI Protease inhibitor 
QD Quasispecies diversity  
RLU  Relative light units 
RAMs Resistance associated mutations  
RAVs Resistance associated variants   
RIG-I Retinoic acid inducible gene-I   
RT Reverse transcription  
RBV Ribavirin  
RdRp  RNA-dependent RNA polymerase  
Sec Seconds 
SBS Sequencing by synthesis  
SNP Single nucleotide polymorphism  
SGR subgenomic replicons  
SVR    Sustained virological response 
TLR Toll-like receptor  
TRIF Total reflection fluorescence  
UTR Untranslated region  
 WT Wild type 
WHO World Health Organisation  
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Amino Acid Name Abbreviations 
Amino acid 
Three 
letter code 
One letter 
code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
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Chapter 1: Introduction – overview of Hepatitis C 
virus infection 
1.1 Discovery of the Hepatitis C Virus 
In the early 1970’s, new viral and antigenic markers were discovered for two 
viruses causing hepatitis; hepatitis A (HAV) and hepatitis B (HBV). The 
subsequent development of new sensitive serologic methods allowed rapid 
diagnosis of these infections in many patients with abnormal liver function. 
However, a significant number of patients with clinical hepatitis, including 
individuals that had had a blood transfusion, could not be diagnosed as having 
either HAV or HBV (Prince et al., 1974, Feinstone et al., 1975); at this time the 
agent responsible, considered to be infectious in nature, was termed non-A, non-
B hepatitis (NANBH). Injecting chimpanzees with plasma or serum from human 
patients with NANBH resulted in elevated serum alanine aminotransferase (ALT) 
levels, demonstrating that the NANBH agent was able to cause infection and was 
capable of establishing chronic infection (Alter et al., 1978, Hollinger et al., 
1978). Infectious plasma from human patients that had been treated with 
chloroform was injected into chimpanzees but did not cause infection, revealing 
that the NANBH agent was sensitive to this lipid solvent (Feinstone et al., 1983). 
Injection of human plasma from infected patients into chimpanzees, having first 
passed it through an 80nm filter (Bradley et al., 1985) also resulted in infection, 
suggesting the presence of an infectious agent smaller than a bacterium. 
Together, all these data suggested that the cause of NANBH was a small, 
enveloped virus. Further studies that attempted to culture the NANBH agent 
were inconclusive due to a lack of cell culture models as well as the inability to 
infect animals other than chimpanzees.  
 The development of new, highly-sensitive molecular biology techniques in 
the 1980s enabled scientists to further characterise the cause of NANBH. At this 
time, all available immunological methods were ineffective in detecting viral 
antigens and antibodies, as there was a low concentration of viral antigen in 
NANBH infection (Choo et al., 1989). To overcome this limitation, nucleic acid 
extracted from infected plasma was used to make complementary DNA (cDNA) 
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using a bacteriophage (strain λgt11) that aided sequencing of the virus and  
expression of the polypeptide encoded by cDNA (Choo et al., 1989). 
 Sera were collected from patients with NANBH. A bacteriophage-containing 
colony called 5-1-1 was found to express polypeptide that was later recognized 
by the serum from NANBH patients but not with serum from control individuals 
(Choo et al., 1989).  
  Subsequent experiments showed that RNA obtained from infected animals 
(chimpanzees) combined with cloned cDNA and was present as a single strand. 
This hybridisation of RNA and cDNA was not dependent on treatment with 
ribonuclease. Based on this, it became clear that the cause of most cases of 
NANBH was a single-stranded RNA virus. Sequence analysis revealed that the 
cDNA from colony 5-1-1 contained a single open reading frame (ORF); this newly 
identified single stranded RNA virus was named hepatitis C virus (HCV) (Choo et 
al., 1989).  
1.1.1 Classification and genotypes of HCV 
The HCV genome is organised in a similar way to other members of the Flavivirus 
family (Choo et al., 1991, Miller and Purcell, 1990), namely, monopartite single 
stranded RNA genomes of positive polarity that encode a single polyprotein that 
is subsequently broken down into individual functional proteins by host and virus 
proteases. The HCV genome has a high level of genetic diversity and 7 different 
major genotypes.  
 New genotypes are defined by 1) having one or more complete coding 
region sequence(s) available following sequencing; 2) belonging to a 
phylogenetic group distinct from any previously described sequence by 30-35%; 
3) the exclusion of intergenotypic or intersubtypic recombinations (Simmonds, 
2004, Smith et al., 2014).  
 Variability between the 7 different genotypes occurs unevenly across the 
genome. The viral E1 and E2 (glycoproteins) genes represent the most diverse 
 21 | P a g e  
regions of the HCV genome while the 5’ untranslated region (5’ UTR) shows the 
lowest variability. The 7 genotypes can be further split into 67 subtypes that 
differ in genome sequence by an average of 20-25% (Simmonds, 2004, Smith et 
al., 2014).  
 The high diversity of HCV, like all other positive-strand RNA viruses, is due 
to an RNA polymerase that contains no proofreading or 5’-3’ exonuclease 
activity, resulting in a high rate of mutations introduced into progeny genomes 
during replication. A comparison of different studies, following sequencing of 
the complete genome over eight and thirteen years in chimpanzees and humans 
respectively, showed an average frequency of mutation of 1.4*10-3 – 1.9*10-3 
changes per single nucleotide yearly (Ogata et al., 1991, Okamoto et al., 1992). 
There is a high rate of genetic variation in viral strains infecting individuals 
(within host variation) and within populations; the mix of circulating mutation(s) 
within viral strains in an infected host is referred to as a quasispecies (Martell et 
al., 1992). 
1.1.2 Global prevalence and incidence of HCV 
The current estimate of global HCV prevalence is around 3% of the world 
population, equivalent to 170 million people (Thomson, 2009). Accurate figures 
of the prevalence of HCV are difficult to determine, however, due to the 
absence of screening programmes in most countries.  As HCV infection is usually 
asymptomatic for a long period of time, it remains unsuspected by those 
infected who may not seek medical attention until they develop advanced 
disease. There is variability in its prevalence in different geographical areas and 
genotypes and distributed variably around the world.  
 HCV is estimated to infect about 0.6% of the population in the UK, while 
almost 2% of the population in the USA are infected with HCV (Thomson, 2009). 
In low-income countries, scant amounts of data are available, despite the 
potential for very high prevalence levels, largely due to iatrogenic transmission. 
In Egypt, for example, between 15-20% of the population have positive 
antibodies (Frank et al., 2000), following parental antischistosomal therapy 
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(PAT) campaigns between the 1960s and 1980s. HCV genotypes can be classified, 
linked and mapped geographically (Nguyen and Keeffe, 2005). For example, the 
predominant and most prevalent genotype found across Europe, the USA and 
China is genotype 1, while in East Africa (including Egypt), genotype 4 is most 
prevalent. South Africa has predominantly genotype 5 infection while genotype 6 
occurs in South East Asia. Global genotype distribution is illustrated in (Figure 
1-1 and Figure 1-2). 
 Age-specific analysis of HCV prevalence varies geographically (Wasley and 
Alter, 2000). In countries such as Australia and USA, a high rate of infection is 
found in patients between 30 and 49 years of age, showing that the risk of 
infection occurs mainly in young adults (Armstrong et al., 2006).  In Japan, China 
and parts of Europe, including Italy and Spain, most HCV infections are found in 
older patients, suggesting that the establishment of HCV risk infection in these 
countries may have been at its highest rate about 40-60 years ago (Campello et 
al., 2002, Dominguez et al., 2001, Zhang et al., 2005). 
 In Egypt, the prevalence of HCV infection increases with age, and high 
rates of infection are found in all age groups (Frank et al., 2000). This suggests 
that as well as an increased risk of HCV in the past, there is also an ongoing risk 
of infection (Wasley and Alter, 2000). Much of this regional variability can be 
attributed to the frequency and extent to which different risk factors have 
contributed to HCV transmission. 
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Figure 1-1: Prevalence of hepatitis C virus genotypes based on the NCBI HCV 
database. 
 
The diagram shows the frequency of different HCV subtypes in the NCBI HCV Database. The subtype 
distribution is shown for 102516 sequences, accessed 01/12/2015 
http://hcv.lanl.gov/components/sequence/HCV/geo/geo.comp.
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Figure 1-2: Global distribution of hepatitis C virus genotypes.  
 
Global prevalence of different HCV genotypes. Size of pie charts is proportional to the number of seroprevalent cases (Messina et al., 2015). 
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The majority of HCV infections are transmitted through direct percutaneous 
exposure to blood, occurring via three main routes: first, the transfusion of 
blood products from infected donors, second, non-sterile therapeutic injections, 
and third, injecting intravenously in recreational drug users (Shepard et al., 
2005). The testing of nucleic acid and antibody screening of donated blood has 
essentially eradicated new cases of transfusion-related HCV infection in high 
income countries. Transmission of HCV this way is a huge problem in low income 
countries that do not have nucleic acid testing. Unsafe medical practices 
contribute to a vast number of HCV infections around the world. One study 
estimated that in one year (2000), approximately 2 million new cases of HCV 
infection were caused worldwide as a result of using unsterile medical injections 
(Hauri et al., 2004). Similarly, in Egypt most cases of HCV transmission happened 
because of poor medical practices. For example, during the PAT campaign, new 
cases of HCV infection were recorded as a result of contaminated glass syringes 
being re-used (Frank et al., 2000).  
 In medium and high income countries including the USA, the UK and 
Australia, intravenous drug use is the most common factor associated with new 
HCV infections (Thomson, 2009). For instance, in 2003, 90% of those diagnosed 
with a new HCV diagnosis in Scotland had used intravenous drugs (Hutchinson et 
al., 2005). HCV infection can also be transmitted perinatally and via sexual 
activity, particularly in HIV-infected men who have sex with men (MSM) (van de 
Laar et al., 2009{van de Laar, 2010 #910, van de Laar et al., 2010, Danta and 
Dusheiko, 2008). 
1.2 Clinical features of HCV infection 
The hepatocyte is the main target of HCV infection. HCV infects and replicates 
within hepatocytes over many years resulting in liver cirrhosis and hepatocellular 
carcinoma (HCC) in a significant number of those infected. It is now one of the 
most common reasons for a liver transplant (Sharma and Lok, 2006). The first 
phase of the infection is the acute phase (within 6 months of infection), which is 
then followed by the chronic phase (more than 6 months of infection). 
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1.2.1 Acute HCV infection 
As a result of the initial exposure to HCV, the majority of new HCV infections are 
mild or asymptomatic; this means that new infections are rarely recognized 
(Thomson, 2009). Nonetheless, during the acute phase, about 20% of individuals 
infected with HCV will exhibit malaise, nausea and jaundice, although 80% of the 
cases will show no symptoms (Pawlotsky, 2004). Fulminant hepatitis can cause 
liver failure during early infection although this is extremely rare. Regardless of 
asymptomatic signs during the acute phase, a high level of ALT can be detected 
in many HCV cases if blood testing is carried out routinely for other reasons (for 
example co-infection with HIV) (Thomson et al., 2009).  
 Some patients (15-30% of cases) will spontaneously eliminate the virus, 
usually during the first 6 months of infection.  The mechanism behind 
spontaneous clearance of HCV is not fully understood but factors contributing to 
clearance include the host and individual’s immune response, age, sex, and 
alcohol intake (Hezode et al., 2003, Peters and Terrault, 2002). The presence of 
HLA-B27 and HLA-B57 are strongly associated with spontaneous elimination of 
the virus and these are linked to early multi-specific T-cell responses. Patients 
who progress to chronicity have weak immune responses (Heim and Thimme, 
2014). 
1.2.2 Chronic HCV infection 
Most (70-85%) of individuals infected with HCV progress to chronicity. During this 
stage, the HCV continues to replicate and viremia is detected, but is not usually 
at as high a level as during the acute phase. During the chronic phase, up to 1012 
new virions are produced every day (Neumann et al., 1998).  
 HCV patients in the chronic phase can remain without symptoms for up to 
35 years, although around 1 in 5 patients develop serious liver disease including 
compensated and decompensated cirrhosis, steatosis (fat accumulation within 
hepatocytes) and hepatic fibrosis (as an outcome of chronic inflammation). 
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Around 20% of HCV chronic patients will develop liver cirrhosis over a period of 
20 years (Ishii et al., 2008).  
 Liver cirrhosis may lead to portal hypertension with consequent risks of 
gastro-intestinal haemorrhage and hepatic encephalopathy (Thomson and Finch, 
2005). Following the onset of cirrhosis, hepatocellular carcinoma (HCC) can 
occur in a small percentage of patients, about 1-3% per year in cirrhotic 
individuals (Ishii and Koziel, 2008). It is thought that HCC may occur as the result 
of a long-term inflammatory response, resulting in oxidative stress, possibly 
leading to DNA cellular damage (Okuda et al., 2002).  
 Other studies have shown evidence that the HCV core protein can play a 
role in oncogenesis (Moriya et al., 1998). Interestingly, different HCV genotypes 
and periods of infection have variable impacts and outcomes (Zein, 2000). For 
instance, HCV genotype 3 can cause a rapid onset of hepatic steatosis and 
fibrosis; it has been shown that genotype 3 leads to significantly faster fibrosis 
progression compared with the other genotypes (Probst et al., 2011). It is also 
more likely to result in chronic infection, compared with HCV genotype 1 
(Lehmann et al., 2004, Rubbia-Brandt et al., 2000) but is more sensitive to 
interferon-based treatment. Response rates to direct-acting antivirals (DAAs) are 
lower than in genotype 1. 
1.3 Diagnosis of HCV infection 
HCV infection may be diagnosed using serological and molecular virological 
methods.  
1.3.1 Serological Assays 
The main screening assay for detecting anti-HCV antibodies is the enzyme 
immunoassay (EIA), that identifies antibodies targeting different epitopes within 
the HCV genome. It has many advantages, including ease of use, ease of 
automation and low cost. There are three different generations of serology 
assay.  
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First generation assays include a single HCV antigen recombinant that was 
obtained from the non-structural protein 4 (NS4) of the HCV genome. 
 This first generation of EIA lacked sensitivity and specificity. For instance, 
in high prevalence centres such as tertiary care centres, only 80% of patients 
with evidence of HCV were detected as positive with anti-HCV using first 
generation assays (Gretch et al., 1992).  Individuals from a low prevalence 
population were tested and of the 70% who tested positive using EIA-1, many 
were not infected by HCV.  Based on this, a supplementary test had to be used 
to confirm infection.  
 In 1992 a new version of EIA was launched and called EIA-2 (Alter, 1992) . 
This assay contained antigen from different regions of HCV including the core 
and NS3 genes in addition to NS4. The sensitivity of the test was improved and 
the specificity relative to EIA-1 also slightly improved (Han et al., 1991, 
Houghton et al., 1991). Using antigen from two different regions (the core and 
NS3) in EIA-2 helped to shorten the average detection time for HCV 
seroconversion: instead of 16 weeks with EIA-1 it became 10 weeks. 
Furthermore, it allowed for the detection of 95% of individuals with molecular 
evidence of HCV. 
 A new third-generation of serological assay (EIA-3) was subsequently 
developed. In this generation, in addition to core and NS3 antigens a new NS5A 
antigen was added which was not present in the EIA-2 generation. With this 
generation the seroconversion detection time was reduced to 2-3 weeks (Kwok 
and Higuchi, 1989, Miller and Purcell, 1990). Sensitivity also increased to 97% 
and specificity was slightly better compared to EIA-2 (Kao et al., 1996). A 
summary of all the different generation assays is given in Table 1-1. 
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Table 1-1: Sensitivity and positive predictive values of EIA for HCV detection 
Assay Sensitivity* (%) 
Positive Predictive Value** (%) 
Low Prevalence        High Prevalence 
EIA-1 70-80 30-50 70-85 
EIA-2 92-95 50-61 88-95 
EIA-3 97 25 Not Done 
* Based on clinical findings and detection of HCV RNA by PCR.  
** Compared with RIBA  
 
1.3.2 Molecular virological assays: 
Virological assays for the detection of HCV RNA allow both quantitative and 
qualitative analysis of viral load. Both assays have more advantages over the 
serological assay as they can detect the virus before seroconversion and 
distinguish between those with chronic infection and those who have been 
treated or spontaneously cleared infection. RNA, extracted from either serum or 
plasma, is reverse transcribed into cDNA that is then amplified using polymerase 
chain reaction (PCR) to create either double stranded DNA (dsDNA) PCR product 
or amplified by transcription-mediated amplification (TMA) that yields ssRNA 
products (Chevaliez and Pawlotsky, 2007).  
 These assays have the advantage that they give qualitative results. HCV 
RNA can be quantitatively measured using RT-PCR or a signal amplification 
method such as the branched DNA (bDNA) assay.  
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Branched DNA (bDNA) utilizes oligonucleotides harbouring enzymes that work to 
catalyse a colour change; these bind to HCV RNA molecules by hybridisation.  
 This technique is different from RT-PCR, as this technique does not need 
the reverse transcription step. Virological assays can also work to detect 
different genotypes of HCV using PCR, by using specific PCR primers that attach 
to well-characterized polymorphisms in 5’ UTR (Tsongalis, 2006). 
1.4 Treatment of co-infected individuals  
Responses to PegIFN alpha plus RBV treatment are lower in patients with co-
infection (HCV/HIV) than in those with mono-infection (HCV) (Bhagani, 2011, 
Torriani et al., 2004a). Clearance of HCV infection using PegIFN/RBV therapy is 
likely to be related to immunogenic factors, as IFN alpha stimulates both innate 
and adaptive immune responses (Feld and Hoofnagle, 2005). Host interleukin 28B 
genotype predicts the outcome of treatment of chronic HCV genotypes 1 or 4 
with PegIFN/RBV (Corchado et al., 2014, Chen et al., 2012) and may also predict 
the outcome of treatment with direct acting antiviral drugs (DAAs) (De Nicola et 
al., 2012). 
While IFN-based therapies are associated with lower sustained virological 
response (SVR) rates in HIV-infected individuals (Torriani et al., 2004b), the use 
of DAAs is equal to that from the same agents used with mono-infection patients 
(Poordad et al., 2011a, Jacobson et al., 2011, Cotte et al., 2014, 2015). Newer 
DAAs treatments target the NS3/4A serine protease, NS5A and the NS5B RNA 
polymerase (Table 1-2). 
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Table 1-2: Recommendation on treatment of HCV (EASL guidelines 2016) 
IFN-free regimens 
Options Genotype 
SOF+RBV 
2,3 
(Suboptimal) 
SOF/LDV (±RBV) 1,4,5,6 
Sofosbuvir/Velpatasvir (± RBV) All 
OBV/Paritaprevir/Ritonavir+ DSV (±RBV) 1 
Grazoprevir/Elbasvir (± RBV) 1,4 
SOF + SMV (± RBV) 1,4 
SOF + DCV (± RBV) All 
OBV/ Paritaprevir/ Ritonavir (±RBV) 4 
The combination of two or more DAAs is important to reduce the possibility of 
resistance (Chung and Baumert, 2014, Rockstroh and Bhagani, 2013). Currently 
licensed DAAs include sofosbuvir which competitively inhibits NS5B, protease 
inhibitors such as simeprevir and paritaprevir that act on NS3/4A and daclatasvir 
and ledipasvir that inhibit NS5A. Interferon-free DAA combination treatments are 
associated with >90% SVR rates in HIV infected and uninfected individuals and 
have a shorter time-period of treatment regimen than IFN-based therapies. The 
side effect profile of these compounds is minimal.   
 Patients infected with genotype 3 HCV and those with cirrhosis are less 
likely to respond to treatment with DAAs than other groups. Genotype 3 HCV has 
a higher prevalence in PWIDs and in HIV –infected individuals (Ampuero et al., 
2014, Morice et al., 2006).  
As many trials have shown there is no difference in the effectiveness of 
DAAs between individuals infected with mono- or co-infection (Poordad et al., 
2011b, Jacobson et al., 2011, Sulkowski et al., 2013a, Sulkowski et al., 2013b, 
Lawitz et al., 2013, Jacobson et al., 2014), physicians recommend that patients 
with mono- or co-infected infection can be treated with the same regime (Kohli 
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et al., 2014) although drug-drug interactions with ARVs may limit the use of 
certain combinations.   
HCV patients treated within the acute phase with PegIFN have a higher SVR 
rate than patients with chronic infection in both HIV infected and uninfected 
populations although HIV-infected patients have lower SVR rates overall 
{Gilleece, 2005 #1670}(Jaeckel et al., 2001). Recent trials show that DAA 
treatment of a shorter duration (for example 6 weeks of sofosbuvir/ledipasir 
therapy) is highly effective and results in minimal side effects (Fierer et al., 
2014).  DAA therapy appears to be equally effective in HIV-infected patients and 
recommended treatment regimens are the same (barring drug-drug interactions) 
(2016). Reinfection with HCV in HIV patients is common, especially with those 
who have high levels of sexual activity and in patients who use recreational 
drugs (Martin et al., 2013) although reinfection in such patients may be over-
estimated due to emerging dominance of treatment-resistant strains 
(Abdelrahman et al., 2015).  
1.5 Molecular features of HCV 
1.5.1 Virion morphology 
HCV particle structure consists of an envelope glycoprotein surrounding a viral 
core (C) protein that associates with the HCV viral genome. HCV particles 
derived from infectious serum have a diameter of between 30-80 nm (Bradley et 
al., 1985, He et al., 1987, Yuasa et al., 1991) whereas HCV particles derived 
from purified HCVcc have a different diameter of about 60 and 75 nm. HCVcc 
particles have more than one distinct form, contain electron-dense cores and 
lack discernible surface properties when observed using electron microscopy 
(Wakita et al., 2005, Gastaminza et al., 2010, Merz et al., 2011).  
1.5.2 The viral genome 
The HCV genome is a positive sense single-stranded RNA molecule and is 
approximately 9.6kb (9600bp) in length (Choo et al., 1991). The genome encodes 
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a single open reading-frame (ORF) that is flanked by 5’ and 3’ UTRs. Translation 
of the HCV RNA genome yields a single polyprotein of 3010 amino-acids. Both 
HCV and the host proteases process the polyprotein to produce the structural 
proteins (core, E1, E2, p7) and the non-structural proteins (NS) (NS2, NS3, NS4A, 
NS4B, NS5A and NS5B) (Figure 1-3), p7 has been previously defined as a protein 
not assigned to any other group; a recent study has shown that p7 may be part 
of the virion and may have ion channel activity (Griffin et al., 2008).  
Figure 1-3: HCV Genome 
The HCV RNA genome contains one long open reading frame (ORF), this is flanked by two untranslated 
region (5′ and 3′ UTRs). A well characterised HLA B27-restricted NS5B epitope within NS5B is highlighted 
(NS5B2841 -2849). 
 The 5’ untranslated region (5’UTR) 1.5.2.1
The 5’ untranslated region (UTR) has been studied extensively and it has been 
shown that it has a highly conserved sequence consisting of 341 nucleotides that 
are involved in RNA replication and in HCV translation (Friebe et al., 2001, 
Honda et al., 1999, Bukh et al., 1992). It's 5’ UTR harbors an internal ribosomal 
entry site (IRES); the IRES is a structure that is important for starting cap-
independent translation of HCV RNA. Secondary structure analyses of the IRES 
reveal four distinct domains named as (I, II, III and IV) (Honda et al., 1996a). 
 The first domain (domain I) has a stem-loop shape and a small size; this 
domain has been classified as being unnecessary overall for IRES activity, but it 
may play a role in regulating translation efficiency (Honda et al., 1996b). 
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Domains II and III play an essential role in HCV RNA translation in association 
(Honda et al., 1996a, Honda et al., 1996b). Domain IV has been found to be non-
essential for the ribosomal binding (Honda et al., 1996a).  
 It has been found that there are several host-encoded factors that play 
important roles in association with the 5’ UTR to regulate HCV genome 
translation and replication. For instance, the elements EIF, La autoantigen, 
polypyrimidine tract binding protein (PTB) and poly (rC)-binding protein (PCBP2) 
bind to specific regions inside the 5’ UTR (Ali and Siddiqui, 1995, Ali and 
Siddiqui, 1997, Fukushi et al., 2001). Recently, it has been discovered that the 
liver-specific microRNA-122 (miR-122) attaches to two different sites inside the 
5’UTR between domains I and II; this binding is important for both HCV 
translation and replication (Jopling et al., 2005, Jopling et al., 2008, Henke et 
al., 2008).  
 Core 1.5.2.2
The first structural protein encoded by the 5’ end of the genome is the core 
protein that forms the viral capsid shield (McLauchlan, 2009, Santolini et al., 
1994). Following translation, a signal peptide is found between core and E1 that 
targets the endoplasmic reticulum (ER) membrane, where the polypeptide chain 
is cleaved by a specific cellular enzyme called signal peptidase (SP) that releases 
Envelope 1 (E1) resulting in the formation of an undeveloped (21 kDa) form of 
HCV core (Santolini et al., 1994). Next, core goes through another cleavage that 
is mediated by the cellular enzyme signal peptide peptidase (SPP), contributing 
to the mature 19 kDa core ~177 amino acid structure (Hussy et al., 1996, 
McLauchlan et al., 2002a, Santolini et al., 1994, Moradpour et al., 1996).   
 The mature form of core (19 kDa) has a uniquely shaped dimeric α-helical 
protein that involves two different domains known as D1 and D2. The first 
domain (D1) is involved in RNA binding (Boulant et al., 2005). Domain D2 has a 
significant impact on core transfer to lipid droplets (LDs); any deletions within 
this region can stop the association between LDs and core (McLauchlan et al., 
2002b). D2 structure consists of two amphipathic elements called α-helices 
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(termed HI and HII); these elements are divided by an unstructured region known 
as the hydrophobic loop (Boulant et al., 2006). Hydrophobic residues, located 
within the helix, interact with the phospholipid layer surrounding LDs, and any 
defined mutations within these residues terminate the association of core-LDs 
(Boulant et al., 2006). 
 E1 and E2 1.5.2.3
The Envelope 1 (E1) and Envelope 2 (E2) proteins are 35kDa and 60/70 kDa in 
size and  160 and 360 amino acids long respectively. They play an important role 
in HCV entry and immune evasion, forming non-covalent heterodimers on the 
surface of viral particles (Dubuisson, 2007).  Both E1 and E2 contain a single C-
terminal transmembrane domain (TMD) of 30 amino acids that attaches the 
proteins to the endoplasmic reticulum (ER) following which, the N-terminal 
becomes placed within the ER lumen (Cocquerel et al., 1999, Cocquerel et al., 
1998) (Dubuisson et al., 2002).  
 The structure of TMD has been found to possess two hydrophobic regions 
and these two hydrophobic areas differ at least by one invariant charge residue 
(Cocquerel et al., 2000). The transmembrane domain of E1 is formed from 
cleaved signal sequence that directs attachment of the envelope to the ER 
membrane. SP-mediated cleavage occurs at the E1/E2 and E2/p7 boundaries 
(Dubuisson et al., 2002). The TMDs of the E1 and E2 play a role in facilitating 
envelope heterodimer formation (Op De Beeck et al., 2000) and the fusion 
properties for both proteins (Ciczora et al., 2007).  
 E1 and E2 have been shown to possess several conserved glycoproteins 
motifs: E1 possesses around five whereas E2 has around eleven; these 
glycoprotein motifs undergo N-linked glycosylation when holding the protein that 
is located within the ER (Goffard and Dubuisson, 2003, Meunier et al., 1999, 
Dubuisson et al., 2000). This change has been believed to help the glycoprotein 
to fold and then to facilitate the entry of HCV (Goffard et al., 2005, Helle et al., 
2010).  
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Several studies from HCV isolates have also shown two highly variable regions 
within the E2 envelope glycoprotein, named as the hypervariable region 1 
(HVR1) and hypervariable region 2 (HVR 2)(Weiner et al., 1991).  
 The HVR1 is situated at the N-terminus of E2, and the variability within this 
region has been referred to as (i) the capability of this area to accept the amino 
acid changes and (ii) a region that undergoes strong selective pressure by the 
host anti-HCV immune responses (Penin et al., 2001). During the course of 
infection, antibodies targeting the HVR1 are frequently altered, illustrating the 
high selective pressure on the HVR1 (Forns et al., 1999).  
 In spite of considerable variation within this region, analysis from different 
isolates shows that some physiochemical and conformational regions of HVR1 are 
conserved, revealing the residues that are essential for example for attachment 
to attach to other proteins, glycosaminoglycans (GAGs) or lipid (Penin et al., 
2001). Both E1 and E2 heterodimers are important for virus entry and E2 
attaches to three different cellular receptor proteins, to gain entry to 
hepatocytes, namely, tetraspanin (CD81), occludin (OCLN) and scavenger 
receptor class B member I (SR-BI) (Liu et al., 2009, Pileri et al., 1998, Scarselli 
et al., 2002). Another co-receptor responsible involved in HCV entry, claudin-1 
(CLDN1), has been less well characterized with regard to interaction sites with 
HCV envelope (Evans et al., 2007). Cyanovirin-N (CV-N) can inhibit the entry of 
HCV by interacting with the N-linked glycans located on the glycoproteins 
(E1/E2), which inhibits the E2-CD-81 interaction (Helle et al., 2006). 
  p7 1.5.2.4
p7 is a hydrophobic protein that is 7kDa in size. This protein is located between 
Envelope 2 and the non-structural protein 2 (NS2) of the HCV polyprotein. During 
HCV translation, p7 is attached to the ER membrane (Lin et al., 1994a). 
Cleavage at the E2-p7 and p7-NS2 boundaries is often delayed and produces 
incomplete precursor proteins such E2-p7-NS2 and E2-p7 (Dubuisson et al., 1994, 
Lin et al., 1994a).  
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It is not known if these precursor proteins have a significant role in virus 
replication (Jones et al., 2007). Different studies show that p7 contains 2 
transmembrane regions TM1 and TM2 and show a double spanning topology with 
N- and C termini locating close to the ER lumen with a loop site in the cytoplasm 
(Carrere-Kremer et al., 2002, Isherwood and Patel, 2005, Cook and Opella, 2011, 
Khaliq et al., 2011, Patargias et al., 2006, Boson et al., 2011, Steinmann et al., 
2007). P7 is not essential for HCV RNA replication (Lohmann et al., 1999). 
 However, inoculating HCV RNA with a p7 deletion into animal models 
(chimpanzees) reduces HCV transmission (Sakai et al., 2003). Furthermore, an 
HCV genome without the p7 gene is incapable of producing active infection virus 
in a cell culture and is associated with a blockage before the assembly step 
(Jones et al., 2007, Popescu et al., 2011, Steinmann et al., 2007).  
 Adaptive mutations in p7 can improve HCV particle production (Russell et 
al., 2008).  A study using chimeric viruses has shown that p7 may play a role as a 
virulence factor (Steinmann et al., 2007, Khaliq et al., 2011). p7 has been 
classified as a member of the viroporin protein family and its structure has a 
unique form, a hexameric structure with cation channel activity; this channel is 
essential for HCV infection in chimpanzees (Griffin et al., 2003, StGelais et al., 
2007, Sakai et al., 2003) and is located on the cytoplasmic loop of the protein 
(Griffin et al., 2004).  
 P7 function can be inhibited using Adamantanes (amantadine and 
rimantadine) that inhibit H+ transport through ion channels. Such therapies also 
block influenza A infection through inhibition of the activity of the M2 ion 
channel (Fleming, 2001, Griffin et al., 2003).  In HCV, sensitivity to these 
compounds has been found to vary according to HCV genotype (Griffin et al., 
2008).  
 NS2 1.5.2.5
NS2 is a protein of 23kDa (Santolini et al., 1995, Yamaga and Ou, 2002). The NS2 
C- terminal end contains a protease domain with a circular structure that is 
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believed to be the exit in the cytosolic side of the ER membrane, while the N-
terminus possesses three TMDs (Lorenz et al., 2006, Wang et al., 2013, Fischer 
and Kruger, 2009). The first TMD has been characterised structurally and 
contains flexible helicase elements that are linked to a constant α- helix (Jirasko 
et al., 2008). NS2 carries out autoproteolytic cleavage at the NS2/NS3 junction 
(Grakoui et al., 1993, Hijikata et al., 1993, Foster et al., 2010), whereas the N-
terminus of NS2 is released by SP (Lin et al., 1994a, De Francesco, 1999). 
Analysis of HCV NS2/NS3 using mutagenic analysis has shown that the dividing of 
these proteins also requires the NS3 serine protease domain to be present 
(Grakoui et al., 1993, Hijikata et al., 1993).  
 Recent studies using a chimeric viral replicon containing the NS3-NS5B 
regions based on the HCV strain JFH1 with structural genes from other HCV 
genotypes, has shown the importance of the intra-/inter-genotypic junction site 
at NS2 and how it has an effect on HCV particle production (Pietschmann et al., 
2006, Steinmann et al., 2013). The whole length of NS2 protein is necessary for 
the production of viral particles, while the proteolytic role of this protein is not 
essential during assembly (Jirasko et al., 2008, Jones et al., 2007).  
 NS3-4A 1.5.2.6
 NS3-4A consists of the non-structural protein 3 (NS3) and a cofactor, non-
structural protein 4A (NS4A). NS3 is a multifunctional protein which is 70 kDa in 
size and contains a serine protease within the first third of the N-terminal 
(amino acid 1-180). The remaining two thirds within the C-terminal end has 
nucleoside triphosphatase NTPase and RNA helicase activity (amino acids 181-
631). Several studies have examined the role of both enzymes and their function 
is well described (Raney et al., 2010, Morikawa et al., 2011, Bartenschlager et 
al., 1995). NS3 to sits on the ER membrane, where it is held in place by the N-
terminal end of NS4A (Wölk et al., 2000). 
 At the ER membrane, the serine-type protease domain of NS3 is initially 
connected to NS2 and is then cleaved. Afterwards, the NS3 serine proteinase 
mediates cleavage between the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and the 
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NS5A/NS5B junctions (Bartenschlager et al., 1993, Grakoui et al., 1993, Lin et 
al., 1994b).  Excluding the NS3/NS4A junction, all junctions are treated in trans 
(Bartenschlager et al., 1994). NS3 mediates cleavage in a binding site that 
possesses a catalytic triad. This catalytic triad contains His 57, Asp 81 and Ser 
139 residues. Mutations introduced within these amino acids can eradicate the 
cleavage mediated by NS3 (Bartenschlager et al., 1993, Grakoui et al., 1993, Lin 
et al., 1994b).  
 The NS3 contains a zinc atom that binds to four residues, three cysteine 
residues and one histamine (De Francesco et al., 1996, Stempniak et al., 1997); 
these residues have been shown to have a significant role in the NS3 activity 
(Hijikata et al., 1993). The association between NS3 and the co-factor NS4A is 
important for the cleavage of NS3/NS4A and NS4B/NS5A (Failla et al., 1994, 
Gallinari et al., 1998, Lin et al., 1994b). NS4A contributes to folding of NS3 (Kim 
et al., 1996, Love et al., 1996, Kwong et al., 1998).  
 The two-thirds of the C-terminal region of the HCV NS3 protein that have 
RNA helicase and NTPase activity and forms a Y-shaped molecule. (Tai et al., 
2001, Kim et al., 1998, Yao et al., 1997). While NS3 binds to an RNA substrate, 
the NS3 dimer is required to untwist the HCV RNA (Serebrov and Pyle, 2004). 
This helicase process needs to be carried out in a series of organized steps 
(Serebrov and Pyle, 2004, Appleby et al., 2011).  
 The NS3 alone has fairly poor RNA helicase activity and supported by NS4A 
and the protease domain, which improve the efficiency of untwisting RNA (Beran 
et al., 2009, Frick et al., 2004, Pang et al., 2002). Interestingly, NS3 itself has 
the ability to untwist DNA duplexes, allowing the protein to act on cellular DNA 
(Pang et al., 2002, Tai et al., 1996) (Dubuisson, 2007). 
 NS3 therefore plays crucial roles in RNA replication (Lam and Frick, 2006, 
Lohmann et al., 1999) (Beran et al., 2009). Cell culture adaptive mutations 
(CCAMs), which improve RNA replication, have been found in both the protease 
and the helicase domain of NS3 (Lohmann et al., 2003, Krieger et al., 2001). 
Recent studies have shown that the NS3 helicase domain is also important for 
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viral assembly, as mutations located within the coding region can rescue the 
production of HCV from inter-genotypic chimeras that are found to be unable to 
produce virions (Ma et al., 2008, Yi et al., 2007, Phan et al., 2011). 
     NS4A 1.5.2.7
NS4A is 6kDa in size (54 amino acids) and is the smallest protein encoded by the 
HCV genome. NS4A is made up of an N-terminal hydrophobic alpha-helix 
sequence that presents NS3 and NS4A to the cell membrane (Wolk et al., 2000), 
a central peptide that builds a beta-strand that is found to stabilize NS3 proteins 
and a C-terminal region that makes an alpha-helix shape at low pH (Phan et al., 
2011) (Lindenbach et al., 2007). NS4A works as a cofactor for both the serine 
protease and helicase activity of NS3 (Bartenschlager et al., 1994, Failla et al., 
1994, Lin et al., 1995, Frick et al., 2004, Pang et al., 2002). NS4A enhances ATP 
binding to NS3 thereby increasing maximum ATP-hydrolysis activity (Beran et al., 
2009).   
 NS4B 1.5.2.8
NS4B is 27 kDa in size and is highly hydrophobic. The structure of NS4B contains 
a central region with 4 TMDs that help the protein to attach strongly to the ER 
membrane (Hugle et al., 2001, Lundin et al., 2003, Elazar et al., 2004).  
 The TMDs are connected by three transmembrane loops. The loop 
connecting the second and third TMD is located within the cytosolic side of the 
ER membrane (Lundin et al., 2003). This loop contains a nucleotide binding 
motif (NBM) that binds GTP (Einav et al., 2004) (Einav et al., 2008b). The last 
five residues of the C-terminus (aa 257 - 261) undergo palmitoylation and may 
play a crucial role in protein-protein interactions during HCV replication (Yu et 
al., 2006). Expressing NS4B can cause rearrangement of cellular ER membranes, 
resulting in formation of punctate shapes that are called ‘membranous web’ and 
membrane-associated foci (MAFs) (Gosert et al., 2003, Egger et al., 2002, 
Gretton et al., 2005). 
NS proteins that are involved in RNA replication sit within this punctate area 
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(Elazar et al., 2004, Hugle et al., 2001) and viral RNA interacts with the non-
structural proteins within this structure on the ER membrane.  
 The membrane changes that are made by NS4B are therefore probably 
crucial for the HCV RNA replication. In addition to providing a suitable 
environment for HCV RNA synthesis, NS4B may contribute to HCV RNA replication 
directly. Two studies published in 2003 showed that cell culture adaptive 
mutations (CCAMs) within NS4B can improve HCV RNA replication by up to 30 
fold when compared with HCV RNA containing wild type NS4B (Lohmann et al., 
2003, Lohmann et al., 2001, Krieger et al., 2001, Nakamura et al., 2008).  
 A single amino acid plays a key role in RNA replication and changes here 
can either enhance or terminate RNA replication (Lindstrom et al., 2006, Blight, 
2007). Making a chimeric replicon by inserting Con1 containing NS4B derived 
from HCV genotype 1b into the HCV H77 strain (genotype 1a) genome increases 
HCV RNA synthesis up to 10 fold compared with WT (Blight, 2007, Pietschmann 
et al., 2009). In addition, a Con1 (genotype 1b) genome containing HCV 
genotype 1a NS4B results in defective HCV RNA replication (Paredes and Blight, 
2008, Pietschmann et al., 2009).   
 Replication of the defective chimeric genome can be improved by 
introducing mutations within NS3. Based on these data, it is likely that NS4B has 
the ability to interact with the replication mechanism in a genotype-specific way 
and compatibility between NS3 and NS4B is needed for RNA replication (Paredes 
and Blight, 2008). NS4B can also inhibit HCV RNA replication through binding to 
the negative-strand (Einav et al., 2008a). Therefore, NS4B has more than one 
role; it contributes to a suitable environment for replication complex (RC) 
assembly, and has an impact on controlling RNA synthesis within RCs. 
 NS5A 1.5.2.9
The non-structural protein 5A (NS5A) consists of a 447-aa membrane-associated 
phosphoprotein. It plays a significant role in controlling HCV RNA replication and 
in the formation of HCV particles. NS5A exists as two types known as hypo- and 
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hyper-phosphorylated forms, with a size of 56kDa and 58 kDa respectively. NS5A 
has three different domains, known as domain I, domain II and domain III, 
separated by low-complexity sequences I and II (LCS I and LCS II) (Tellinghuisen 
et al., 2004). The first domain has been well characterized. It is attached to a 
zinc atom that contributes to RNA replication (Tellinghuisen et al., 2004). The 
crystallographic structure of domain I reveals a dimer with a groove that binds 
either ssRNA or dsRNA (Tellinghuisen et al., 2005).  
 NS5A can bind to both positive and negative strands of RNA (Huang et al., 
2005). Domain I also contains an amphipathic α-helix (AH) that is conserved 
across all isolates and is necessary for membrane localization; disruption of the 
AH leads to impaired HCV replication (Elazar et al., 2003, Brass et al., 2002). 
Domains II and III are less well characterised; domain II is unstable in normal 
conditions (Liang et al., 2006). Domain III is natively unfolded (Hanoulle et al., 
2009, Verdegem et al., 2011) and displays a propensity to partially fold into an 
α-helix (Verdegem et al., 2011).  
 Domains I and II are essential for RNA replication. The third domain (D-III) is 
unnecessary for HCV RNA replication (Appel et al., 2008, Tellinghuisen et al., 
2008b, Ross-Thriepland et al., 2013) but can be manipulated to allow molecules 
containing green fluorescent protein (GFP) to be inserted without inhibiting the 
HCV RNA replication process (Appel et al., 2005, Liu et al., 2006, McCormick et 
al., 2006, Moradpour et al., 2004), thus illustrating the features of NS5A within 
live cells. A study using GFP showed that the NS5A fusion protein is associated 
with HCV RNA undergoing active replication (Targett-Adams et al., 2008).  
 The phosphorylation of NS5A has an impact on HCV RNA replication; HCV 
RNA replication can increase when hyperphosphorylation of NS5A is reduced 
(Appel et al., 2005, Evans et al., 2004, Neddermann et al., 2004). An interaction 
has been reported between NS5A and the human vesicle-associated-membrane 
protein A (hVAP-A). This protein is involved in intracellular trafficking and HCV 
RNA synthesis (Gao et al., 2004, Tu et al., 1999, Zhang et al., 2004).  
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Experiments have shown that hyperphosphorylated NS5A binds less efficiently to 
hVAP-A when compared to basally phosphorylated protein (Evans et al., 2004). 
Phosphorylation may therefore have a specific role in regulating HCV RNA 
replication.  
 Domain III of NS5A is necessary for HCV particle formation and is involved in 
binding to HCV core during viral replication (Appel et al., 2008, Tellinghuisen et 
al., 2008a). A single mutation within a single serine site in domain III results in 
impaired HCV particle production without eradicating the association between 
HCV NS5A and lipid droplets (LDs)(Tellinghuisen et al., 2008a). Deletions within 
domain III do not affect the ability of NS5A to interact with LDs, but they do 
disrupt the domain III connection with core (Appel et al., 2008).  
 NS5A is involved in a number of other interactions (Macdonald and Harris, 
2004). Protein kinase R, an INF-induced protein that phosphorylates eIF-2a binds 
to NS5A (Samuel, 1993, Kim et al., 2011, Gale et al., 1997) and can interact with 
epidermal growth factor (EGF), activating factor of the Ras-Erk signalling 
pathway (Macdonald et al., 2003, Macdonald et al., 2005, Mankouri et al., 2008).  
 NS5B 1.5.2.10
HCV replication starts with the synthesis of a complementary negative RNA 
strand (–RNA), utilizing the positive stranded HCV genome as a template. This 
negative strand acts as a template for further positive strand synthesis. The HCV 
RNA dependent RNA polymerase (RdRp) encoded by the NS5B gene carries out 
both steps. RdRp enzyme is a 68 kDa protein consisting of 591 amino-acids and 
has been comprehensively characterized (Behrens et al., 1996, Lohmann et al., 
1997, Lesburg et al., 1999, Simister et al., 2009). It is a major target for 
antiviral intervention.  The NS5B catalytic domain has a distinct sequence that is 
shared by other RdRp enzymes - GDD.  
 The ssRNA template attaches to a groove between the finger and thumb 
domains. Nucleotide triple phosphates (NTPs) can access the RNA active site 
within a tunnel within the palm domain.  
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The HCV RNA-dependent RNA polymerase (RdRb) fits within the membrane 
proteins known as tail-anchored proteins 20. These proteins have features 
including 1) a posttranslational membrane targeted by an insertion sequence 
(hydrophobic C-terminal) mapped to 21 C-terminal amino acid residues within 
the NS5B region; 2) integral membrane association; and 3) a functional protein 
domain (Wattenberg and Lithgow, 2001)Two different studies have shown that 
the RdRp of HCV contains an insertion sequence that penetrates through the 
phospholipid bilayer of the ER as a transmembrane segment (Ivashkina et al., 
2002). Old structure predictions have indicated that this segment is 
implemented as a helical fold within the hydrophobic membrane (Schmidt-
Mende et al., 2001).   
The NS5B crystal structure shows a specific catalytic domain that is followed by 
a C-terminal extension that binds to the transmembrane region by an active site 
groove. The catalytic domain consists of 530 N-terminal amino acids, showing 
the three subdomains (fingers, palm and thumb). NS5B has a special feature; the 
fingers’ subdomains have an extension that interacts with the thumb subdomain; 
this interaction limits the flexibility of one subdomain by the other. This results 
in a totally surrounded active site into which NTP molecules can attach. The RNA 
template is enclosed in a groove that leads to the active site; the NTPs access 
this site via an NTP tunnel.  RNA synthesis by NS5B initially happens via a 
specific mechanism in the absence of primer (known as a de novo mechanism). 
Mapping of the NS5B complex with oligonucleotides has shown that the NTP 
binding site used for de novo initiation has two locations (catalytic and priming 
sites) (Bressanelli et al., 2002).  
 This mechanism suggests that this enzyme is essential for de novo RNA 
synthesis. The current NS5B structural model is based on the conformation of the 
enzyme that is assumed during the synthesis step. The enzyme may be modified 
to a different conformation when it is moved to the elongation step of 
replication. The current NS5B structural model shows no clear exit path for 
double-stranded RNA. So far, it is not clear whether recently synthesised RNA 
develops as a double-strand or if it unwinds after new nucleotides leave the 
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active site area. The NS5B structure has been characterised in association with 
non-nucleoside inhibitors; these drugs attach to the thumb surface about 30 A ̊ 
away from the active site. This binding site within the thumb surface is close to 
the allosteric GTP site within the fingers–thumb interface (Bressanelli et al., 
2002). Non-nucleoside inhibitors may work by stopping the initiation step of the 
enzyme via inhibition of a conformational change that is needed in order to 
proceed with elongation.  Oligomerisation of NS5B from HCV may be crucial for 
RNA synthesis activity (Wang et al., 2003), similar to RdRp in the poliovirus (Lyle 
et al., 2002). 
 The 3’ untranslated region (3’ UTR). 1.5.2.11
The 3’UTR contains three different parts; a variable region of 26-70 nucleotides 
in length, a poly U tract of variable length sequence (20 to 200 nucleotides) and 
an X-tail of a 98-100 nucleotide sequence. All of these elements are involved in 
both replication and translation of HCV (Anjum et al., 2013, Blight and Rice, 
1997, Tanaka et al., 1996, Dutkiewicz et al., 2006).  
 The variable region contains two stem loops (VSL1 and VSL2). These regions 
are not essential for HCV RNA replication in cell culture (Friebe and 
Bartenschlager, 2002, Blight and Rice, 1997). The poly U region, highly variable 
in size and structure is made up of uridine residues in combination with other 
cytidine residues. The poly U poly UC region must be at least 26 nucleotides to 
allow HCV RNA replication (Friebe and Bartenschlager, 2002). The third part of 
the 3’ UTR, the 3’ X-tail is a highly conserved region that contains three stable 
structure stem loops  (SL1-3). Deletion of any of these stem loops leads to RNA 
replication in cell culture or in chimpanzees being abolished (Friebe and 
Bartenschlager, 2002, Yi and Lemon, 2003, Yanagi et al., 1999). 
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1.6 The immune response to HCV 
1.6.1 Innate immunity  
Innate immunity represents the first line of defence against RNA viruses 
including HCV. It is characterised by the recognition of viral RNA by pathogen 
associated molecular patterns (PAMPs). Foreign RNA inside cells is recognised by 
pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) and 
binding protein receptors of intracellular nucleic acid (Cook et al., 2004, Iwasaki 
and Medzhitov, 2004) that elicit their effects by upregulating expression of 
antiviral genes.  
In hepatocytes, TLR3, protein kinase R (PKR) and retinoic-acid-inducible gene I 
(RIG-I) are pattern recognition receptors that bind to HCV. Following adaptor 
protein signalling, IFN type I is activated and secreted (Horner and Gale, 2013). 
Binding of type I IFN to the cell receptor activates the JAK-STAT signaling 
pathway eventually resulting in expression of interferon-stimulated genes in the 
infected cell and in neighbouring cells (Wieland et al., 2014, Gale and Foy, 
2005). Interferon-stimulated genes (ISGs), expressed as a response to infection, 
encode many different proteins including ISG15 and USP18, that have been 
known to inhibit HCV replication in vitro (Randall et al., 2006, Chen et al., 
2010).  
 HCV has counter-mechanisms that act against the antiviral effect of the 
innate immune response (Bigger et al., 2001, Su et al., 2002, Thimme et al., 
2002, Bigger et al., 2004). Serine protease activity from NS3/4A interferes with 
the viral detecting pathways at the early stage of infection via degradations of  
MAVS and TRIF in the innate immune response pathway (Horner and Gale, 2013). 
Core, E2 and NS5A are also associated with the inhibition of JAK- STAT signalling 
(Taylor et al., 1999, Taguchi et al., 2004, Foy et al., 2005). Interestingly, the 
presence of ISGs is associated inversely with interferon therapy success (Chen et 
al., 2005). This may indicate that in cells where ISGs have been already 
generated, counter-mechanisms may be already be induced by HCV which 
cannot be overcome with external interferon.  
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1.6.2 Natural killer cells  (NK). 
Natural killer (NK) cells are among the first lines of innate defence against 
harmful organisms. NK cells kill cells infected with viruses by producing 
cytotoxic molecules such as perforin and granzyme or by tumour necrosis factor 
(TNF)-related apoptosis-inducing ligand (TRAIL)-mediated killing. NK cells 
secrete IFN, TNFα, IL- 10, and IL-21, which are all known already to regulate the 
innate and adaptive immune system.  
 The activity of NK cells is balanced by both activating and inhibitory signals 
produced by the interaction between NK receptors and their ligands that are 
found on the target cells (Jost and Altfeld, 2013). NK cells are present in high 
levels in the liver and play an important role controlling hepatotropic infections, 
including HCV (Doherty and O'Farrelly, 2000, Crispe, 2009).  
 NK cell hyper-activation is often present during the acute phase of 
infection; for example, NK cell activity has been detected in high levels in 
intravenous drug users (IDUs) during early infection (Golden-Mason et al., 2010). 
In one small study of 12 healthcare workers exposed to HCV, NK cell activation 
was associated with control of infection in 11/12 individuals (Werner et al., 
2013). However other studies have shown NK cell activation regardless of 
outcome (Alter et al., 2011, Amadei et al., 2010, Pelletier et al., 2010). 
 NK cells remain highly activated in patients with chronic HCV infection and 
the level of activity correlates with liver inflammation outcome (Bonorino et al., 
2009, Oliviero et al., 2009). Natural killer cells from peripheral blood express 
markers of activation including NKp30, NKp44, NKp46, NKG2C, and NKG2D and 
can play a role in increasing the degree of inhibiting the receptor expression in 
NKG2A in positive HCV patients compared to negative HCV individuals (Shoukry 
et al., 2011, Golden-Mason and Rosen, 2013, Rehermann, 2013). HCV E2 may 
bind to CD81 on the NK surface and this may inhibit NK cell function (Crotta et 
al., 2002, Tseng and Klimpel, 2002).   
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Study data using the rodent lymphocytic choriomeningitis virus (LCMV) model 
show that NK cells can control CD4 helper cells that then mediate the function 
of CD8 T cells in the chronic phase (Waggoner et al., 2012). NK cells also 
interact with dendritic cells and this may also influence innate and adaptive 
responses. NK cells generate IFNγ and TNFs, that stimulate mature DCs and 
improve their ability to target virus T cells. DCs also secrete IL-2 and IL-15, 
which are known to increase NK cell activation (Marcenaro et al., 2012).  
1.6.3 Dendritic cells (DC) 
Dendritic cells alongside macrophages are the major antigen-presenting cells 
(APCs) in humans. They connect the innate and adaptive immune systems and 
influence the direction of the specific immune response to HCV. DCs promptly 
mature as a reaction to danger signals including TLR ligands bound to PAMPs and 
cytokines released from other cells (Steinman and Banchereau, 2007).  
 They are divided into two different types: myeloid dendritic cells (mDCs) 
and plasmacytoid dendritic cells (pDC). mDCs contains two subsets: the first 
subset is the mSC-1 which is a primary T cell stimulator. The second subset is 
the mDC-2 that have an impact on recognising wound infections. The second 
type of dendritic cells are pDCs, similar to plasma cells. mDCs are involved in 
antigen processing and presentation, whereas pDCs, which can recognise virus 
infection as well, secrete type I and III interferons. Plasmacytoid dendritic cells 
have been shown to have a strong ability to recognize HCV RNA via toll-like 
receptor 7 (TLR-7) when it exists as part of the hepatocyte-infected cells 
(Takahashi et al., 2010). mDCs and pDCs have both been shown to have an 
association with HCV infection outcome. 
 Low frequencies of mDCs and pDCs have been shown to correlate with a 
chronic outcome of infection (Longman et al., 2004, Wertheimer et al., 2004, 
Longman et al., 2005, Piccioli et al., 2005). Pelletier and colleagues found that 
hyper-responsiveness of dendritic cells correlated with spontaneous clearance of 
HCV as a result of better priming of specific T cells (Pelletier et al., 2013). Other 
groups have linked defective DC activity and chronicity, and the correlation of 
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DC response to TLR ligand interactions that increase T regulatory cell (Treg) 
propagation (Bain et al., 2001, Dolganiuc et al., 2003, Sarobe et al., 2003, 
Rodrigue-Gervais et al., 2007, Dolganiuc et al., 2008). 
 Dendritic cells may polarise the adaptive immune response during early 
infection by releasing different quantities of regulatory cytokines. The anti-
inflammatory cytokine, IL-10 limits activation of cells from both the innate and 
the adaptive immune system to maintain a homeostatic state. IL-12, in contrast, 
activates the adaptive immune response and polarises T- helper type 1 CD4+ T 
cells  towards a Th1 profile (Ma et al., 2015, Steinman and Hemmi, 2006). 
1.6.4 Adaptive immune responses to HCV  
The adaptive immune system (that includes the specific B and T-cell mediated 
response) plays an essential role in clearance of HCV. The role of cell-mediated 
immunity is indicated by the link between class I and II human leukocyte 
antigens (HLA) and outcome. Studies in chimpanzees have also shown that CD4 
and CD8 T cells are essential for the spontaneous clearance of HCV. The role of 
neutralising antibodies (nAbs) in achieving viral clearance needs to be explored 
in wider studies. In one study, memory CD4 and CD8 T cells were detected in 
both blood and peripheral blood cells from patients who had spontaneously 
cleared HCV 20 years before, while antibodies had declined at that this time 
(Takaki et al., 2000). Re-infected individuals show a higher rate of clearing HCV 
spontaneously compared to individuals with primary infection, indicating that 
adaptive immunity is central to the control of infection (Mehta et al., 2002, 
Aitken et al., 2008, Osburn et al., 2010).       
 The CD8+ T cell response during acute HCV infection  1.6.4.1
Following primary HCV infection, CD4 and CD8 T cell responses appear after 6-8 
weeks.  The delay before virus-specific T cells emerge includes the time that is 
required for the HCV antigen to reach the lymph nodes and be recognised by 
antigen-presenting cells (APCs) but could also be delayed by the liver’s ability to 
produce immunologic tolerance (Bowen and Walker, 2005a, Crispe, 2009).  
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An early strong specific CD8 T cell response is associated with spontaneous 
clearance of HCV. Several different epitopes are recognised in both animal 
models and humans (Cooper et al., 1999b, Lechner et al., 2000c) and 
spontaneous clearance has been linked particularly to CD8 T cell responses 
directed against the non-structural proteins (Smyk-Pearson et al., 2006).  
 Patients who progress to chronicity often exhibit evidence of immune 
escape due to mutations within CD8 T cell epitopes. Epitopes containing 
mutations may lose the ability to bind to MHC class I alleles, are therefore not 
detected and stimulate responses from CD8 T cells poorly (Erickson et al., 2001, 
Bowen and Walker, 2005b). HLA alleles from the host exert selective pressure on 
specific epitopes; these mutations may return to wild type sequences when the 
HCV is transferred to a new patient who does not carry the same HLA type or 
when the HCV epitope is not pressured by the immune system any more (Timm 
et al., 2004a).  
 The host HLA may also induce selection pressure at a population level, 
resulting in viral adaptation within a specific genetically-related population 
(Gaudieri et al., 2006). (Soderholm et al., 2006). Viral fitness limits the 
variability within some epitopes and the likelihood of those epitopes persisting in 
a population (Soderholm et al., 2006, Uebelhoer et al., 2008).  Several class I 
HLA alleles such as HLA-B27 play a strong role in HCV outcome. Such HLA-
restricted epitopes often cannot withstand mutation due to a high virus fitness 
cost (Dazert et al., 2009, Neumann-Haefelin et al., 2006, Neumann-Haefelin et 
al., 2011). Lack of binding to the TCR is another way in which HCV can evade the 
T cell response. A single mutation within the MHC class I NS31406 epitope, for 
example, can result in poor responses as this mutant exploits a ‘hole’ within the 
T cell repertoire (Wolfl et al., 2008).  
 A strong CD8 T cell response is associated with the spontaneous clearance 
of HCV. Studies using MHC class I tetramers have shown that specific T cell 
responses can increase to as much as 8% of the T cell population recognising one 
single epitope during spontaneous clearance (Lechner et al., 2000c, Badr et al., 
2008).  Studies in chimpanzees show even higher levels of tetramer stained cells 
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in the liver compared to the peripheral blood in association with a high level of 
the T cell activation marker CD69 (Shoukry et al., 2003b).  
 MHC class I tetramer may be used to carry out phenotypic characterisation 
of HCV-specific CD8 T cells ex vivo. Early expression of the IL-7 receptor (CD127) 
on specific CD8 T cells is a predictor of clearance, whereas the loss of specific 
CD8 T cells correlates with chronicity (Golden-Mason et al., 2006, Shin et al., 
2013). Memory T cells produced after primary HCV clearance also express high 
levels of CD127, in addition to Bcl-2 (CD127hi, Bcl-2hi) (Abdel-Hakeem et al., 
2010, Badr et al., 2008).  
 These data reflect that seen in the LCMV mouse model, where CD127 is a 
marker that occurs in long-lasting memory T cells (Kaech et al., 2003).  
 Specific CD8 T cells targeting HCV may commonly express exhaustion 
markers and this phenotype is associated with progression to chronicity. PD-1 
may play a role in activating memory cells as well as exhaustion in patients with 
HCV (Urbani et al., 2006, Bowen et al., 2008, Kasprowicz et al., 2008). The 
exhaustion markers cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), killer 
cell lectin-like receptor G1 (KLRG1), 2B4 (CD244), mucin-domain-3 (TIM-3), 
CD160 and T cell immunoglobulin are associated with exhaustion and progression 
to chronicity (Bengsch et al., 2010, Kared et al., 2013). Galectine-9 (Gal-9) is a 
TIM-3 ligand that is upregulated during acute HCV infection in patient plasma 
and liver before progression to chronicity (Kared et al., 2013, Mengshol et al., 
2010). Blocking TIM-3, CTLA-4 or PD-1 can result in preservation of specific CD8 
T cell function and blocking more than one of these results in a synergistic 
decrease in exhaustion (Penna et al., 2007, Nakamoto et al., 2009b). CD4 T cell 
mediators such as IL-21 can also help in saving the T cell from TIM-3 and Gal-9 
mediated cell death (apoptosis) (Kared et al., 2013).  
 Analysing virus-specific CD8 T cells that are associated with HCV clearance 
has resulted in the identification of multiple CD8 cell effector molecules (Badr 
et al., 2008). The secretion of IFNγ, IL-2 and CD107a (a marker of CD8+ T cell 
degranulation) are associated with clearance (Alter et al., 2004, Badr et al., 
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2008). T cell proliferation capacity is also central to outcome (Einav et al., 
2008b, Lauer, 2013). Patients that progress to the chronic phase have impaired 
CD8 T cell cytokine production and proliferation (Gruener et al., 2001, Appay et 
al., 2002, Wedemeyer et al., 2002).  
 Detecting specific CD8 T cells within HCV chronic patents is difficult in the 
peripheral blood whereas in the liver they can be detected quickly (He et al., 
1999, Radziewicz et al., 2007b). Patients in the chronic phase of HCV infection 
express high levels of 2B4, PD-1 and TIM-3.  
 HCV specific T cells in the peripheral blood are weaker in cytokine 
production and proliferation than when they are detected in the blood for the 
first time, confirming a stunned phenotype (Lechner et al., 2000a).  
 In conclusion, spontaneous clearance of HCV is associated with strong 
polyfunctional HCV CD8 T cell responses while progression to chronicity is 
associated with T cell escape and weak T cell responses in association with the 
expression of exhaustion markers. During progression to chronicity, mutations 
within the targeted epitope may lead to immune escape. A loss of specific T 
cells or a change in the immune regulatory profile that cooperates with specific 
CD8 T cells may result in progression to chronicity. Finally, a high level of HCV 
replication may impair HCV-specific T cells via persistent antigenic stimulation 
that leads to function loss and reduces the CD8 T cell response to HCV. CD8 T 
cell exhaustion can be worsened by increased expression of ligand that binds to 
an inhibitory receptor such as (Gal-9) (Abdel-Hakeem and Shoukry, 2014).   
 CD4+ T cell responses during acute HCV  1.6.4.2
A strong and effective CD4 response is an important factor in virus clearance 
(Missale et al., 1996, Gerlach et al., 1999). The association of proliferation 
following stimulation with peptides derived from the non-structural proteins was 
one of the first insights into CD4 T cell function during clearance of acute HCV 
infection (Diepolder et al., 1995, Missale et al., 1996). 
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Loss of CD4 responses is associated with progression to chronicity (Thimme et 
al., 2001b, Lechner et al., 2000c, Gerlach et al., 1999).  
 One study identified 14 unique CD4 epitopes that were presented by 
patients in the acute phase in HCV clearance (Day et al., 2002). Out of these 14 
epitopes, some were recognised as promiscuous epitopes that are presented by 
many class II HLA-DR alleles (Shoukry et al., 2004, Schulze zur Wiesch et al., 
2005). Unlike CD8 epitopes, escape mutations were found to happen rarely 
within MHC class II restricted CD4 T cells epitopes (Fleming et al., 2010, Fuller 
et al., 2010). However, the CD4 response to HCV has been much less well 
characterized - in spite of increased technical knowledge about MHC class II 
tetramers, there has been a lack of direct ex vivo studies of HCV-specific CD4 T 
cell responses during acute HCV infection in humans.  
 While difficult to detect, HCV-specific CD4 T cells have been found in 
chimpanzees up to 7 years after resolved HCV infection using MHC class II 
tetramers (ex vivo) (Bowen et al., 2008). Proliferation of CD4 T cells was found 
to be rapidly lost, which has an impact on cytokine production, especially IL-2 
(Semmo et al., 2005a, Schulze Zur Wiesch et al., 2012). Blocking PD-1, IL-10 and 
TGF-β pathways in vitro can lead to rescue of CD4 T cell proliferation capacity 
and the increased production of cytokines in chronically infected patients 
(Raziorrouh et al., 2011). The central role of CD4 T helper cells to maintain CD8 
T cell function has been demonstrated in chimpanzees where declining CD4 
function is associated with the accumulation of escape mutations within CD8 T 
cell epitopes (Grakoui et al., 2003b).  
 The phenotype of CD4 cells in patients that spontaneously clear HCV has 
been described in small studies. One such study showed an increase in CD161hi 
CCR6+ CD26+ CD4+ Th17 T cells in spontaneous clearance. These immune cells 
secrete high amounts of IL-17A and IL-21, and these two cytokines have also 
been found in high concentrations in plasma from patients who have 
spontaneously cleared HCV (Kared et al., 2013). Increased plasma levels of IL-21 
in late acute infection is associated with reduced apoptosis of virus-specific CD8 
T cells mediated by Tim-3/Gal-9 (Kared et al., 2013).  
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This highlights the function of IL-21 as one of the main cytokines influencing 
outcome in acute HCV. Interestingly, similar findings have been found in the HIV 
and LCMV model (Johnson and Jameson, 2009). More studies are needed to 
investigate the role of alternative IL-21 sources such as NK cells and follicular 
helper T cells (Tfh).  
 As well as classic Th1 and Th2 type CD4 cells, Th17 and T regulatory cells 
(Tregs) may influence outcome during acute HCV infection (Manigold and 
Racanelli, 2007, Ebinuma et al., 2008, Rowan et al., 2008). Treg cells may have 
an impact on the inhibition of HCV-specific CD4 and CD8 T cells. CD39+ CTLA4+ 
Treg cells were found to be present for longer when patients progressed to the 
chronic phase (Kared et al., 2013).  
 As described above, Gal-9 has an effect on CD4 and CD8 T cells via an 
interaction with Tim-3; Tregs are a source of Gla-9 and therefore may inhibit 
HCV-specific T cell responses via this mechanism (Kared et al., 2013). In the 
chimpanzee model, Treg cells can inhibit the specific immune response to HCV 
in a subsequent infection (Park et al., 2013). Chronic HCV patients have been 
found to have expanded Treg cell populations; it may be that these expanded 
Treg populations may limit disease during persistence by reducing inflammation. 
 In conclusion, during acute HCV infection, specific CD4 T cells responses 
are primed. Exhaustion of CD4 T cells has a negative impact on IL-2 production, 
IFNγ and proliferation. Reduced proliferation of CD4 T cells results in a failure to 
support a strong CD8 T cell responses and leads to chronicity. Early induction of 
IL-21 can increase CD4 responses and reduce CD8 T cell exhaustion. Treg cells 
may inhibit CD4 and CD8 effector T cells via producing Tim-3 ligand and the 
regulatory cytokines IL-10 and TGF-β. 
 Humoral responses during acute HCV infection 1.6.4.3
As HCV reaches high levels in serum following initial transmission, the antibody 
response (seroconversion) is detected around 2-8 weeks of infection (Rehermann 
and Nascimbeni, 2005, Dustin and Rice, 2007). Numerous studies have shown 
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that antibodies classically target the highly variable regions (HVR) of the HCV 
envelope 2 (E2) glycoprotein both in vitro and in vivo (Farci et al., 1996, Shimizu 
et al., 1996). In some chimpanzee studies, spontaneous clearance is not 
associated with antibodies (Bassett et al., 1999, Major et al., 1999).  
 In humans, antibodies are associated with spontaneous clearance in some 
studies (Logvinoff et al., 2004, Netski et al., 2005). However, neutralizing 
antibodies (nAbs) may only appear after the patient progresses to chronicity in 
association with rapid generation of B cell HCV escape mutations (von Hahn et 
al., 2007). A recent study showed that nAbs can have activity against 
heterologous HCV infection but a major feature of HCV B cell responses is that 
they are directed against patient-specific isolates. 
 Methods for investigating B cell responses often require the use of HCV 
pseudo-particles (HCVpp) that consist of a lentiviral backbone and the envelope 
genes of HCV. Using HCVpps, HCV clearance correlates with the emergence of 
high titres of nAbs (Osburn et al., 2014). HCV antibodies may also induce 
antibody-dependent cellular cytotoxicity (ADCC) (Nattermann et al., 2005). 
ADCC is based on the attachment of the variable region of Abs to HCV-infected 
cells and binding of the Fc region to fragment crystalisable (Fc) receptors, 
expressed on innate immune cells such as natural killer cells.  
 Targeting of infected cells and lysis occurs as a result of binding the FcγR3a 
(CD16) that triggers cytokine production and degranulation of NK cells.  Several 
studies have shown that ADCC also plays a role in reducing viral replication in 
patients infected with HIV (Baum, 2010, Berger and Alter, 2011). More studies 
are needed to understand the role of ADCC-inducing antibodies during early HCV 
infection and reinfection.  
 In HCV humoral immunity protection is limited by several factors. First, it is 
known that envelope protein immunogenicity if it is not high, can lead to a 
slowed Ab response especially during first exposure to the virus (Dowd et al., 
2009). Second, the E2 protein contains the HVR, characterized by a high 
mutation rate, and these mutations can help the HCV to be escape Ab 
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neutralization (Weiner et al., 1992). These mutations often follow a reduction in 
cellular immunity around 6 months into infection during progression to chronicity 
(Liu et al., 2010). Lastly, epitopes targeted by nAbs are protected via 
glycosylation as well as by complex linking to lipoproteins from the host. This 
mechanism slows or limits Ab efficiency in vivo (Helle et al., 2007).  
 In conclusion, current data shows a link between the appearances of nAbs 
and how they can play an important role in clearing the HCV spontaneously. 
However, these findings are still tentative and more studies are needed. A 
recent study showed the crystal structure of E2 and how it is linked to the 
neutralizing antibody AR3C (Khan et al., 2014, Kong et al., 2013).  
 Such studies of the HCV envelope structure will help to provide more 
information about the interaction between E1/E2 with their receptors as well as 
with nAbs. More studies of how T cells interact with B cells are still needed.  
1.6.5 Summary of immune responses and immune evasion during 
acute HCV infection 
HCV infection initially activates the immune system following triggering of the 
innate immune system via cellular sensors such as TLR, RIG-I, and PKR. These 
stimulate the IFN signaling cascade resulting in the production of interferon 
types I and III and interferon-stimulated genes (ISGs) in infected cells. Natural 
killer cells in the liver are activated via interferon. These, hepatocytes, and 
other APCs (Kupffer and dendritic cells) then activate the immune system 
against HCV by presenting peptides via MHC class I and II receptors to CD8 and 
CD4 cells, respectively. Migratory DCs transfer the HCV antigens from the 
infected liver to draining lymph glands.  
 CD4 T cells including Th1 cells are primed, and support CD8 T cells in 
inhibiting viral replication through the production of IFNγ and TNFα. CD4 cells 
also produce IL-2 which increases proliferation of CD8 T cells. Th2 CD4 responses 
support the production of B cells and IL-4 and IL-6 may help in the generation of 
nAbs. It is not clear yet what the role of Tfh cells is in developing nAbs within 
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the acute HCV phase, and in addition it is unclear what the role of ADCC is in 
maintaining HCV infection. The interaction between NK and DCs and the 
influence of this interaction on the specific CD8 T cell function also needs to be 
studied further.  
 HCV has the ability to evade the immune response by inhibition of the 
interferon signaling pathway, limiting the function of NK cells, the production of 
escape mutations within CD8 T cell epitopes and exhaustion of the acquired 
immune system (both CD4 and CD8 T cells) via upregulation of PD-1, Tim-3 and 
CTLA-4.  
Tregs can reduce the response of the innate immune system against HCV 
directly via IL-10 and TGF-β production or producing Gal-9 that has been well 
defined as increasing apoptosis of virus specific CD4 and CD8 T cells (Abdel-
Hakeem and Shoukry, 2014).  
1.6.6 The HLA-B27 allele and disease  
The human leukocyte antigens (HLA) are encoded on chromosome 6 and are the 
human major histocompatibility complex (MHC). Three MHC class I molecules (A, 
B and C) are expressed on the cell surface of all nucleated cells and express 
endogenous (intracellular) peptides to T-cell receptors on cytotoxic T cells 
(Bowness, 2015). The MHC class I HLA-B27 allele has traditionally been 
associated with disease, for example, it is strongly associated with arthritides 
including ankylosing spondylitis, Reiters syndrome and psoriatic arthritis. It has 
also been shown to have importance in viral infection and acts as a restriction 
factor for the highly specific CD8+ T-cell response (Gomard et al., 1984).   
 Peptide Presentation by HLA-B27 to CD8+ Cytotoxic T Cells 1.6.6.1
HLA-B27 is synthesised in the endoplasmic reticulum as a multiprotein complex 
that has peptide-loading capcity. MHC-restriction with relation to was initially 
described by Zinkernagel and colleagues in mice with lymphocytic 
choriomeningitis virus (LCMV) infection (Zinkernagel and Doherty, 1973, 
Zinkernagel and Doherty, 1974). Subsequently, in humans, the internal 
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nucleoprotein of influenza virus was found to be targeted by cytotoxic T cells 
(rather than surface hemagglutinin). The targeted region was noted to be short 
in length – the size of a short peptide (Townsend et al., 1986). The HLA-B27- 
restricted peptides from both influenza and HIV shared common structural 
features between them (the HLA binding sites), but differed in amino acids that 
affected T cell receptor recognition (Huet et al., 1990). The crystal structure of 
HLA-B27 was subsequently described by Madden and colleagues (the second HLA 
epitope to be described after HLA-A2) (Madden et al., 1991). The HLA-B27 
molecule contains a binding groove with a B pocket (which contained different 
residues than HLA-A2) and is oriented to attach a positively-charged side chain 
(arginine) located at the second position of the bound peptide (Madden et al., 
1992). Several thousand different peptides with arginine at the second position 
have been found to be bound to B27 alleles expressed on the cell surface. These 
may include self-proteins, including HLA molecules as well as foreign antigens 
(Jardetzky et al., 1991). 
 HLA-B27-restricted cytotoxic T lymphocyte responses to several viruses 
have been studied at length and ae associated with immunodominant responses 
targeting a small number of epitopes. For instance, in HIV infection, a mutation 
within the gag protein of the virus that is targeted by the CTL response impairs 
recognition and is associated with clinical progression (Goulder et al., 1997). 
HLA-B27 has been shown in several studies to be strongly associated with 
protection against viral infections, including infection with HIV and HCV (den Uyl 
et al., 2004). Immune escape from CD8 responses is limited by low viral fitness 
of mutated viruses and by cross-reactivity of T cells (Dazert et al., 2009).  
In individuals infected with HIV, HIV-specific CD8+ T-cells recognise an 
immunodominant HLA-B27-restricted epitope (KK10) and this is associated with 
partial control of infection and long-term non-progression of HIV infection (Nixon 
et al., 1988a) (Kaslow et al., 1996) (Goulder and Walker, 2012). The importance 
of HLA-B27-restricted epitopes in limiting HCV infection and protection of 
patients from progressing to the chronic phase has also been described (Hraber 
et al., 2007, McKiernan et al., 2004).  
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There are more than 100 subtypes of HLA-B27 recognised so far. These subtypes 
differ in primary amino acid sequence but have common elements between them 
including the key structure, peptide binding and antigenic features (Bowness, 
2015). 
 HLA-B27 and HCV 1.6.6.1
While the immune response defining HCV clearance versus persistence outcome 
is not very well understood, several studies have shown that the broad, diversity 
and T cell qualities are essential in controlling HCV infection outcome (Cooper et 
al., 1999a, Thimme et al., 2001a). Evidence for the role of T-cell function is 
supported by the presence of specific HLA molecules that impact the outcome of 
HCV infection (Mina et al.). Some HLA alleles are associated with reducing the 
disease progression of HIV-1 to AIDS level; HLA-B27 and HLA-B57, for example 
(Bashirova et al., 2011). These also have an association with the clearance of 
HCV infection. Protective HLA alleles classically present immunodominant 
epitopes to cytotoxic lymphocytes (CTL). Mutations within these epitopes can 
lead to progression to chronicity in patients infected with HCV (Kim et al.).  
 The protein targeted is often essential for the life cycle of the virus; such 
proteins are often highly expressed and may be vital for viral replication. 
Targeted proteins often contain conserved epitopes, within which mutations will 
result in a high fitness cost, which will lead to the low possibility of escaping 
from a CTL response.  Such epitopes are listed in Table 3-4. 
 The protective role of HLA-B27 in HIV infection  1.6.6.2
Early HIV infection is usually associated with a peak HIV viral load followed by 
the initiation of an immune response that controls the infection. This control 
coincides with lowering of the HIV viral load and stabalisation of the CD4+ cell 
count decline. Following an asymptomatic period that lasts from 2-10 years, the 
HIV viral load starts to increase as the CD4+ T-cell count drops, resulting in AIDS 
in untreated patients. A small number of patients develop strong CD8 responses 
to HIV; these patients can control the HIV and have lower HIV viral loads and 
longer asymptomatic periods before the onset of AIDS (Neumann-Haefelin, 
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2013). These patients may be infected for decades before symptoms start to 
appear.  
 A study carried by Kaslow et al. illustrated the key role of HLA class I 
alleles in HIV-infected patients and associated slow progression to AIDS by 
describing the protective effect of the class I HLA-B27 and HLA-B57 alleles 
(Kaslow et al., 1996). A more recent study in a cohort of 2700 HIV-infected 
patients showed similar outcomes and confirmed the protective role of HLA-B27 
and HLA-B57 in HIV-infected patients (Goulder and Walker, 2012). HLA- B27 and 
B57 alleles are not unique in their association with HIV control, but are extremes 
in a continuous spectrum of ‘protective’ to ‘hazardous’ HLA class I alleles 
(Goulder and Walker, 2012).  
   The protective role of HLA-B27 in HCV infection  1.6.6.3
Interestingly, HLA B27 and B57 alleles are also associated with control of HCV 
infection. Unlike patients infected with HIV who always progress to chronicity, 
around 30% of patients with acute HCV will clear the infection spontaneously. 
HLA class I has a major role in resolution of HCV infection. Patients with HCV 
infection infected from a single source (rhesus negative women treated with 
blood products) were protected if they had the class I alleles HLA-B27 or HLA-A3 
and were more likely to exhibit spontaneous clearance.  The role of HLA-B27 
protection in HCV patients has been supported by another large US cohort study; 
the strongest protection occurred in those patients with HLA-B27, HLA-B62, and 
HLA-B39 alleles (McKiernan et al., 2004).    
 More research shows growing evidence about virus-specific CD8+ T-cell 
responses in individuals with varying HLA types (Dustin and Rice, 2007).  
Detecting HCV specific CD8+ T-cells responses in the peripheral blood and liver is 
associated with HCV control and clearance of infection within the acute phase. 
This may occur in association with the development of antibodies and both can 
reduce or delay replication of HCV in chimpanzees (Lechner et al., 2000a) 
(Shoukry et al., 2003b) (Thimme et al., 2001b).   
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The significant role of the specific CD8+ T-cell response in HCV is strongly 
supported by the association of HLA-B27 (HLA class I), dominant HLA-B27-
restricted epitopes and spontaneous resolution of HCV. The most well 
characterised epitope is located within the C-terminal region of the 
nonstructural 5B protein and is nine amino acids in length (at position 2841-9 of 
the HCV genome and amino acids 421-429 of NS5B) (Neumann‐Haefelin et al., 
2006) (McKiernan et al., 2004). In patients with HCV monoinfection, a clear 
association has been found between this HLA-B27 epitope and protection (Dazert 
et al., 2009). The situation in HIV-infected patients has not been well 
characterized and is studied further in this thesis. 
1.6.7 HIV and hepatitis C virus co-infection 
Around 185 million individuals have been infected with HCV (WHO, 2011) and 37 
million individuals have been infected with HIV (WHO, 2015). Recently, AIDS has 
been described as one of the main causes of death in patients who have received 
highly active antiretroviral therapy (HAART) (Bica et al., 2001). 
 Up to 30% of HIV-infected patients have co-infection with HCV, with some 
populations showing an even higher prevalence rate (Vallet-Pichard and Pol, 
2006). A minimum of 4-5 million people have been identified as having co-
infection (HCV/HIV) due to the same routes of infection transmission (Alter, 
2006). It has also been found that 60-90% of HIV-infected haemophiliacs and 50-
70% in HIV-infected persons who inject drugs (PWID) have co-infection with HCV 
(Rockstroh and Spengler, 2004). 
The transmission of HIV has dropped since 2001, due to the advent of 
antiretroviral therapy (ART). More people are living with HIV than ever before 
for the same reason. A study carried out by Platt et al. in 2016 looked at HCV 
prevalence in co-infected HIV patient population samples. The highest 
prevalence was found in North Africa and the Middle East and the lowest 
prevalence was found in East Africa, whereas, the midpoint of the prevalence of 
HCV co-infection in HIV-infected individuals (heterosexual people or pregnant 
 62 | P a g e  
women) was 4.0% (Platt et al., 2016). In MSM, the midpoint prevalence in 80 
samples was 6.4%. The highest percentage was found in North America and the 
lowest was found in East Asia and South and Southeast Asia. In PWID, the 
prevalence was 29.0%. In general, there was an increase of about 5.8 times ratio 
of HCV antibody positive in HIV patients compared to mono-infected patients 
with HCV (Platt et al., 2016). 
There are an estimated 2,278,400 patients with co-infection worldwide, 
of which 1,362,700 are PWID. This overall global prevalence of HCV co-infection 
in HIV-infected people is about 6.2% (Platt et al., 2016). 
 Various countries, including France, Germany, the UK, the Netherlands, 
the USA and Australia have reported epidemics of sexual transmission of HCV 
between men who have sex with men (MSM). Globally over 1000 cases of co-
infection with acute HCV have been reported as a result of sexual or IDU 
transmission in HIV-infected MSM (Vogel et al., 2011). Phylogenetic analysis of 
the HCV sequences from infected patients show worldwide links between HCV-
infected patients (van de Laar et al., 2009).  
 The influence of HCV on HIV infection 1.6.7.1
The effect of HCV on HIV progression has been investigated in a number of 
studies. A study carried out on an HIV cohort in Switzerland suggested that HCV 
infection may result in faster progression to AIDS (Greub et al., 2000). Mono-
infected patients with HIV had higher CD4 counts (more than 50 cells/ml) (Greub 
et al., 2000). CD4 counts were seen to increase by more than 200 cells/mm3 in 
HIV mono-infected patients started on HAART when compared with co-infected 
patients, with a risk ratio of 1.52 (Stebbing et al., 2005, Sullivan et al., 2006). 
Other studies have shown there is no development risk of a progression to the 
advanced phase when co-infection with HCV/HIV occurs (Rockstroh et al., 2005, 
Sullivan et al., 2006). Co-infection with HCV may complicate HIV treatment as 
well; there is evidence showing an increase of drug-related hepatoxicity in 
patients treated with ART.  
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 The influence of HIV on HCV infection 1.6.7.2
The impact of HIV on HCV co-infection is clearer and affects both the natural 
history and transmission of HCV. The transmission of HCV has been found to be 
increased in co-infected patients with HIV; with parental transmission, the risk 
is—about two-fold higher in HIV-infected mothers (Sulkowski, 2008, Valle Tovo et 
al., 2007). Patients who have not been treated for HIV have a lower chance of 
clearing HCV spontaneously; they show a high level of HCV viral load and 
experience more rapid progression to HCV-related cirrhosis and cancer compared 
to patients with HCV infection only (Thomas et al., 2000). Patients treated with 
ART show improved outcomes in patients with co-infection, with a lower level of 
HCV-related mortality (Shepard et al., 2005).  
 In MSM, an eight-time increase in the probability of infection with HCV is 
present in HIV-infected individuals (van der Helm et al., 2011, Wandeler et al., 
2012). It has also been suggested that there is a higher rate of re-infection 
following the spontaneous clearance or treatment in positive MSM with co-
infection (HCV-HIV), confirming the need for repeating HCV testing in this 
population (Martin et al., 2013).  
 A study by Thomson et al. (2009) showed there was a delay in diagnosing 
acute HCV in HIV-infected patients; this was due to delayed seroconversion. Late 
diagnosis and treatment of HCV can impact the outcome of the HCV infection 
(Thomson et al., 2009).  
 HCV viral loads are higher in co-infected patients than in patients with 
mono infection, by around 1.08 log copies/ml in body fluids and blood (Shire and 
Sherman, 2005, Dionne-Odom et al., 2009, Mohsen et al., 2002). Anti-retroviral 
therapy reduces HCV viral load during HCV infection; in co-infected patients a 
decrease can be observed in the HCV viral load of up to 1 log, following a 12-
month treatment course of HAART; this decline is associated with an increase in 
the immune response against HCV (Rockstroh and Spengler, 2004). 
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Progression to the chronic phase is also more common in co-infected patients; 
and is likely due to immune response perturbation to the HCV infection (Danta et 
al., 2008). Patients diagnosed with HIV have a greater chance of proceeding to 
severe liver disease (Mohsen et al., 2002) and progress more rapidly to liver 
cirrhosis than patients with mono-infection. Progression to liver cirrhosis in co-
infected patients versus mono-infected patients occurs an average of 32 years 
after diagnosis versus 23 years (Mohsen et al., 2003). Patients with HCV cirrhosis 
who are HIV-infected also have a higher rate for progression to hepatocellular 
carcinoma (HCC). This occurs after a shorter time and in younger patients, with 
an estimated rate of 1-4% annually (Garcia-Samaniego et al., 2001, Singal and 
Anand, 2009). 
1.7 Methods used to study HCV 
1.7.1 Cell culture of HCV  
Kolykhalov et al. and Yanagi et al. were the first scientists to create a full 
consensus genome of HCV from a patient who had been infected with  genotype 
1a; this isolate was designated as “H77” (Kolykhalov et al., 1997, Yanagi et al., 
1997). It proved to be highly high infectious when inoculated into an animal 
model (chimpanzee). There were many attempts to establish replication of this 
and other genomes in vitro, but they were not immediately effective.  
 The first in vitro system developed successfully was the development of an 
HCV replicon using the non-structural part of the genome of the genotype 1b 
isolate Con1. In this model, replication-enhancing mutations (REMs) within NS3, 
NS4a and NS5A have been introduced that enhance replication within tissue 
culture but may interfere with the production of HCV infectious particles 
(Pietschmann et al., 2009). An adaptive mutation within NS4B of the Con1 
replicon (K1846T) reduces production of HCV infectious particles (Pietschmann 
et al., 2009). Recently, a modified H77 genome known as H77S has been created 
that contains several mutations that allow replication and also permits the 
production of HCV infectious particles (Yi and Lemon, 2009, Yi et al., 2006).  
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In 2001, Kato et al. developed a new subgenomic replicon based on genotype 2a 
called JFH1 that was able to replicate without adaptive mutations in cell culture 
efficiently (Kato et al., 2003, Kato et al., 2001, Date et al., 2004).  Four years 
later, a full JFH HCV genome was found that efficiently replicates in Huh7 cells 
and produces HCV infectious particles in both the tissue culture and in animal 
models (Lindenbach et al., 2005, Wakita et al., 2005, Zhong et al., 2005). This 
isolate and chimeric variants are now used widely in many research laboratories 
and are known as culture-derived HCV (HCVcc).  
 This system can be used to study the HCV life cycle starting from viral 
entry, HCV replication, genome packaging, HCV virion assembly and release of 
HCV as the last step of the life cycle. Electron microscopy showed circular 
particles with a diameter of 50-65 nm and the same density compared to other 
viruses from serum (Lindenbach et al., 2005, Wakita et al., 2005, Zhong et al., 
2005).  
 The viability of HCV recombinant particles was assessed by measuring the 
infectiousness of HCVcc in animal models including chimpanzees and mice 
possessing xenografts of human liver (Lindenbach et al., 2005, Wakita et al., 
2005). HCVcc recovered after passage in vivo were detected at high levels 
(Lindenbach et al., 2006).  These infectious viral particles derived from infected 
animal models exhibit lower levels of density in comparison with viral particles 
derived from cell culture, however. Following the first passage of cell culture, 
these characteristics (higher infectiousness and low density) disappear. HCVcc 
have been found to be susceptible to inhibitors that target the polymerase and 
protease as well as interferon-α (Lindenbach et al., 2005, Wakita et al., 2005, 
Zhong et al., 2005). 
 As the current HCVcc is based on genotype 2a, the challenge for the future 
is to find another genotype with the ability to produce infectious viruses in cell 
culture. In 2006 Yi et al. report the first infectious clone of a new genotype (1a) 
called H77S that contains 5 REMs. These 5 mutations were obtained following a 
long iterative procedure introducing multiple adaptations into the subgenomic 
replicon (H77); these adaptive mutations were located within non-structural 
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genes (Yi and Lemon, 2004). Virus recovered from transfection into Huh7.5 cells 
was lower in titre by about 100-1000 fold in comparison with JFH1 replicon.  
 Chimeric JFH-1 genomes 1.7.1.1
As described above, it is possible to create chimeric genomes by joining JFH1 
with heterologous HCV genotypes. So far, the essential elements for generating 
the membrane-bound replicase complex and non-translated areas are obtained 
from the JFH1 strain. Core to NS2 genes may be introduced from a different 
genotype. HCVcc particles were first formed using an intragenotypic chimera 
utilizing genotype 2a JFH-1 and J6 (Yanagi et al., 1997, Lindenbach et al., 2005). 
While JFH-1 grows in culture, J6 does not. Further studies were carried out to 
produce chimeras using JFH-1 and other genotypes.  
 An initial construct of the genotype 1b Con1 isolate carrying core to NS2 
genes was successfully created (Pietschmann, 2006). However, despite the 
production of infectious HCV, titres of HCV were low. Adaptations were 
introduced by creating different chimeras with varying crossover regions starting 
from the C-terminus of E2 up to NS2-NS3. Intensive analysis showed that a 
crossover position situated after the initial trans-membrane domain of NS2 is the 
best place to build new chimeras including JFH1-Con1, JFH-J6 and JFH1-H77 
(Pietschmann, 2006).  
 Several studies have shown similar findings about generating chimeric 
genomes of all seven different genotypes of HCV (Pietschmann, 2006, Gottwein 
et al., 2007, McMullan et al., 2007, Yi et al., 2007, Jensen et al., 2008, Scheel et 
al., 2008, Gottwein et al., 2009, Gottwein et al., 2011a, Scheel et al., 2011a) 
 In vivo, liver-chimeric mice have been used to assess titres of infectious 
particles following inoculation with different HCV genotypes (genotypes 1-6) 
(Bukh et al., 2010). The highest virus titre was obtained with a chimeric J6-
JFH1, called Jc1, that resulted in 106 of infectious HCV virus particles per ml of 
blood (Pietschmann et al., 2006).  
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A further advance has been the ability to construct a reporter genome from 
several HCV chimera genomes that contains luciferase or GFP in order to 
increase the detection of HCV infection (Koutsoudakis et al., 2006, Tscherne et 
al., 2006, Schaller et al., 2007).  Chimera construction has now been carried out 
to include the non-structural genes. Viable JFH1 chimeras have now been made 
that contain the non-structural proteins NS3/NS4A or NS5A was changed from 
other HCV genotypes (Gottwein et al., 2011b, Scheel et al., 2011a, Scheel et al., 
2011b), allowing researchers to study the activity of antiviral compounds against 
NS3/NS4A and NS5A. 
1.7.2 The HCV replicon system 
The propagation of HCV within cell culture (JFH-1 or chimeras of JFH-1) remains 
imperfect due to low levels of replication within cell culture and the need to 
carry out experiments in containment level 3 facilities. 
 However, it is possible to increase levels of replication in vitro using HCV 
complementary DNA (cDNA) that contains the sequence from the NS3-NS5B genes 
(Bartenschlager and Lohmann, 2001). The first HCV subgenomic replicons were 
derived from the HCV genotype 1b Con1 isolate. As well as the non-structural 
genes, this sub-genomic replicon contained the 5' UTR and the beginning of core 
protein (12 codons) linked with a marker gene (neomycin phosphotransferase 
(Neo)) allowing for G418 (geneticin) selection, an internal ribosome entry site 
(IRES) derived from the encephalomyocarditis virus (EMCV) and the 3' UTR from 
HCV (Lohmann et al., 1999).    
 The original sub-genomic Con1 replicon tends to result in a low frequency 
of G418 resistance of 1 colony per one million transfected cells (Lohmann et al., 
1999, Blight et al., 2000). This is due to adaptive mutations that are required to 
allow efficient replication within permissive cell lines. Analysis of Con1 replicons 
passaged in culture show several adaptive mutations within the non-structural 
protein region, particularly within NS5A (Blight et al., 2000) (Blight et al., 2000, 
Krieger et al., 2001, Lohmann et al., 2003, Lanford et al., 2003, Enomoto et al., 
1995, Enomoto et al., 1996).  
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A replicon derived from the Hutchinson genotype 1a strain (H77) has also been 
successfully created and requires a minimum of two adaptive mutations to be 
able to replicate efficiently within the cell culture system  (Blight et al., 2003, 
Grobler et al., 2003, Gu et al., 2003, Yi and Lemon, 2004). Such H77 replicons 
contain a mutation within the NS5A region (S2204I) that allows the replicon to 
replicate efficiently within human hepatoma cells 7.5 (Huh 7.5) (Blight et al., 
2002a, Blight et al., 2003).  
 Analysis of such replicons following passage has revealed that high 
replication efficiency of sub-genomic H77 is associated with an additional 
adaptive mutation (P1496L) within the nonstructural protein 3 (NS3) (Blight et 
al., 2003). A more robust H77 replicon was described by Voitenleitner et al. in 
2012 following the introduction of adaptive mutations within two other regions.  
 The first adaptive mutation was introduced within NS4A (K1691R) and the 
second within NS4B (E1726G). These two adaptive mutations have been found to 
substantially improve replication in vitro (Voitenleitner et al., 2012).  
 Following the development of new replicons, transient RNA replication 
assays were developed to measure the efficiency of replicon replication. 
Different reporter genes were used to measure replication following the RNA 
transfection into Huh 7.5 cells; these reporter gene include lactamase and 
luciferase (Blight and Norgard, 2006).  
 The luciferase gene is used as a reliable indicator for RNA replication, as 
production of each single luciferase gene indicates RNA synthesis. Firefly 
luciferase was introduced into a bicistronic sub-genomic replicons; replication 
can thus be measured and compared with a polymerase defective replicon that 
is designed to carry a mutation in the RNA (changing the GDD to GND). 
Generally, the adapted sub-genomic replicon (Con1) can replicate up to 100-fold 
higher than a defective replicon containing GND after 48 to 72 hours (Krieger et 
al., 2001).    
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1.7.3 Permissive cell lines for HCV replication  
HCV targets hepatocyte cells as the main site for replication, while other cells, 
such as dendritic cells, lymphocytes and monocytes, may be targeted by HCV 
although there is conflicting evidence regarding replication within these cells 
(Laskus et al., 2000, Goutagny et al., 2003). Huh 7.5 cells, a hepatoma cell line, 
were derived from Huh 7 cells following treatment with a high concentration of 
human interferon- α (IFNα). This allowed them to have a high tolerance to IFN, 
which assists the sub-genomic replication.  
 These cells are currently the most important permissive cell lines available 
at the time of writing. Their permissive behaviour is in part related to defective 
the retinoic acid inducible gene-I (RIG-I) production, a protein known to 
stimulate interferon production (IFN -type I) (Blight et al., 2002a, Sumpter et 
al., 2005). 
 In culture, Huh 7 and 7.5 cells are highly variable and permissiveness for 
infection is variable and relates to the number of passages carried out over 
time. This can make large differences, as much as 100-fold. These differences 
are not related to other factors such as adaptive mutations that were introduced 
to enhance the quality of sub-genomic replicon replication (Blight et al., 2002a, 
Blight et al., 2000).    
 The replicon system has been used to characterize HCV protein function, to 
study host-virus interactions and in vitro replication and can be readily altered 
using site-directed mutagenesis. In this thesis, a genotype 1a replicon system 
was used to investigate the impact of mutations that emerged in patients as a 
result of pressure from the T cell mediated immune response. 
1.7.4 Next-generation sequencing (NGS) 
Next-generation sequencing has dramatically changed the possibilities for viral 
population analysis within infected hosts. NGS can be used to examine HCV 
strains present as majority and minority variants and is far more reliable for 
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producing whole genome coverage than classical sequencing methods (Sanger 
sequencing).  
 As NGS is such a powerful technique, generating millions of sequence reads 
in a single run, a metagenomic approach can be used to identify whole viral 
genomes and as the technique is unselected (and does not require specific PCR 
primers) can be used to discover new viruses. NGS has recently been used to 
identify the aetiology of Merkel cell cancer (Feng et al., 2008) and to identify a 
novel bunyavirus in patient with “severe fever with thrombocytopenia 
syndrome” (Xu et al., 2011).  
 This metagenomic approach recently aided the characterisation of the 
virome in children with acute diarrhea and fever (Wylie et al., 2012). While this 
technique is powerful, it is inefficient as the majority of sequence reads 
produced is not viral in origin. It can be improved, as described later in this 
thesis by the use of target enrichment (magnetic beads attached to virus-
specific oligonucleotides) in order to purify the virus of interest.  
 This thesis describes the use of a metagenomic and target enrichment 
approach for sequencing HCV (and HIV in co-infected patients). 
 NGS using the Illumina platform 1.7.4.1
The Illumina platform is currently used more widely than other available NGS 
platforms due to efficiency and cost. The principle is based on a sequencing-by-
synthesis approach, meaning that the four nucleotides are added with DNA 
polymerase into a flow cell channel. These are detected as each nucleotide is 
associated with a separate fluorescent label (Zhang et al., 2011). The NGS 
process involves several steps 1) the addition of nucleotides to elongating 
strands of DNA; 2) the simultaneous detection of nucleotides to multiple DNA 
fragments; 3) A wash step removing fluorescent labels and allowing the next 
reaction to be detected (Mardis, 2011). This process is described further in 
Chapter 2.  
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The main error found when using the Illumina platform is a substitution error, 
meaning that an incorrect nucleotide is identified due to the de-blocking step 
not being well performed causing a cluster to fall out of phase or due to 
interface noise as a result of the incomplete cleavage of fluorescence label prior 
to DNA cycles (Mardis, 2013). However, Illumina currently produces data of 
higher quality than other platforms, with low error rates, making it the first 
choice for many genome-sequencing projects (Zhang et al., 2011).          
Next-generation sequencing creates a library of millions of DNA fragments. 
These DNA fragments may be read from both sides; this is called paired-end 
sequencing and allows for greater fragment lengths to be detected. This also 
enhances the analysis of the NGS data by providing overlap areas that are 
duplicated. Alignment scripts used to align sequences of interest to reference 
genomes take into account the length of the synthesized DNA fragments in the 
sequence library to reach the most accurate alignments (Korbel et al., 2007).           
 Errors and limitations of NGS 1.7.4.2
NGS requires a small number of non-specific PCR steps, and this may result in 
PCR-based error (Poh et al., 2013). The use of high fidelity polymerase enzymes 
and limiting the number of PCR cycles reduces this error to lower than that seen 
with traditional PCR-based methods. It is a highly sensitive technique and is also 
highly prone to cross-contamination error. 
 Sequence reads tend to be shorter using the Illumina platform than those 
generated using other methods e.g. Sanger sequencing. This is due to the signal-
to-noise ratio that limits the NGS read length (Mardis, 2013). Sequence read 
length is increasing over time with advances in Illumina-based technology. 
 Control samples may be included in each run to assess error rates (Hillier et 
al., 2008b). This can be used to give a detailed picture about 1) the type of error 
that has occurred within each sequence, for instance, deletion, insertion or 
substitution; 2) the kind of error mode that should be used to correct sequence 
reads and 3) missing regions from the sample sequenced (Mardis, 2013).    
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Many tools have been designed to align large amounts of data from short 
fragment reads created by NGS instruments against a reference genome. 
Defining variants or single nucleotide polymorphisms (SNP) or spotting an over or 
under-enriched region can be achieved using a variety of different methods.  
 Mapping 1.7.4.3
The most important step in NGS data analysis is the assembly and mapping of 
sequence reads to a reference sequence. As NGS produces a huge amount of 
data, two fundamental issues need to be considered: one is that the required 
usage of the data needed as NGS produces a huge amount of it and the other is 
the error profile. Traditional methods require several days to map the data to 
original reference genomes or computationally intensive software such as Smith-
Waterman dynamic programming, BLAT or BLAST. To overcome these problems, 
new methods have been developed.  
 Two bioinformatics researchers from Ohio State University initially 
introduced six different programs to overcome this problem and improved 
hash/index-based short sequence alignment to reference genomes. These six 
parallel methods include dividing the reads, dividing the genome, dividing reads 
and genome, suffix-based assignment (SBA), SBA after partitioning reads and SBA 
after partitioning genome. Another method called CloudBurst was introduced by 
Schatz et al. and used to read single-end reads.  
 Another two complementary algorithm methods were introduced by 
BreakDancer (BreakDancerMax and BreakDancerMini), which allow analysis of 
more than one pool and more than one library in more than one sample. New 
algorithm analysis software was introduced using quality scoring to obtain the 
maximum accurate analysis from fewer sequences; this software is called 
GNUMAP (Bao et al., 2011). Recently, more software has been developed and 
introduced to the market; examples of this are PASS (a program to align short 
sequences)(Campagna et al., 2009), SOAP (short oligonucleotide alignment 
program) (Li et al., 2008b), Bowtie, an ultrafast, memory-efficient short read 
aligner (Langmead et al., 2009), CloudBurst (Schatz, 2009), MAQ (mapping 
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quality) (Li et al., 2008a), ZOOM (Zillions of oligos mapped) (Lin et al., 2008), 
SHRIMP (accurate mapping of short colour-space reads) (Rumble et al., 2009), 
and PERM (efficient mapping of short sequencing reads with periodic full 
sensitive spaced seeds (Chen et al., 2009).  
 In this thesis, an in-house mapping programme called Tanoti (manuscript 
under review) designed by Dr Vattipally Sreenu was used to overcome errors 
related to the presence of highly divergent viral genomes. 
1.7.5 Enzyme-Linked ImmunoSpot (ELISPOT) assays 
The ELISPOT technique was established 1983 in Sweden by Cecil Czerkinsky’s 
group who were interested in defining antigen-specific Antibody Secreting B 
Cells (ASCs). Since then, ELISPOT has been modified for use in different 
applications and is used widely to monitor cellular immune responses in both 
humans and animals; this application has been found to be a clinically helpful 
tool in diagnosing tuberculosis and graft tolerance or rejection in transplant 
patients. The technique has been verified as one of the most effective 
methodologies used in monitoring the cells mediating immunity due to its 
accuracy and sensitivity in detecting low levels of antigen-specific T or B cells. It 
is capable of detecting one positive cell from a PBMC population; each spot 
represents a single reactive T or B immune cell. 
 The test gives both qualitative and quantitative measurement, as it 
qualifies specific cytokines such as IFN or other secreted molecules and 
quantifies the number of cells responding to stimuli. The high sensitivity of the 
ELISPOT test allows the detection of rare antigen-specific frequencies, which 
was difficult or impossible by other methodologies in the past.Aims and 
hypotheses  
 Patients with the HLA B27 allele were studied from a larger cohort of 
patients with acute HCV infection. These included individuals with and without 
HIV co-infection. 
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1.8 Aims and hypothesis  
We aimed to study the impact of the HLA B27 allele in defining the immune 
response in spontaneous clearance versus progression to chronicity in patients 
with and without HIV co-infection during the acute phase. 
 In order to achieve the above aim, we used the following methods: 
Next-generation sequencing to detect variation in the HCV genome over time in 
HLA B27+ patients with acute infection. 
2. Viral fitness of variants detected using NGS, quantified in the HCV genotype 
1a replicon system. 
3. T cell assays (ELISpot and flow cytometry) to characterize the adaptive 
immune response in HLA B27+ patients. 
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Chapter 2: Materials and Methods 
2.1 Materials 
Table 2-1 DNA Manipulation & Purification  
Solution Components 
Equilibration buffer (EQ1) 
0.1 M sodium acetate (pH 5.0), 0.6M 
NaCl, 0.15% (v/v) Triton X-100 
Cell Resuspension buffer (R3) 
50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 
100 μg/ml RNase A 
Lysis buffer (L7) 0.2 M NaOH, 1% (w/v) SDS 
Precipitation buffer (N3)            3.1 M potassium acetate (pH5.5) 
Wash buffer (W8) 
0.1 M sodium acetate (pH 5.0), 825 mM 
NaCl 
Elution buffer (E4) 100 mM Tris-HCl (pH 8.5), 1.25 M NaCl 
Buffer  
TBE (10x) 
0.9 M Tris-HCl, 0.9 M boric acid, 0.02 M 
EDTA 
TE buffer 10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA 
Agarose gel loading 5x TBE, 50% sucrose, 1μg/ml BPB 
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Table 2-2:  Cell lines 
Cells Description Source References 
Huh-7 cells 
Human hepatoma 
cell line 
Dr John McLauchlan                             
University of Glasgow 
Centre for Virus Research 
[CVR] 
(Lohmann et al., 1999) 
Huh-7.5 
cells 
Human hepatoma 
clonal cell line 
derived from 
Huh-7 cells 
Prof. Charles Rice                                     
[Rockefeller University] 
(Blight et al., 2002b) 
Huh-
7/SGR-
JFH1 cells 
Human hepatoma 
cell line 
harbouring the 
JFH1 subgenomic 
replicon 
Dr John McLauchlan                                      
[CVR] 
 
(Lohmann et al., 1999) 
 
Table 2-3: Enzymes 
Restriction enzymes  Source 
Mung bean nuclease New England Biolabs 
Taq polymerase Applied Biosciences 
 
Multiscribe RT 
Applied Biosciences 
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Table 2-4 Cell culture medium 
Component Source 
Dulbecco’s Modified Eagles Medium (DMEM) Gibco (Invitrogen Life Technologies) 
10% Fetal calf serum (FCS) Gibco (Invitrogen Life Technologies) 
100 units/ml Penicillin/streptomycin Gibco (Invitrogen Life Technologies) 
1x Trypsin (10x Stock) Sigma 
Phosphate buffer solution (PBS) Gibco (Invitrogen Life Technologies) 
 
Table 2-5 Commonly Used Chemicals 
Chemical Abbreviation Source 
Agarose - Melford 
Ampicillin Amp Melford 
Ethanol  
EtOH 
 
Fischer Scientific 
Ethidium bromide EtBr Sigma 
Methanol MeOH BDH Chemicals 
Sodium chloride NaCl BDH Chemicals 
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Table 2-6 Bacterial Expression   
Solution 
 
Component 
L-Broth 170mM NaCl, 10g/l Bactopeptone, 5g/l yeast extract 
L-Agar L-Broth plus 1.5% (w/v) agar 
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Methods 
2.1.1 Patient cohort  
In this study, patients were selected based on HLA type from two acute HCV 
cohorts recruited in St Mary’s Hospital, Imperial College London NHS Trust and 
Gartnavel Hospital, Greater Glasgow and Clyde. In this study, plasma and 
peripheral blood mononuclear cells (PBMC) were collected from patients 
prospectively at 1–3 monthly intervals and stored residual samples from the 
clinical virus laboratory were also available for analysis. Where appropriate, 
patients were offered treatment for 24-48 weeks with pegylated interferon 
alpha (pegINFα) and weight-based ribavirin following the diagnosis of HCV 
infection, according to local guidelines. Patients with spontaneous clearance did 
not receive treatment. Differences in study sampling times were due to 
differences in the availability of stored plasma samples obtained retrospectively 
after diagnosis. In some cases, infection had been present but remained 
undiagnosed for several months prior to recruitment into the study. 
 Written consent was obtained from each patient. The study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki. This 
work was a part of the study that was approved by the Riverside Research Ethics 
Committee and the West of Scotland Research Local Ethics Committee. 
2.1.2 Diagnosis of acute HCV 
Diagnosis of acute HCV was defined as a positive HCV RT-PCR test result within 
six months of a preceding negative HCV RT-PCR or antibody test. The infection 
date was calculated as the midpoint between the last negative and first positive 
test. Spontaneous clearance was defined as two sequential negative RT-PCR 
tests (<12 IU/ml) separated by a minimum of three months.  
 HCV viral load and liver function (measurement of ALT, bilirubin, and 
albumin levels) were assessed every month for a period of three months 
following initial diagnosis, and every three months subsequently. Immunology 
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tests such as CD4, CD8, and HIV quantification were assessed every three 
months.  
2.1.3 Patient treatment outcome 
Patients were classified as having had a sustained virological response (SVR) if 
they remained negative using HCV RT-PCR for 24 weeks after the last treatment 
dose (2014). Failure to respond to treatment was defined as relapse (detectable 
viral load after a negative viral load at the end of treatment), null response 
(<2log10 drop in viral load during treatment) or partial response (>2 log10 drop in 
viral load during treatment but failure to become PCR negative). 
2.1.4 Storage of blood samples: 
Blood samples were collected in a Vacutainer® blood collection tube containing 
EDTA. Plasma and PBMCs were separated by desity-gradient centrifugation. 
Plasma was stored in 2 ml tubes at –80 °C and PBMCs in liquid nitrogen at -
140°C.  
2.1.5 RNA Extraction  
Plasma was thawed on ice prior to ribonucleic acid (RNA) extraction. Two 
different methods were used during the study: initially, manual extraction was 
carried out using a QIAamp® Viral RNA kit (Qiagen) following the manufacturers’ 
instructions; subsequently, extraction was automated using an automated 
platform; EasyMAG® (Biomerieux).  
 QIAamp® Viral RNA kit (Qiagen) 2.1.5.1
Sample processing was carried out by mixing 140 μL of plasma and 560 μL cell 
lysis buffer (buffer AVL) containing 5.6 μL carrier RNA. The mixture was 
incubated for 10 min at room temperature before adding 560 μL of ethanol. The 
solution was then transferred into columns and centrifuged at 8,000 g.  
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Two washing steps were then carried out: 500 μL of wash buffer AW1 was added; 
the sample was centrifuged at 8,000g, 500 μL of wash buffer AW2 was added; 
centrifugation at 8,000g was repeated.   
 A further step was carried out to remove any remaining ethanol from the 
washing buffer, since this can affect the RNA yield.  Finally, the RNA was eluted 
using 60 μL of AVE buffer (RNase-free water containing 0.04% sodium azide). 
 EasyMAG® NucliSENS Extractor 2.1.5.2
Extraction with the EasyMAG® was performed according the manufacturers’ 
instructions. Briefly, 400 µL of each sample was loaded on to a disposable 
sample vessel, which was then loaded onto the EasyMAG®.  Following the initial 
lysis incubation, 100 µL of magnetic silica was added to each sample. Samples 
were eluted in 60 µL of elution buffer and before being transferred to a 1.5 ml 
microcentrifuge tube and stored at –80°C. 
2.1.6 cDNA Synthesis 
Complementry DNA (cDNA) synthesis was carried out using either Superscript III 
(Invitrogen) or Maxima H (Thermo Scientific) according to the manufacturers’ 
instructions.  
 Superscript III ® reverse transcriptase kit 2.1.6.1
The Superscript III RT-PCR kit (Invitrogen) was used to reverse transcribe-
extracted RNA into complementary DNA (cDNA) using random hexamers. A 
solution containing 15µL extracted RNA, 1µL random hexamers, and 9µL of 10 
mM dNTPs was heated at 70°C for 5 minutes. The mixture was then placed on 
ice for 5 minutes. Reverse transcription was carried out by adding 9 µL of 5X 
First-stand Buffer, 2 µL of 0.1 M DTT, 4 µL of RNAse OUT (20 u/µL), and 1 µL of 
Superscript III enzyme, and incubating the reaction mixture at 50°C for 90 
minutes.  
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Following this, a further 1 µL of Superscript III was added and the temperature 
was increased to 55°C for a further 90 minutes. Superscript III was inactivated at 
70°C for 15 min, then 1 µL of RNAse H was added and the mixture was incubated 
for 20 min at 37°C.  
 Maxima H Minus Reverse Transcriptase® 2.1.6.2
Complementary DNA (cDNA) was prepared using Maxima H minus reverse 
Transcriptase® (Thermo Scientific) by adding 1 µl of random hexamer primers 
and 1 µl NTPs to 13 µl extracted RNA. The mixture was incubated at 65°C for 5 
min before being placed on ice to chill. Subsequently, 4 µl of 5X reverse 
transcriptase buffer and 1 µl of reverse transcriptase were added and the sample 
was incubated for 10 min at 25°C followed by 60 min at 65°C. The reaction was 
terminated by incubation at 85°C for 5 min.    
2.1.7 DNA second strand synthesis  
The Second Strand Synthesis kit from New England Biolabs was used to make 
double stranded cDNA. The cDNA products described in Section 2.1.6 were mixed 
with 8 μL of 10X second strand synthesis reaction buffer, 4 μL of second strand 
synthesis enzyme, and 48 μL of nuclease-free water. The reaction mixture was 
incubated at 16°C for 2.5 hours.  
2.1.8 Quantitative RT-PCR assays  
Real-time PCR reactions were amplified using fast universal conditions on a 7500 
Fast Real-Time PCR machine (Applied Biosystems). The total volume of Real-
Time PCR Reaction Mix was 18 μL prepared as follows: 1 μL of 18m Forward 
Primer, TCTGCGGAACCGGTGAGTAC (Final 900nM), 1 μL of 18m Reverse Primer, 
GCACTCGCAAGCACCCTATC (Final 900nM), 1 μL of 5m FAM Probe, FAM-
AAAGGCCTTGTGGTACTG-MGB (250nM), 10 μL of TaqMan Fast Universal Mix® (2x), 
and 5 μL of nuclease-free water, with 2 μL cDNA added to each well of 96 well 
plates.  
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After covering the plate with an adhesive seal, it was centrifuged for 1 min on 
1000 RPM before performing the Thermal Cycler Protocol, which involves initially 
holding at 95°C for 20 sec, before moving on to the second stage of 40 cycles of 
the following steps: 1) hold at 95°C for 3 sec, and 2) hold at 60°C for 30 sec. 
2.1.9 Gel electrophoresis  
PCR products were run on a 1% or 2% agarose gel containing ethidium bromide 
(Life Technologies). PCR products were mixed with 10X BlueJuice® gel loading 
buffer (1:10) (Invitrogen). DNA ladders of 100 bp and 1 Kbp (Promega) were used 
to determine sizes of DNA fragments, with choice of ladder based on the DNA 
fragment size that needed to be excised. DNA bands were visualised under 
ultraviolet light and appropriate bands were cut out using a clean scalpel blade. 
2.1.10 DNA purification 
 Purification of DNA from agarose gels 2.1.10.1
The DNA fragment of interest was excised from an agarose gel, placed in a 
microcentrifuge tube and weighed. Binding buffer was added at a ratio of 1:1 
weight:volume. The chaotropic agent in the binding buffer dissolves agarose, 
denatures proteins, and promotes DNA binding to the silica membrane in the 
column. The mixture was incubated at 60°C for 10 minutes, or until the gel slice 
was completely dissolved and the colour of the solution had changed to yellow 
(indicating optimal pH for DNA binding). Subsequently, 800 μL of the solubilised 
gel solution was transferred to a purification column and centrifuged for 1 
minute at 13,000 rpm.  
 The flow-through was discarded, the column was placed back into the same 
collection tube, and 100 μL of binding buffer was added to the purification 
column. The column was centrifuged for one minute, the flow-through was 
discarded, and the column was returned to the same collection tube. Next, 700 
μL of wash buffer was added to the purification column and centrifuged for one 
minute. The flow-through was discarded, and the column was returned to the 
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same collection tube. The empty purification column was centrifuged for an 
additional minute to completely remove residual wash buffer. For elution, 50 μL 
of elution buffer was added to the centre of the purification column membrane, 
and the purification column was transferred into a clean 1.5 ml microcentrifuge 
tube and centrifuged for one minute. Purified DNA was stored at –20°C. 
 Agencourt AMPure XP® beads 2.1.10.2
Magnetic beads were warmed to room temperature before use. DNA was added 
to the beads, mixed thoroughly, and incubated for 3–5 minutes at room 
temperature.  The reaction was placed on a magnetic plate for 5–10 minutes to 
separate the beads from the solution. Once separation was complete, the liquid 
was aspirated from the reaction tube and discarded. Beads were washed twice 
by adding 200 μL of freshly made 80% ethanol. DNA was eluted in 40 μL of 
nuclease-free water (Figure 2-1). 
Figure 2-1: Agencourt AMPure XP beads workflow 
                       
 
1.Addition of AMPure XP. 2. DNA fragments binding to specific paramagnetic beads. 3. Magnets applied to 
seperate beads with attached DNA fragments from the solution containing contaminants. 4. Beads with 
attached DNA fragments were washed twice with 80% Ethanol to remove contaminants. 5. DNA fragments 
were eluted from magnetic beads. 6. Transfer of eluate to fresh tube (Source: Beckman Coulter user 
guide). 
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2.1.11 Measuring DNA concentration 
 Measurement of nucleic acid concentration using Qubit® 2.1.11.1
A Qubit working solution was prepared by mixing 199µL of buffer and 1µL of dye 
for every sample to be tested and vortexing. Standards were prepared by adding 
190 µl of working solution to 10 µl of Standard 1 (representing 0 ng/ µl) and 
Standard 2 (10 ng/µl) and vortexing. Samples were measured by adding 198 µl of 
working solution to 2 µl of each sample and vortexing.  
 All standards and samples were contained in tubes provided by 
manufacturer during Qubit analysis. DNA concentration was measured using a 
Qubit® 2.0 Fluorometer (Invitrogen). To measure DNA quantity, a Qubit® ds DNA 
High Sensitivity Assay kit was used. During RNA quantification, the Qubit® RNA 
Assay Kit was used. The fluorometer calculates the nucleic acid concentration in 
the original suspension and displays the result in ng/μL. 
 Nucleic acid QC using the 2200 TapeStation 2.1.11.2
The Agilent 2200 TapeStation® system is an automated electrophoresis platform 
that has flexible throughput capabilities, which can be used from one sample up 
to a 96-well plate.  D1K ScreenTape analysis on the 2200 TapeStation allows the 
analysis of DNA fragments of sizes ranging from 35 bp to 1000 bp. It is therefore 
suitable for analysing library preparations. Analysis was carried out following the 
manufacturers’ instructions. Libraries were prepared for TapeStation analysis by 
mixing 1 μL of sample with 3 μL of D1K Sample Buffer Mixtures are loaded on to 
the TapeStation.  
 For the R6K, protocols are similar with the exceptions that 1 μL High 
Sensitivity R6K Sample Buffer is mixed with 2 μL of RNA sample, and that 
samples are denatured by incubation at 72°C for three minutes before being 
placed on ice for two minutes. We then place the samples on ice for 2 minutes 
before briefly centrifuging the samples to collect the contents in the base of the 
tubes.  
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2.1.12 Bacterial cloning   
 TOPO-TA® Cloning kit  2.1.12.1
A mixture was made containing 4 μL of PCR product, 1 μL of salt solution 
containing 1.2M NaCl and 0.06M MgCl2, and 1 μL of TOPO
® vector.  The mixture 
was incubated at room temperature for 30 minutes. The PCR product disrupts 
the expression of the lethal E.coli suicide gene ccdB, therefore only colonies 
containing the PCR product will grow when the mixture is transformed into One 
Shot® TOP 10 cells (Invitrogen). 
 Transformation was carried out as follows: 2 μL of the PCR product/TOPO 
vector mixture was added to a vial of chemically competent One Shot® TOP10 
E.coli cells and incubated on ice for 30-60 minutes. Cells were then heat-
shocked for 30 sec at 42°C  before being transferred back to ice immediately 
and incubated for a further 5 minutes before adding 250 μL of SOC medium (2% 
tryptone, 0.5% yeast extract 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose).  
 The resulting mixture was shaken horizontally (300 rpm) at 37°C for 50-90 
minutes. An aliquot of 100 μL from each transformation vial was spread on a pre-
warmed agar plate containing 100 μg/ml ampicillin or 30 μg/ml tetracycline 
depending on the plasmid antibiotic selection gene used. Plates were incubated 
overnight at 37°C. Separate colonies were then picked and processed to clonal 
analysis. 
 CloneJET® PCR cloning kit 2.1.12.2
The CloneJET® PCR Cloning Kit from (Thermo Scientific) was used to clone PCR 
products generated by proofreading DNA polymerases, such as Pfu DNA 
polymerase. The first step is a ligation reaction containing the following 
components: 1 μL of 2X Reaction Buffer, 100 ng of PCR product, 1 μL of plasmid 
vector, and nuclease-free water to a final volume of 20μL. Samples were 
incubated at room temperature for 30 minutes.  
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2.1.13  High efficiency transformation protocol  
 One shot® Top 10 cells 2.1.13.1
One shot® Top 10 cells from Invitrogen® were used following the manufacturer’s 
protocol. First, the vial containing the cells was thawed on ice, using one vial of 
One Shot® TOP10 chemically competent cells for each transformation. Next, 
approximately 5 μL (depending on the DNA concentration) of DNA (10pg to 100 
ng) was added into a vial of One Shot® cells and mixed gently. We avoided 
mixing the vial containing the DNA and the cells by pipetting up and down. The 
vial(s) were incubated on ice for 30 min. They were next heat-shocked for 
exactly 30 sec at 42°C without shaking, removed from the bath, and placed on 
ice for 2 min.  
 Aseptically 250 μL of pre-warmed SOC Medium was added to each vial. The 
vial(s) was capped tightly and shaken horizontally at 37°C for 1 hour at 225 rpm 
in a shaking incubator. Afterwards, 150 μL from each transformation were 
spread on a pre-warmed selective plate and incubated for 24-36 hours at 30°C. 
next, the remaining transformation mix stored at 4°C, before continuing to a 
downstream step.  
 NEB 10-beta Competent E. coli 2.1.13.2
One tube of NEB 10-beta Competent E. coli cells was thawed on ice. Once 
thawed, 50ng of plasmid DNA was added in a volume of 1-5 μL. Mixing was done 
by flicking the tube 4-5 times. The mixture placed on ice for 30 minutes before 
being heat-shocked at 42°C for 30 sec. Following heat shock, the mixture was 
returned to ice for five minutes before 950 μL of it was pipetted into SOC 
medium and the resulting mixture was placed on a shaker (250 rpm) at 37°C for 
60 min. Once this incubation was complete, 200ul of the mixture was spread on 
an agarose plate containing antibiotics for colony selection and incubated at 
30°C for 24-36 hours.  
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2.1.14 Preparation of DNA following bacterial cloning  
 Small scale plasmid preparation from transformed bacteria  2.1.14.1
The GeneJET Plasmid Miniprep Kit (Thermo Scientific) was used to extract DNA 
from colonies. To purify high-copy plasmids, 5 ml of E. coli culture was used. 
Bacterial cultures were harvested by centrifugation at 8000 rpm in a 
microcentrifuge for 2 min at room temperature. The supernatant was decanted 
and pelleted cells were resuspended in 250 μL of resuspension solution. The cell 
suspension was transferred to a microcentrifuge tube: the bacteria were 
resuspended completely by pipetting up and down until no cell clumps 
remained.  
 Once this was done 250 μL of the lysis solution was added and mixed 
thoroughly by inverting the tube 4-6 times until the solution became viscous and 
slightly clear, before subsequently adding 350 μL of the neutralisation solution 
and mixing by inverting the tube 4-6 times.  
 The suspension was centrifuged for 5 min to pellet cell debris and 
chromosomal DNA. The supernatant was transferred to a GeneJET spin column. 
The column was centrifuged for 1 min. The flow through was discarded and the 
column was returned to the same collection tube. The column was washed twice 
by adding 500 μL of wash solution, centrifuging for 30-60 sec, and discarding the 
flow-through.  
 We returned the column to the same collection tube and centrifuged for an 
additional minute to remove residual wash solution. The GeneJET spin column 
was transferred to a into a fresh microcentrifuge tube and 50 μL of the Elution 
Buffer was added to the centre of the column membrane to elute the plasmid 
DNA. It was incubated for two minutes at room temperature and then 
centrifuged for two minutes. The eluate was collected for downstream 
applications. 
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 Large scale plasmid preparation from transformed bacteria 2.1.14.2
The GeneJET Plasmid Midiprep Kit (Thermo Scientific) was used to extract DNA 
from LB broth culture. After growing up to 50 mL of bacterial culture to an 
OD600 of 2-3, cells were harvested by centrifugation for 10 min at 5,000 x g, 
with the supernatant being discarded. The pelleted cells were resuspended in 2 
ml of resuspension solution. Lysis was carried out by adding 2 ml of lysis solution 
and mixed by repeatedly inverting the tube until the solution became viscous 
and slightly clear. (Vortexing should be avoided as it results in the shearing of 
chromosomal DNA.)  
 The tube was incubated for 3 min at room temperature (longer incubations 
should be avoided as it can cause denaturation of supercoiled plasmid DNA). 
Following this incubation, 2 ml of neutralisation solution was added and mixed 
immediately by inverting the tube 5-8 times before adding 500 μL of the 
Endotoxin Binding Reagent and again mixing by repeated inversion.  
 The mixture was incubated for five minutes at room temperature, before 
adding 3 mL of 96% ethanol and mixing by repeated inversion. The mixture was 
centrifuged for 40 minutes at 4,000-5,000 × g to pellet cell debris and 
chromosomal DNA. The supernatant was then transferred to a 15 mL tube by 
pipetting, while avoiding disturbing the white precipitate. Subsequently, 3 mL of 
96% ethanol was added and mixed by repeated inversion. Approximately 5.5 ml 
of the sample was transferred to the supplied column pre-assembled with a 15 
ml collection tube. The column was centrifuged for three minutes at 2,000 ×g.  
 The flow-through was discarded and the column was returned to the same 
collection tube. Centrifugation was repeated to process any remaining lysate 
through the purification column. The sample was washed by adding 4 ml of Wash 
Solution I to the purification column and centrifuging for 2 min at 3,000 × g. 
Flow-through was discarded and the column was returned to the collection tube 
before adding 4 mL of Wash Solution II and repeating centrifugation as for Wash 
Solution I.  
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Flow-through was discarded and the column was returned to the collection tube. 
Washing with Wash Solution II was repeated with a centrifugation for 5 min at 
3,000 × g to remove residual wash solution. Once this was completed, the 
column was transferred into a fresh 15 mL collection tube and 350 μL of elution 
buffer was added to the centre of the purification column membrane.  
The column was incubated for 2 min at room temperature before centrifuging 
for 5 min at 3,000 × g to elute plasmid DNA. 
 Alignment of NGS Data  2.1.14.3
Sequences obtained from NGS were mapped to the H77 reference genome 
sequence of HCV genotype 1a and 64 other reference (Smith et al., 2014) 
genomes  using an in-house bioinformatics pipeline; Tanoti which is available at 
http://www.bioinformatics.cvr.ac.uk/tanoti.php.  
 NGS raw data analysis and quality assessment.  
The quality of NGS raw data was assessed using FastQC® (Babrahman 
Bioinformatics). Low quality sequence (normally located toward the end of the 
second read when using paired-end sequencing) was filtered, cleaned, and 
removed, with the aim of reaching a phred score of Q30 (1 in 1000, 99.9).  
2.1.15 Nucleotide sequencing and analysis 
2.1.16 Illumina bioinformatic analysis 
 Removal of custom adaptors  
Prior to sequencing, more than one adaptor was used to prepare the NGS library. 
When analysing sequences bioinformatically, these custom adapters were 
removed from the Nextera® library using the Trim galore command. This resulted 
in cleaned sequences being shortened by approximately 15% from 150bp to 
131bp DNA fragment length. This step improved the quality of DNA fragment to 
Phred quality scores of at least Q30.  
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2.1.17 Human hepatoma cells (Huh7.5) 
Human Hepatoma Cells Huh7.5 (derived from Huh7 cells harbouring HCV replicon 
subjected to interferon treatment) (Blight et al., 2002a) were propagated in an 
incubator at 37°C and with 5% CO2 in Dulbecco’s modified Eagle’s medium 
(DMEM) with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin. Cell lines 
were typically grown in 175 cm2 tissue culture flasks (Nunc).  
 Passage was carried out when cells reached 80% of confluence (typically 
twice per week) by adding 5 ml of ice-cold phosphate buffer saline (PBS) twice 
and passing over the cell surface by gently rotating the flask. This wash step was 
used to remove dead cells and any residual fetal bovine serum. This was 
followed by adding 3ml of 0.05% Trypsin/EDTA to de-attach the cells from the 
flask. Cells were re-suspended in 10 ml of complete DMEM before re-seeding or 
use in experiments.  
2.1.18 In vitro transcription 
 Site-Directed Mutagenesis 2.1.18.1
Mutagenesis reactions were performed using the Quick Change II XL Site-Directed 
Mutagenesis kit (Stratagene), according to the manufacturer’s instructions.  The 
Quick Change site-directed mutagenesis kit is used to make point mutations. 
Forward and reverse primers (Table 2-8) were designed according to instructions 
detailed by SDM primers. The desired mutation(s) were included in the middle of 
the primer sequence of length between 25 and 45 bases.  
 A PCR mixture of 50 μL consisted of 50 ng plasmid DNA template, 5 μL of 
10x reaction buffer, 1.25 μL each of 10 μM forward and reverse mutagenic 
primers, 1 μL of dNTPs, 1.5 μL of Quick solution (which improved linear 
amplification), and 1 μL of pfu ULtra high-fidelity (HF) DNA polymerase. The PCR 
conditions are shown below (Table 2-7). Following amplification, each reaction 
was chilled on ice for 2 minutes before adding DpnI restriction enzyme (10 units) 
to digest the non-mutated dam-methylated parental DNA.  
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Table 2-7  PCR  cycle for Site-Direct mutagenesis 
Segment Cycles Temperature Time 
1 1 95°C 1 minute 
2 18 95°C 50 seconds 
60°C 50 seconds 
68°C 1 minute/kb of plasmid length 
3 1 68°C 7 minutes 
PCR cycling conditions for the site-directed mutagenesis method used to introduce mutations during 
replicon experiments. 
 
The reactions were gently mixed by pipetting and then centrifuged at 13,000 
rpm for one minute, before incubating at 37 oC for one hour. Following 
incubation, 2 μL of the DpnI-treated DNA was transformed into NEB 10-beta 
competent E. coli cells as described in Section 2.1.13.2. 
 Introduction of mutations into the HCV-1a subgenomic replicon 2.1.18.1
Several mutations found within and outside an immunodominant HLA B27-
restricted epitope within NS5B (NS5B2841-2849) were introduced into the 
SG/Luc/HCV-1a replicon using site-directed mutagenesis. Ten colonies from each 
agar plate were selected and used to prepare plasmid mini-preps as described in 
Section 2.1.14.1. Plasmids obtained from the mini-prep were sequenced using 
Sanger sequencing with appropriate sequencing primers and aligned using CLC 
Genomics software to assess the successful introduction of mutations.   
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Figure 2-2: Site-direct mutagensis 
 
An overview of the QuickChange II XL site-direct mutagenesis method (adapted from the QuickChange II XL 
protocol). 
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 Oligonucleotide Synthesis for Site-Direct Mutagenesis 2.1.18.2
Site direct mutagenesis primers was designed using web-based application 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). Following the 
addition of HCV sequence, specific nucleotides were changed by identifying 
alternative nucleotides based on the NGS sequencing analysis.  
Table 2-8: Oligonucleotide sequences designed for site direct mutagenesis: 
Oligo name Sequence Bases 
A2841V-Fore CCC-CCA-CAC-TGT-GGG-TGA-GGA-TGA-TAC-TGA-T 31 
A2841V-Rev ATC-AGT-ATC-ATC-CTC-ACC-CAC-AGT-GTG-GGG-G 31 
R2842V-Fore CCC-CAC-ACT-GTG-GGC-GGT-GAT-GAT-ACT-GAT-GAC-C 34 
R2842V-Rev GGT-CAT-CAG-TAT-CAT-CAC-CGC-CCA-CAG-TGT-GGG-G 34 
M2843V-Fore CAC-ACT-GTG-GGT-GAG-GGT-GAT-ACT-GAT-GAC-CCA 33 
M2843V-Rev TGG-GTC-ATC-AGT-ATC-ACC-CTC-ACC-CAC-AGT-GTG 33 
I2844V-Fore CAC-TGT-GGG-TGA-GGA-TGG-TAC-TGA-TGA-CCC-ATT-TC 35 
I2844V-Rev GAA-ATG-GGT-CAT-CAG-TAC-CAT-CCT-CAC-CCA-CAG-TG 35 
 
2.1.19 DNA digestion  
DNA digestion was carried out using NEB restriction enzymes and buffers at 37°C 
for two hours unless otherwise specified. In each case, the total reaction volume 
was 50 μL, which included 10 ul units of restriction enzyme for 10μg DNA. 
Reactions utilised the supplier cut smart buffer and BSA, unless stated 
otherwise.  
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Figure 2-3 Subgenomic replicon (APP 238 pH/SG-Neo (L+I) 
 
 
Plasmid encoding a genotype 1a HCV subgenomic replicon was supplied by Apath. (Figure provided by 
Tamer Abdelrahman). 
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2.1.20 DNA ligation 
A DNA Ligation kit from Thermo Scientific was used for DNA ligation reactions. 
The aim of ligation was to introduce the intermediate insert into the plasmid 
vector. The inserts containing the specific mutations were introduced and then 
analysed in vitro. In all cases, the SG/Luc/HCV-1a replicon was used as a vector. 
Material Volume (μL) 
Linearised vector DNA 100 ng 
Insert DNA (at 3:1 molar excess over vector) Variable 
5X Rapid Ligation Buffer 4 μL 
T4 DNA Ligase, 5 u/μL 1 μL 
Water, nuclease-free Up to 20 μL 
Total reaction volume 20 μL 
 
 Linearisation of HCV genomic plasmid DNA and sub-genomic 2.1.20.1
replicon (SGR) DNA 
SGR plasmids were linearised using the restriction enzyme XbaI. 10 μg of plasmid 
DNA was digested in a total volume of 50 μL. The reaction was incubated at 37 
οC for two hours. Linearised DNA was purified using magnetic beads (Section 
2.1.10.2) before adding mung bean nuclease (2 units). The reaction was 
incubated for 30 minutes at 30 οC. This step enables the sticky end (generated 
during Xbal digestion) to be removed completely.  
 Linearised DNA was purified using magnetic beads (Beckman Coulter, USA). 
HCV genomic plasmids were processed using the same protocols but with 
different restriction enzymes: two single cutter enzymes (Bsu36I and ClaI) were 
used to separate the region of interest containing the desired mutation which 
had been already introduced using site-direct mutagenesis from the 
intermediate replicon.  
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 Transcription procedure 2.1.20.2
In vitro transcription was performed using the T7 RiboMAX Express Large Scale 
RNA Production System (Promega). The reaction was carried out in a volume of 
20 μL, which consisted of a RiboMAXTM Express T7 2X Buffer, a linear DNA 
template (1μg total), an enzyme Mix, a T7 Express and nuclease-free water. The 
reaction was mixed gently and incubated at 37°C for 60 minutes. Following 
incubation, 1-2 μL of transcribed RNA was examined on an agarose gel to check 
the RNA quality before electroporation of the RNA into Huh 7.5 cells.  
 Electroporation of RNA into Huh 7.5 mammalian cells 2.1.20.3
Cells were trypsinised and transferred into the appropriate volume of DMEM 
medium. Cells were centrifuged at 1500 rpm for five minutes at room 
temperature. Supernatant was removed, and cells were re-suspended in 5 ml of 
PBS before centrifugation for 5 minutes at 1500 rpm. Supernatant was discarded 
and the cells were re-suspended into a volume of PBS that was appropriate to 
produce a cell density of approximately 1x106 cells/ml.   
 For electroporation, 1 ml of re-suspended cells was transferred into a 
cuvette (4 mm gap, Apollo) and 10 μg of transcribed RNA was added to the 
cuvette. Electroporation was done using a Bio-Rad Gene Pulser. Electroporated 
cells were mixed with DMEM complete medium seeded into 24 well plates at 
2x105 cells/well. Seeding was carried out in duplicate wells. Plates were 
incubated at 37°C in a humidified incubator with 5% CO2. Plates were checked 
for bioluminscence at 4 hours, 24 hours, 48 hours, 72 hours, 96 hours and 120 
hours post transfection. 
 Firefly luciferase activity assay 2.1.20.4
  Following the electroporation of Huh 7.5 cells with sub-genomic viral RNA 
carrying the luciferase reporter enzyme, the media wasremoved and the wells 
were washed twice with PBS (200 µL/well). Cells were lysed using a 1X cell 
culture lysis buffer (Promega) by adding 100 μL and then incubating for five 
 98 | P a g e  
minutes at room temperature, before transferring 50 μL of lysate to a 
microcentrifuge tube containing 100 μL of luciferase assay substrate (Promega). 
The mixture was vortexed and luciferase activity was measured using a GLOMAX 
luminometer (Turner Biosystems). Luciferase assays were performed in 
duplicate.  
2.1.21 Enzyme-linked immunospot (ELISPOT) assay 
Based on HCV Genotype 1a (H77), overlapping peptides were used as described 
below (supplied by BEI Resources), covering the whole HCV genome (Core, E1, 
E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B). Peptides were pooled together in 
ten different pools. The specific HCV T-cell response was measured following 
overnight incubation with peptide pools. Thawed PBMCs were tested from 
spontaneous clearer and progressor patients.  
 A 96-well plate pre-coated with capture mouse anti-human IFN-γ mAb (1 
DIK, Mabtech) was used. Plates were initially washed four times with PBS (200 
μL/well) and then blocked with 200 µL/well  R10 media (RPMI 1640, Sigma-
Aldrich: 10 mol/l Hepes buffer, 2 mmol/l glutamine; and 50 U/ml penicillin-
streptomycin, 10% fetal calf serum) and incubated for 30 minutes at room 
temperature.  
 Peptides were added at a final concentration of 6 µg/ml with 2.0x105 
PBMCs and incubated overnight at 37°C in a humidified incubator with 5% CO2. 
Plates were washed five times with PBS (200μL/well). Detection antibody (7-B6-
1- biotinylated secondary mouse anti-human IFN-γ  mAb (Mabtech)) was diluted 
to 1 μg/ml with PBS containing 0.5% fetal calf serum and 100 μL/well of 
detection antibody was added to plates and incubated for two hours at room 
temperature.  
 Plates were rinsed five times with PBS, and 100 μL streptavidin-alkaline 
phosphate (Mabtech) was added and incubated for 1 hour. Excessive conjugate 
was removed by washing with PBS. Following this, 100 μL of filtered (BCIP/NBT-
plus) substrate solution (Mabtech) was added and plates were incubated until 
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the spot colour started to be distinct. The reaction was stopped by washing the 
plates in the sink extensively. Plates were left to dry and spots were calculated 
using an automated ELISpot reader (AID ELISPOT Reader System, Autoimmune 
Diagnostika Gmbh). Phytohemagglutinin (PHA 250mg/ml), Influenza, Epstein-
Barr virus and Cyromegalovirus (FEC) were added to each plate and used as a 
positive control to validate the sensitivity of the assay. For the negative 
controls, cells were added without any peptides (stimuli) and 1 μL of DMSO 
added. Analysis was carried out using an automated ELISpot reader (AID). 
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Figure 2-4 The ELISpot procedure 
 
 
The stages of the ELISpot procedure A) Capture antibody is used to coat the wells. B) Incubation of the 
PBMC cells and peptides. C) Cytokine is secreted and binds to the capture Ab. D) Addition of specific 
detection antibodies (biotinylated cytokine). E) Streptavidin-enzyme conjugate added. F) Substrate is 
added to form a colour as a final step before reading the spots on a reader. 
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2.1.22 Peptides: 
Peptides based on HCV virus H77 (genotype 1a) (genotype 1a; GenPept: 
AAB67036) were obtained free of charge from BEI Resources. These peptides 
cover the entire HCV genome (Core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, 
NS5B). Each peptide was shipped as lyophilised powder (1 mg per vial). Peptides 
are supplied as 13 to 18-mers with overlaps of approximately 11 to 12 amino 
acids.   
 The core protein was covered by a core peptide pool of 28 peptides, E1- 29 
peptides, E2 - 56 peptides, p7 8 peptides and NS2 32 peptides respectively. NS3 
was spanned by two pools of 49 and 47 peptides. NS4A and NS4B were covered 
by an NS4A and NS4B pool (47 peptides). The NS5A peptide pool contained 71 
peptides. NS5B was split into 2 pools of 45 peptides. The final concentration of 
each peptide pool was 6 μg/ml, which were used in the ELISpot experiments to 
stimulate the PBMCs.  
2.1.23 Flow cytometry  
PBMCs obtained from HLA-B27 patients were thawed in R10 and 100μl of 1-2x106 
live cells/well were added to a 96 well plate. Cells were washed with 100μl PBS, 
spun at 1500g for 5 min and resuspended in 50 μl PBS. Cells were stimulated 
overnight with peptides (for stimulation flow cytometry) or stained directly with 
antibody panels 1 and 2. 1ul of live/dead stain was added to the cells, 
resuspended in PBS (50 ul) and incubated shielded from light for 20 min at room 
temperature.  
Cells were then washed again with 50ul PBS. Next, the cells were re-
suspended in FACS fix solution (2%), mixed carefully to ensure no clumping, then 
incubated at room temperature for 20 min, protected from light. Cells were 
then washed and resuspended in PBS and incubated overnight.  
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At the same time, panel 2 were permeablised by adding 100 ul of Perm buffer, 
spun at 1600 rpm for 5 min and 100 µl was added to panel 1 (Table 2-9). 
Pentamers was centrifuged at 14000g for 10 min in a chilled centrifuge and 1μl 
added to the cells and incubated for 20 min at room temperature protected 
from light. Secondary antibodies were added and incubated shielded from light 
for 30 min (Table 2-10).   
 Table 2-9: Flow cytometry panels 
Panel 1 
 
Panel 2 
1/50 CD3-PO 
 
1/50 CD3-PO 
1/200 CD8-PB 
 
1/200 CD8-PB 
1/50 CCR7-PE Cy7 
 
1/50 Perforin-FITC 
1/50 CD45RA-FITC 
 
1/50 GzB- Alexa700 
1/50 CD127-APC  
 
1/100 GzA- PerCpCy5.5 
1/50 CD38 – PerCp Cy5.5 
 
1/100 CD161-APC  
1/50 HLA-DR Alexa700 
 
1/50 PD-1 PeCy7 
PBS 
 
Perm Buffer 
 
Table 2-10: Flow cytometry antibodies 
Antibody 
FACS: 
Fluorochrome 
FACS: Clone 
Live/dead NIR Invitrogen 
CD3  Pacific Orange UCHT1 / Invitrogen 
CD8  Pacific Blue RPA-T8 / Beckton Dickinson 
CD45RA  FITC HI100 / Beckton Dickinson 
Granzyme B AlexaFluor700 GB11 / Beckton Dickinson 
CD38  PerCpCy5.5 HIT2 / Biolegend 
CD127  APC MB15-18C9 / Miltenyi 
CD161  APC 191B8 / Miltenyi 
CCR7  PeCy7 3D12 / Beckton Dickinson 
HLA-DR  AlexaFluor700 G46-6 / Beckton Dickinson 
PD-1 PeCy7 EH12.1 / Beckton Dickinson 
Perforin FITC dG9 / Beckton Dickinson 
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2.1.24 Extraction of DNA from whole blood 
A mixture of 200 μL of whole blood and 20 μL of proteinase K was incubated at 
room temperature for ten minutes.  Following this incubation, 200 μL of AL 
buffer was added to the sample mixed thoroughly. The mixture was incubated at 
56ºC for 10 minutes, before adding 200 μL of 100% ethanol, mixing. The mixture 
was transferred to a QIAamp Mini spin column and centrifuged for one minute at 
8000 rpm.  
 The filtrate was discarded. The sample was washed using buffers AW1 and 
AW2 (500 μL for each wash). The Mini spin column was placed in a 
microcentrifuge tube and 200 μL of elution buffer added before centrifugation 
for one minute at 8000 rpm. 
2.1.25 HLA Typing 
Following DNA extraction, HLA typing was carried by the Histocompatility and 
Immunogenetics service at Gartnavel General Hospital, Glasgow.  
2.1.26 Sanger sequencing and analysis 
Sanger sequencing was carried out by Eurofins, which uses cycle-sequencing 
technology (dideoxy chain termination/cycle sequencing) on ABI 3730XL 
sequencing machines and the corresponding forward or reverse primer were 
used. Chromatograms were examined for misclassified nucleotides by 
visualisation using CLC Genomics software. 
2.1.27 Nextera XT® DNA Sample Preparation 
Using Nextera XT technology, a DNA sample is randomly fragmented into a 
library of segments of approximately 300 bp by engineered transposomes. 
Transposomes have free DNA ends and insert randomly into DNA in a ‘cut and 
paste’ reaction. This library is then attached to adaptors.  
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The adptor sequences have binding sites for dual index sequences that are 
unique to each sample library and allow the fragments to bind to a glass slide or 
flow cell (Figure 2-5).   
 DNA samples are normalised based on their concentration, and measured 
using a Qubit® as described in Section 2.1.11.1. DNA libraries are then pooled 
and diluted to a concentration of 12 pM for use on the MiSeq® system. In Illumina 
instruments, the immobilised templates are clonally amplified to generate 
millions of molecular clusters, each containing 1,000 copies of the same 
template. The clustered templates are then sequenced using Illumina’s 
sequencing-by-synthesis technology.  
 In this process, the addition of fluorescently labelled nucleotides liberates 
one of four colours that are detected by laser excitation and high-resolution 
cameras in every run cycle. After 100 to 500 cycles, the instrument will have 
recorded all or a portion of the sequence of bases in each molecular cluster. The 
newly identified sequences of bases are then assembled into a new or de novo 
sequence or aligned to a reference genome. A single NGS run may generate 
paired-end reads of up to a total of 30 million bases. 
2.1.28 Illumina sequencing 
 Illumina sequencing is known as a “sequence-by-synthesis technique”. The 
technique was first described in 2006. During library preparation, template DNA 
is fragmented and tagmented, and adapters ligated to each end of DNA 
fragments.  Indices are added to label the DNA, thus enabling multiplexing and 
the attachment of oligonucleotides to the flow cell. The glass in the flow cell 
contains pre-attached oligonucleotides. Following denaturation, the DNA single 
strand attaches to the glass via these oligonucleotides and starts to synthesise 
the complementary strand.  
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Figure 2-5: Nextera XT workflow 
 
Two tagmentations are required to produce PCR amplifiable library molecules for sequencing. (a) 
Transposomes integrate into genomic DNA. (b) Tagmentation produces amplifiable and non-amplifiable 
library molecules until transposomes run out. (c) The library is cleaned to remove Tn5 proteins bound to the 
ends of DNA fragments, and is then PCR-amplified to add flow cell compatible adapters and dual-indexes 
for multiplexed sequencing. 
 
Following the synthesis of complementary DNA, denaturation occurs and the 
original fragment is moved to the washing step. The PCR amplification bridge is 
then performed: during this step the newly synthesised DNA fragment curves and 
attaches to the nucleotides on the surface of the flow cell glass. The same 
process is repeated and, resulting in denaturing of the double stand, which in 
turn produces two single strands attached to the glass surface. This process is 
repeated until it produced a high cluster density with multiple copies 
surrounding the first DNA strand.  
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 Following the generation of cluster density, the first DNA strand is removed and 
washed away. During this step a fluorescent label is bound to the dNTPs and 
used for polymerisation. Due to the 3’ termination of the incorporation 
nucleotide, only one nucleotide is added duringeach single cycle. Consequently, 
the number of cycles in each sample is related to read length.  
 Two lasers determine the dye attached to each nucleotide: one identifying 
red fluorescence and detecting nucleotides A and C, while the other identifies 
green fluorescence and detects nucleotides G and T. Based on the signal 
intensity of the emission a spectrum is determined and the nucleotide is 
recognized. Each fragment attaches to the flow cell glass, generates a forming 
cluster, and each added nucleotide is detected instantaneously. This enables 
signals from tens of millions of clusters to be read simultaneously.  The product 
is washed away and more nucleotides attach to oligonucleotides on the flow cell 
surface again (Figure 2-6). 
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Figure 2-6: Overview of Illumina sequencing 
 
 
A) Flow cell B) Genomic DNA is fragmented and adaptors ligated to both ends of the fragments. C) DNA 
attaches to the surface. D) Bridge amplification. E) Fragments become double stranded and double-
stranded bridges are formed on the flow cell. F) Denaturation of the double-stranded molecules. G) 
Amplification: several million dense clusters of double-stranded DNA are generated. H) To determine the 
first base, the first sequencing cycle begins by adding four labelled reversible terminators. I) Image of the 
first base after laser excitation. J) The next cycle repeats the incorporation of four labelled reversible 
terminators, K) Image of the second cycle following laser excitation; this image is taken as earlier, and the 
second base is recorded. L) Sequencing over multiple chemistry cycles, one base at a time. M) Alignment of 
data. The data are aligned and compared to a reference and sequencing differences are identified. 
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 Phi X control 
Phi X 174 (or ΦX174) was used to assess the quality of each run. Due to the small 
genome size and the extensive work has been done on it; alignment of Phi X is 
straightforward. In NGS, Phi X is used at a concentration of 4 nM. Phi X is 
denatured by adding an equal quantity of 0.2M NaOH to Phi X. The mixture is 
then incubated at room temperature for five minutes before being diluted again 
to 20 pM by adding 980 μL of Hybridization Buffer 1 to the Phi X solution.. The 
solution is then added to the DNA library (100 μL Phi X to 90 μL of DNA library) 
resulting in a Phi X concentration of 10%.   
2.1.29 Statistical analysis 
Non-parametric analyses were performed using the two-tailed Mann-Whitney U 
test or Fisher’s exact test as appropriate (parametric testing was not used due 
to small sample sizes in all comparisons). Data with p values less than or equal 
to 0.05 were considered to be significant. All statistical analysis was carried out 
using Graph Pad (Prism) version 6.0. 
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Chapter 3: Results 
3.1.1 Patient cohort 
The cohort in this thesis was a study of a larger cohort of patients with acute 
HCV infection. subsequentely Characteristics of the general cohort are shown in 
Table 3-1  while the smaller cohort is summarised in Table 3-2. Ten HLA-B27+ 
patients with acute HCV infection were identified, of whom 9 had samples 
available for analysis.  Patient characteristics including age, route of infection, 
viral load, HIV status and genotype are shown in Table 3-1. Control patients used 
in T cell assay experiments are shown in Table 3-2. Overall, 50% (5/10) patients 
spontaneously cleared HCV; this percentage was 100% (2/2) in HIV uninfected 
individuals and 37.5% (3/8) in HIV infected individuals.  The difference between 
groups did not reach statistical significance (p=0.44). 
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Table 3-1 General Cohort description 
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*Significant p value<0.05, **highly significant p value <0.01. †p values shown represent all progressors (fluctuating viraemia and plateau viraemia) versus clearer (spontaneous 
clearance) groups. ††Indicates baseline. $Intravenous, intramuscular or subcutaneous drug use (crystal methamphetamine, cocaine, anabolic steroids, heroin). ¶Intranasal drug 
use (ketamine, cocaine). ALT, alanine aminotransferase; HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; MSM, men-who-have-sex-with-men; VL, viral load 
(Thomson et al., 2011). 
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Table 3-2 Characteristics of the HLA-B27 patient cohort 
Patient 
number 
Genotype Age Sex 
HCV 
outcome 
HIV status 
 
HAART 
 
CD4 
Count 
Route of 
infection 
G5 1a 30 M Clearer Positive No 471 MSM 
G17 1a 32 F Clearer Negative NA NA IDU 
G18 1a 35 M Clearer 
Negative 
 
NA NA Needlestick 
P49 1a 
43 
M Clearer Positive 
No  
490 
  
MSM 
P110 1a 
43 
M Clearer Positive 
Yes 
500 
 
MSM 
P28 1a, 4d 
33 
M Progressor Positive 
No 
380 
 
MSM 
P45 1a 
40 
M Progressor Positive 
No 
330 
 
MSM 
P113 1a 
43 
M Progressor Positive 
No 
520 
 
MSM 
P10 1a 
35 
M Progressor Positive 
No 
580 
 
MSM 
P3 1a 48 M Progressor Positive No 380 MSM 
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Table 3-3 Patients characteristics – controls 
Patient 
number 
Genotype Age Sex HCV stage 
HIV 
status 
HLA
B27 
CD4 
 
Route of 
infection 
P75 1a 31 M Acute (P) Positive - 220 MSM 
P96 1a 28 M Acute (P) Positive - 370 MSM 
GC1 1a/3a 49 F Chronic Negative - NA IDU 
GC8 1a 53 M Chronic Negative - NA 
Tattoos          
/assault 
GC10 1a 51 M Chronic Negative - NA IDU 
P32 1a 27 M Acute (SC) Positive - 340 MSM 
 
 
3.1.2 DNA library quality  
Following AmpureXP® magnetic bead purification, DNA fragment quality was 
checked and visualized using a 2200 Tapestation (Agilent Technologies), as 
shown in (Figure 3-1).  
3.1.3 Sequencing quality scores  
Next-generation sequencing using the Illumina MiSeq platform is a highly 
sensitive method but is subject to sequencing error. To assess the quality of NGS 
sequencing, a metric method called Phred score used to report base-calling 
accuracy. FastQC® (Babrahman Bioinformatics) was used to measure the Phred 
score for each raw fastq file.  
 Low quality reads were frequently found at the end of sequences and 
second paired end sequence reads showed a drop in quality score when 
compared with first paired end reads (Figure 3-2); these were trimmed and 
removed to raise the average quality of the Phred score to a minimum of Q30 (1 
base call error in 1000 bases or 99.9 accuracy). Additionally, the algorithm 
designed to calculate the Phred score assesses the probability of a base calling 
error (Ewing and Green, 1998). 
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 Figure 3-1:  DNA fragment size assessed using a 4200 Tapestation® (Agilent) 
A) 
 
B) 
 
Following Nextera library preparation, DNA fragment size was measured using a D1K DNA screen tape, A) 
DNA Ladder, B) Nextera library sample with a 300bp peak. 
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Estimating the accuracy of base calling error can be calculated using the formula 
Q = -10 log10 (P), where Q is the quality score value and P is the base-calling 
error probability. Having a Q value of 30 meaning the error probability is 1 in 
1000. The amount of data produced by Illumina platform is huge, so the quality 
score can be used to remove all low quality reads and limit the downstream 
sequence analysis to the high quality score reads. High quality sequence data is 
essential for accurate alignments and other downstream analyses. 
 
Figure 3-2: Illustrative example of Phred score data obtained from fastq file 
 
 
 
 
 
 
 
 
 
The Average Phred score in this file is Q35 with a reduction in quality towards the end of the sequence 
reads  
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3.1.4 Raw data 
Sequence data were produced in fastq format (typically 1-2 million reads per 
fastq file). Fastq files contain sequence data in fasta format with attached 
quality scores; an example is shown below: 
Figure 3-3: An example of Fastq file sequence format 
 
Line 1 (red) begins with an '@' character and is followed by a sequence identifier and a description of the 
sequence to follow, Line 2 (blue) contains the raw sequence, Line 3 (green) begins with a '+' character, Line 
4 (purple) encodes the quality values for the sequence in line 2 and contains the same number of symbols 
as letters in the sequence 
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3.1.5 Sequence alignments 
Fastq sequences were assembled and aligned to several HCV reference 
sequences from 64 genotypes and sub-genotypes (Smith et al., 2014) and 60 HIV 
reference sequences. This was carried out using an in-house mapping program 
(Tanoti) which is more sensitive than other alignment programs such as BWA and 
BowTie (personal communication Sreenu Vattipally). Tanoti is based on the 
BLAST algrithm and maximizes both the alignment depth and coverage when 
used with NGS reads from highly diverse small genomes such as viruses. Tanoti 
was compared with other programs to evaluate the speed of performance, reads 
that mapped to the reference genome and errors, using different viral datasets 
(real and simulated datasets). Tanoti mapped reads faster and was able to 
produce more relaible insertion and deletion data. Tanoti employs batch 
processing and minimizes the usage of memory compared with other programs. 
It aligns each fastq sequence to reference sequences using BLAST and can 
increase the number of mapped reads to the reference up to ten fold (as it 
allows for high diversity; a characteristic feature of viral sequence reads). An 
example of coverage obtained following mapping with Tanoti is shown in Figure 
3-4. 
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Figure 3-4: Read coverage across the whole HCV genome using Tanoti 
 
Sam coverage carried to show the coverage across the whole HCV genome from a single sample analysed 
using Tanoti. 
 
Following mapping, variations across the whole HCV genome were identified 
within unknown and known HLA-B27 restricted epitopes using in-house scripts. 
Within the HCV genome, previously described B27 restricted epitopes occur in 
the p7, NS3 and NS5B genes and within the HIV genome; a single gag epitope has 
previously been well described (Setiawan et al., 2015). The HLA-B27 restricted 
HCV epitopes we studied are listed in (Table 3-4). HLA-B27-restricted epitope 
variations within the HIV gag epitope shown in Table 3-5 were also studied. 
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Table 3-4: HLA-B27 restricted epitopes within the HCV genome. 
Epitope Protein Position (nucleotide) Position (aa) HLA 
restriction 
 
GRWVPGAAY P7 2679-2708 780-788 HLA-B*27 
GRGKPGIYR NS3 4815-4844 1492-1501 HLA-B*27 
KGGRKPARLIVFPDL 
 
NS5B 8052-8096 2571-2585 HLA-B*27 
ARHTPVNSW 
 
 
 
 
NS5B 8799-8825 2820-2828 HLA-B*27 
ARMILMTHF NS5B 8862-8888 2841-2849 HLA-B*27 
GRAAICGKY NS5B 9147-9173 2936-2944 HLA-B*27 
HLA-B27 restricted epitopes within the HCV genome are listed. Positions are indicated with respect to the 
H77 HCV reference sequence (accession number AF009606). Italics indicate the most likely CD8+ epitope 
within longer sequences. 
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Table 3-5: HLA-B27 restricted epitope within the HIV genome.  
Epitope Protein Position (nucleotide) Position (aa) HLA 
 
KRWIILGLNK Gag (p24) 788-817 263-272 HLA-B*27 
Positions are indicated with respect to the HXB2CG HIV reference sequence (accession number K03455). 
Percentage coverage and depth following alignment to the nearest reference 
sequence was assessed in HLA B27+ progressors and spontaneous clearers using 
an in-house programme called Sam Statistics (SAM_ STATS; Table 3-6 and Table 
3-7). 
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Table 3-6: HCV read depth and coverage of samples from HLA-B27+ patients (spontaneous clearers) with acute HCV 
Patient ID Days post   infection Genotype Viral load Mapped area Coverage % 
Average 
depth 
Total reads Method 
G5 80 (4.09.2015) 1a 1870000 9387 99.91 9225 454494 TE 
G18 108 (17.7.2015) 1a < 12 9309 99.08 16 799 TE 
P49 60 (10.8.2005) 1a 50 9387 99.91 158565 7797018 TE 
P49 60 (10.8.2005) 1a 50 9069 96.53 22 1520 MG 
P49 60 (10.8.2005) 4d 50 9278 98.48 24852 1349661 TE 
P110 86 (25.3.2010) 1a 5325 9357 99.60 5518 268138 TE 
P110 450 (24.3.2011) 1a 9548 9179 97.70 4404 209742 TE 
 
Samples sequenced are shown with respect to number of days post-infection, genotype (some patients were infected with more than one genotype) and the average depth and 
coverage calculated using SAM_STATS. Results from enriched (TE) and unenriched (MG) sequencing are shown. TE–target enrichment MG–metagenomic (unenriched). Viral load 
data was provided by the clinical diagnostic laboratories.
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Table 3-7: HCV read depth and coverage of samples from HLA-B27+ patients 
(progressors) with acute HCV. 
ID   Days post   
infection 
Genotype Viral load Mapped 
area 
Coverage 
% 
Average 
depth 
Total 
reads 
Method 
P28 406  
(6.12.2005) 
1a 175004 9378 99.8 2403 135721 TE 
P28 406  
(6.12.2005) 
1a 175004 4428 47.1 6 249 MG 
P28 406  
(6.12.2005) 
4d 175004 9299 100 19179 921986 TE 
P28 406 
 (6.12.2005) 
4d 175004 9171 97.3 35 1817 MG 
P28 
602  
(20.6.2006) 
4d 407756 9378 99.5 19055 918851 TE 
P28 2366 
 (19.4.2011) 
4d 9338 9378 99.5 19055 918851 TE 
P28 2366 
 (19.4.2011) 
1a 9338 9386 99.9 10180 503679 TE 
P45 108  
(30.4.2007) 
1a 10012463 9386 99.9 182297 32892823 TE 
P45 108  
(30.4.2007) 
1a 10012463 9209 98 247 18050 MG 
P45 377  
(24.1.2008) 
1a 908557 9365 99.6 9659 474027 TE 
P45 391  
(07.2.2008) 
1a 812612 9386 99.9 83694 4297447 TE 
P45 440  
(27.3.2008) 
1a 996533 9386 99.9 16041 785549 TE 
P113 19  
(1.10.2008) 
1a 5671269 9390 99.9 53392 25541816 TE 
P113 19  
(1.10.2008) 
1a 5671269 9147 97.3 143 9787 MG 
P113 19 
 (1.10.2008) 
4d 5671269 9370 99.4 51043 2903676 TE 
113 56 
 (7.11.2008) 
1a 1537342 9120 97 56 3809 MG 
P10 180  
(05/4/2006) 
1a 17755 758 8.07 33 178 MG 
P10 418  
(29.11.2006) 
1a 927653 565 6.01 1 5 MG 
Samples sequenced are shown with respect to number of days post-infection, genotype and the average 
depth and coverage calculated using SAM_STATS. Results from enriched and unenriched sequencing are 
shown. TE–target enrichment MG–metagenomic (unenriched).  
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Metagenomic sequencing was significantly less sensitive than target enrichment 
sequencing (this was particularly evident in samples from P28 and P10). Initial 
batches were carried out using MG sequencing but subsequently, TE was selected 
as the method of choice. 
 For each sample, an HCV consensus sequence was calculated (using 
SAM2CONSENSUS) from sam files with coverage over 90%. Both the consensus 
sequence and the full alignment sam file were used to identify mutation(s) 
within and outwith HLA-B27 restricted HCV and HIV epitopes. Mutated 
nucleotides within the sam alignment were tested using a third in-house program 
called SamVariation (all in-house scripts provided by Dr Vattipally B Sreenu).  
 A mapping threshold of 1% was used to report minority variants (10x above 
the calculated error threshold). Reads calculated at less than 1% were excluded 
due to the possibility of error during the Illumina clustering process, the 
possibility of low-level cross-contamination during sample preparation or index 
sequencing error (Kircher et al., 2011). It has previously been reported that the 
error rate of the Illumina Miseq platform is  < 0.001 indels, ~0.1 substitutions per 
site (McElroy et al., 2014). 
3.1.6 Quality control for NGS data: 
 Cross-contamination during next-generation sequencing: 3.1.6.1
Next generation sequencing is a powerful technique but is limited by a high risk 
of accidental contamination during RNA extraction, cDNA synthesis and during 
library preparation. The sensitivity of the technique (millions of sequence reads 
generated from only 1ng of input DNA) means that it is far more prone to cross-
contamination than other less sensitive techniques, including PCR (Naccache et 
al., 2013, Lysholm et al., 2012, Cheval et al., 2011).  
 Run-to run contamination may occur on the MiSeq platform (and can be 
minimised or eradicated using bleach in the wash cycle). Cross-contamination 
during factory processing is also known to occur within the indexes used to ligate 
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to samples in order to allow multiplexed sequencing and therefore very low-
level cross-contamination is a problem that must be contained and managed 
rather than completely eradicated (Kircher et al., 2011). 
 NGS library preparation needs to be carried out with a high level of 
precautions (including separation of all pre-amplification steps from post-
amplification in different preparation rooms). 
 In order to identify significant cross-contamination, consensus sequences 
from each sample were mapped to the closest HCV reference(s) and a 
phylogenetic tree constructed using MEGA 6.6 software in order to identify any 
evidence of cross-contamination. Negative control samples were included in the 
sequencing run. One sequencing run generated a consensus sequence in a 
negative control sample (sample G17) – this came from a very high viral load 
sample processed in the same batch. It was correctly identified as a contaminant 
due identity of the full genome to the sample processed next to it following 
phylogenetic analysis and removed from further analysis. 
 Alignment bias during mapping to closely related HCV references 3.1.6.2
sequences 
Mapping, the alignment of sequences from raw NGS fastq files to known HCV 
reference sequences, can be carried out rapidly and is more sensitive than de 
novo assembly so is an attractive technique. However, when the wrong 
reference sequence is used (for example a different genotype or sub-genotype), 
bias can be introduced (Bull et al., 2011b). 
 To overcome this issue, we created an alignment to multiple HCV reference 
sequences and selected in our analysis only the alignment with the highest level 
of depth and coverage (using an in-house script called runallReadMapRatio).  
 An example of bias created by using the wrong reference sequence for 
mapping is shown in Figure 3-5. Data generated from patient 45 (P45) showed 
that when NGS sequence reads were mapped to genotype 1b HCV (the patient 
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was infected with genotype 1a), a bias occurred, resulting in a consensus 
sequence that was still genotype 1a but subsequently different from the 1a 
mapped sequence. 
Figure 3-5: Phylogenetic tree illustrating bias when the mapping reference 
sequence used comes from a different HCV subgenotype (P45).  
 
A phylogenetic tree was calculated using maximum likelihood from consensus sequences generated from 
HCV genomes obtained at different time points in patient 45, using reference sequences from genotype 1a 
and 1b. Evidence of significant bias introduced during the mapping process is shown. Bootstrap values >70 
are shown. 
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These biases could lead to variation in the phylogenetic tree and in 
interpretation of epitope data, if variations occurred in these regions (due to 
minority variants preferentially mapping to the wrong reference sequence). 
Selection of the correct mapping reference is therefore essential to avoid 
calculating a biased consensus sequence and wrong conclusions about selection 
within the genome. In order to identify the correct reference sequence, the 
ratio of mapped to unmapped reads was calculated and the highest used to 
identify the correct reference sequence (Table 3-8). For P45 the enrichment was 
far lower for g1b than 1a indicating the correct genotype was 1a. 
Table 3-8: Calculated enrichment in P45 HCV reads mapped to genotype 1a and 1b 
reference sequences.  
 
Patient No 
 
Days post 
infection 
 
Genotype 
 
Total 
reads 
 
Mapped reads 
 
Enrichment 
(Mapped / total reads) 
P45 108 1a 33690336 32892823 97.63 
P45 108 1b 33690336 18055468 53.59 
P45 391 1a 4478054 4297447 95.96 
P45 391 1b 4478054 2469370 55.14 
Although a reference sequence with >90 coverage was generated using both genotype 1a and 1b sequences, 
the  enrichment can be seen to be low when the wrong reference sequence was used. 
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3.1.7 Phylogenetic analysis  
16 consensus full genome sequences from seven clinical samples were aligned 
against HCV references (including genotypes 1, 2, 3 and 4) using the alignment tool 
MUSCLE, implemented in MEGA software version 6. Bootstrapped trees (1000 data 
sets) were constructed using the Maximum likelihood (Figure 3-7). The best model 
was calculated and chosen based on calculation of AIC and BIC using MEGA 6.6 
(section 3.1.8). The GTR+G+I had the lowest AIC score and was selected as the best 
model.  
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3.1.8 Best model calculation 
The GTRGI model was selected as the best fit using AIC and BIC calculations within MEGA 6.6. 
Model #Param BIC AICc lnL Invariant Gamma R Freq A Freq T Freq C Freq G 
GTR+G+I 59 131565.1618 130953.3109 -65417.64044 0.37924878 1.176578608 2.003189012 0.202540824 0.216385601 0.29844506 0.282594592 
GTR+G 58 131718.1372 131116.6562 -65500.31359 n/a 0.335237396 2.009268591 0.202540824 0.216385601 0.29844506 0.282594592 
T92+G+I 53 131842.2232 131292.5918 -65593.28376 0.385436508 1.287739357 1.688433932 0.209480174 0.209480174 0.290519826 0.290519826 
TN93+G+I 56 131867.8556 131287.1144 -65587.54367 0.385086359 1.243577189 1.773033123 0.202540824 0.216385601 0.29844506 0.282594592 
HKY+G+I 55 131939.3788 131369.0075 -65629.4907 0.383492613 1.24035354 1.685755414 0.202540824 0.216385601 0.29844506 0.282594592 
T92+G 52 132011.1024 131471.841 -65683.90879 n/a 0.346495695 1.688433932 0.209480174 0.209480174 0.290519826 0.290519826 
TN93+G 55 132048.8198 131478.4485 -65684.2112 n/a 0.344607965 1.699863419 0.202540824 0.216385601 0.29844506 0.282594592 
HKY+G 54 132099.4428 131539.4414 -65715.7081 n/a 0.34337372 1.685755414 0.202540824 0.216385601 0.29844506 0.282594592 
Models with the lowest BIC scores (Bayesian Information Criterion) and AICc values (Akaike Information Criterion, corrected) are considered the best fit. Maximum Likelihood value (lnL), and the number of 
parameters (including branch lengths) are also presented. Non-uniformity of evolutionary rates among sites may be modeled by using a discrete Gamma distribution (+G) with 5 rate categories and by 
assuming that a certain fraction of sites are evolutionarily invariable (+I). Assumed or estimated values of transition/transversion bias (R) are shown for each model. They are followed by nucleotide 
frequencies (f) and rates of base substitutions (r) for each nucleotide pair. For estimating ML values, a tree topology was automatically computed. Codon positions included were 1st+2nd+3rd. All positions 
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with less than 95 site coverage were eliminated. There were a total of 9103 positions in the final dataset. Evolutionary analyses were conducted in MEGA6 [2]. Abbreviations: GTR: General Time Reversible; 
HKY: Hasegawa-Kishino-Yano; TN93: Tamura-Nei; T92: Tamura 3-parameter; K2: Kimura 2-parameter; JC: Jukes-Cantor.  
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To identify the impact of the CTL escape mutations on HLA-B27 epitope. Next-
generation sequence analysed using in-house bioinformatic tools. Data from the 
NGS run shown in details in Figure 3-7 
3.1.9 Target enrichment versus metagenomic (unenriched) sequencing 
Paired samples where available were compared using both metagenomic and target 
enrichment sequencing in separate sequencing experiments (target enrichment was 
developed in house around a year after the metagenomic sequencing experiments). 
A phylogenetic analysis was carried out of paired samples revealing no evidence of 
bias when using a TE approach (Figure 3-6). 
Figure 3-6: Phylogenetic analysis of samples sequenced using metagenomic (MG) or 
target enrichment (TE). 
 
All MG and TE samples were identical, indicating that bias during target enrichment is minimal or non-existent. 
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Figure 3-7: Phylogenetic tree calculated using consensus sequences from all samples 
sequenced.  
                               
A phylogenetic tree was constructed using maximum likelihood (using consensus sequences from HCV in HLA 
B27+ patients using MEGA 6.0 and 1000 bootstrap replicates. Bootstrap values >70 are shown. 
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3.1.10 Viral load dynamics  
HCV viral loads and sampling times are plotted over time in Figures 3-8 to 3-17. 
Patients that spontaneously cleared HCV are shown in Figures 3-8 to 3-14. 
Figure 3-8: Viral load dynamics and sampling from patient G5  
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR). 
Figure 3-9: Viral load dynamics and sampling from patient G17  
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR). 
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Figure 3-10: Viral load dynamics and sampling from patient G18 
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR). 
Figure 3-11: Viral load dynamics and sampling from patient P49 
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell 
assays. The estimated date of infection occurs where the line crosses the y axis (midpoint between 
the last negative and first positive PCR). 
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Figure 3-12: Viral load dynamics and sampling from patient P110 – episode 1 (E1)  
 
 
Figure 3-13: Viral load dynamics and sampling from patient P110 – episode 2 (E2)  
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell 
assays. The estimated date of infection occurs where the line crosses the y axis (midpoint between 
the last negative and first positive PCR). Negative viral loads after the onset of viraemia indicate 
treatment with IFN and RBV. 
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Viral load dynamics and sampling time points for patients that progressed to 
chronicity are shown in Figures 3-14 to 3-17. 
Figure 3-14: Viral load dynamics and sampling from patient P28 
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR).   
Figure 3-15: Viral load dynamics and sampling from patient P45 
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR).   
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Figure 3-16: Viral load dynamics and sampling from patient P113 
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR).   
Figure 3-17: Viral load dynamics and sampling from patient P10 
 
Black arrows indicate samples examined for NGS, gray arrows indicate those available for T cell assays. The 
estimated date of infection occurs where the line crosses the y axis (midpoint between the last negative and 
first positive PCR).   
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3.1.11 Mutations located within HLA-B27 restricted HCV epitopes 
We carried out NGS on eight patients (seven successfully; one patient had samples 
only of very low viral load and these were not successfully sequenced), four of 
whom spontaneously cleared the HCV within the acute phase and another four of 
whom progressed to chronicity. Two further patients were identified but plasma 
samples with detectable viraemia were not available. HCV sequence analysis 
showed varying mutations within the HLA-B27-restricted epitopes. 
 Both single and multiple clustered mutations were observed among the 
patients; most patients that progressed to chronicity had two or three mutations 
within the CD8+ T cell restricted epitope whereas patients who spontaneously 
cleared HCV had a single mutation or no mutations at all within HLA-B27 epitopes. 
 Spontaneous clearer patients 3.1.11.1
Patient G5 had a single mutation within HLA-B27 restricted epitope within NS3 - 
G1497T and within the NS5B2841-2849 epitope, single mutations at L2846T/V/P/I and 
F2849S. A single mutation was also detected within (NS5B2820-2828) at V2825I. Later 
on, the patient had a negative viral load, following this time-point, and cleared the 
HCV (Table 3-9).  
 Patient G18 had several mutations within HLA-B27-restricted epitopes. The 
previously described p7 epitope showed mutations as follows: W782F, P784S, 
G785R, A786V and Y788C, as well as at NS5B2820-2828 R2821K, T2823N, P2825L/I/F, 
V2825K/H, N2826K/H and W2828L. A single mutation was found within NS5B2841-2849 
at (1, 4, 5, 6, 8) A2841V, I2844V, L2845M, M2846T/I/L and T2847Y,F (Table 3-10). 
 Patient 49 (P49) had single mutations within two different epitopes (HLA-B27) 
p7 A786V and HLA-B27 NS31492-1501 at K1495R and NS5B2841-2849 at A2841V, I2845V, 
L2845T/M and M2846L/V/M/I (Table 3-11). HIV gag sequence observed within this 
patient displayed no mutations (Table 3-17). 
 
 138 | P a g e  
Patient P110 (P110) was infected twice with HCV and spontaneously cleared 
infection twice.  Over time, the patient developed three and four mutations within 
the HLA-B27-restricted NS5B2841-2849 epitope at the following sites A2841V, M2843T, 
I2844V and M2846V/A/T. The HLA-B27 epitope within NS3 showed only a single 
mutation K1495R. At NS5B2936-2944, mutations were present at A2939V and K2943R. A 
single mutation was observed within the p7 epitope R35W (Table 3-12).  
 Progressor patients 3.1.11.2
Patient 10 (P10) developed multiple clustered mutations within the NS5B2841-2849 
epitope T418A, A2841V, M2843V, I2844V (Table 3-13).  
 Patient P28 had no or only one mutation at the first time-point except in one 
sequence when two mutations occurred within this time-point. Mutations were 
observed in the first amino acid (A2841V); two mutations were also reported in this 
first amino acid (A2841V, M2846L and F2849S) (Table 3-14). Multiple mutations 
occurred within the HLA-B27 restricted epitope in the p7 region; these mutations 
were observed as R35K, V783A, P784A, A786V and A787T. Two other epitopes 
NS5B2571-2585 and NS5B2571-2585 had only one mutation for (NS5B2571-2585) mutations 
observed as K2575R, L2579P and F162Y. The last epitope (NS5B2936-2944) contained 
multiple mutations (R2937K, I2940V and K2843R). 
 At the second time-point post-infection (day 602) multiple mutations were 
detected within the (NS5B2936-2944) G2936C, A2939P/D, G2942R, and G2943M/R. The 
last time- point for this patient showed cluster mutations in the (NS5B2841-2849) 
(M2844V and M2846V/L), with single mutations within the (p7780-788) and (NS31492-
1501). These mutations within different highly conserved epitope regions of the HLA-
B27 restricted epitope led to viral escape from the CD8+T cell response.  
 Co-infected patients were assessed for variation within the HLA-B27-restricted 
HIV gag epitope and mutations were found including L268M, L270H and N271H 
(Table 3-18).  
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Another progressor patient in the cohort Patient 45 (P45) showed multiple 
mutations within the HLA-B27 epitope at p7 and showed a single mutation across 
all other HLA-B27 epitopes. This patient exhibited one mutation within two 
different epitopes at the first time-point (p7780-788) and NS5B2820-2828 A787V and 
R2821K mutations also. Other time-points showed multiple “cluster” mutations 
within p7780-788 at V783A and A786V and a single mutation within I1498T K2571R and 
R2821K. Two subsequent time points showed the same pattern of (Table 3-15).  
 The HIV sequence from this patient (P45) displayed mutations within the 
gag263-272 at W265C, I266M, L268Q, G269E and N271K (Table 3-19).  
 Mutations were found mainly within the TCR binding sites and on a few 
occasions within the anchor binding sites, as has already been described (Stewart-
Jones et al., 2005, and Dazert et al., 2009).    
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Table 3-9: Mutations observed within HLA-B27 restricted epitope within patient G5  
Day HLA-B27 restricted epitope variation in patient G5 (spontaneously cleared + HIV) 
 
 
P7 (780-788) 
GRWVPGAAY 
NS3 (1492-1501) 
GRGKPGIYRF 
NS5B (2571-2585) 
KGGRKPARLIVFPDL 
NS5B(2820-2828) 
ARHTPVNSW  
NS5B (2841-2849) 
TLWARMILMTHFFSV 
NS5B (2936-2944) 
GRAAICGKY  
 
80 
 
.........     
100%(4491) 
..........  
94%(6655) 
.....T.... 
5%(389) 
...............  
100%(5157) 
.....I...  
100%(17853) 
........T......  
35%(6890) 
........V......  
58%(11400) 
...........S...   
2%(417) 
........P......   
2%(493) 
........I......   
1%(330) 
........  
100%(9799)  
Amino acid sequence of HLA-B27 epitopes in acute HCV patients using NGS technology. Points indicate homologous residues.  
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Table 3-10: Mutations observed over time within HLA-B27 restricted epitopes in patient G18 (G18)  
Day HLA-B27 restricted epitope variation in patient G18 (spontaneously cleared) 
 P7 (780-788) 
GRWVPGAAY 
NS3(1492-1501) 
GRGKPGIYRF 
NS5B(2571-2585) 
KGGRKPARLIVFPDL 
NS5B(2820-
2828) 
ARHTPVNSW 
NS5B(2841-2849) 
TLWARMILMTHFFSV 
NS5B(2936-2944) 
GRAAICGKY 
 
108 
......... 25% (2) 
......V.. 50% (4) 
.....RV.. 12% (1) 
..F.S...C 12% (1) 
..........     
100%(6) 
................... 
100%(14) 
.........  
33%(13) 
.K.......  
28%(11) 
.....L...   
2%(1) 
.....I...   
23%(9) 
......K..   
2%(1) 
...N.I...   
2%(1) 
.....LH..   
2%(1) 
.....F..L   
2%(1) 
.K..Q....   
2%(1) 
............... 
66%(30) 
..........Y....  
2%(1) 
..........F....  
2%(1) 
...V...........  
11%(5) 
......V........ 
2%(1) 
........T......  
4%(2) 
........I......  
2%(1) 
.......M.......  
4%(2) 
........L...... 
4%(2) 
.........   
62%(17) 
.K.......   
33%(9) 
.......R.   
3%(1) 
Amino acid sequence of HLA-B27 epitopes in acute HCV patients using NGS technology. Points indicate homologous residues.  
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Table 3-11: Mutations observed over time within HLA-B27 restricted epitopes in patient 49 (P49)  
 
Day 
 
HLA-B27 restricted epitope variation in patient 49 (spontaneously cleared + HIV) 
 
 
P7 (2651-2677) 
GRWVPGAAY 
NS3 (4787-4816) 
GRGKPGIYRF 
NS5B (8024-8068) 
KGGRKPARLIVFPDL 
NS5B(2820-2828) 
ARHTPVNSW  
NS5B (2841-2849) 
TLWARMILMTHFFSV 
NS5B(9119-9145) 
GRAAICGKY  
 
60 
......V.. 
100%(101856) 
...R......   
100%(73302) 
............... 
100%(145959) 
.........  
100%(527936) 
...............   
2%(11987)  
.......T.......  
32%(170276) 
........L......  
4%(25382) 
......V........  
29%(151530) 
........V......  
12%(65359) 
.......MM......  
6%(31960) 
...V...........  
10%(53610) 
........I......  
2%(12121) 
.........  
100%(268802)  
Amino acid sequence of HLA-B27 epitopes in acute HCV patients using NGS technology. Points indicate homologous residues.  
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Table 3-12: Mutations observed over time within HLA-B27 epitopes in patient 110 (P110)  
Day HLA-B27 restricted epitope variation in patient 110 (spontaneously cleared + HIV) 
 
 
P7 (780-788) 
GRWVPGAAY 
NS3 (1492-1501) 
GRGKPGIYRF 
NS5B (2571-
2585) 
KGGRKPARLIVFPDL 
NS5B (2820-
2828) 
ARHTPVNSW 
NS5B (2841-2849) 
TLWARMILMTHFFSV 
NS5B (2936-2944) 
GRAAICGKY 
 
86 
.........     
100%(2870) 
..........  
91%(3350)  
...R......   
9%(294) 
............... 
100%(3379)  
.........   
100%(7032) 
...V..V.V......   
47%(2701) 
...V.T..V......   
10%(616) 
...V....V......   
 8%(479) 
...V....A......  
 16%(960) 
...V..V.T......   
 2%(164) 
........A......  
 29%(795) 
.......R.  
98%(2430) 
...V...R.   
2%(26) 
 
450 
 
........  
95%(1760)  
.W.......  
5%(92) 
..........   
100%(3316)  
............... 
100%(843234) 
.........    
100%(7300)  
...V.TV.V......   
82%(4300) 
...V..V.V......  
13%(714) 
...V.T..V......   
5%(219) 
.......R. 
100%(1144) 
 
Amino acid sequence of HLA-B27 epitopes in acute HCV patients using NGS technology. Points indicate homologous residues  
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Table 3-13: Mutations observed in HLA-B27+ restricted epitopes in patient 10 (P10)  
Day HLA-B27 restricted epitope variation in patient 10 (progressor + HIV) 
 
P7 (780-788) 
GRWVPGAAY 
NS3(1492-1501) 
GRGKPGIYRF 
NS5B (2571-2585) 
KGGRKPARLIVFPDL 
NS5B (2820-2828) 
ARHTPVNSW  
NS5B(2841-2849) 
TLWARMILMTHFFSV 
NS5B (2936-2944) 
GRAAICGKY  
180 
ND ND ND 
.K....... 97%(31) 
.K..T.... 3%(1) 
............... 
66%(121) 
A..V.V.........   
31%(57)  
....v......... 
2%(4) 
 
......... 100%(10) 
418 
 
ND 
 
ND 
 
ND 
.........  
100% (2) 
...V.VV........  
100%(3) 
.....L......... 
100%(1) 
.........  
100%(1) 
Amino acid sequence of HLA-B27 epitopes in acute HCV patients using NGS technology. Points indicate homologous residues  
 145 | P a g e  
Table 3-14: Mutations observed over time within HLA-B27 restricted epitopes in patient 28 (P28)  
 
Day 
 
HLA-B27 restricted epitope variation in patient 28 (progressor + HIV) 
 P7 (780-788) 
GRWVPGAAY 
NS3 (1492-1501) 
GRGKPGIYRF 
NS5B (2571-2585) 
KGGRKPARLIVFPDL 
NS5B(2820-2828) 
ARHTPVNSW  
NS5B (2841-2849) 
TLWARMILMTHFFSV 
NS5B (2936-2944) 
GRAAICGKY  
 
 
406 
...AA.V.. 14%(1) 
...A..V.. 43%(3) 
...A..VT. 29%(2) 
.K....V.. 14%(1) 
.......... 75%(3) 
.....T.... 25%(1) 
............... 67%(8) 
....R.......... 8%(1) 
........P...... 8%(1) 
...........Y... 17%(2) 
.........     
100%(9209) 
............... 
63%(5) 
...V........... 
13%(1) 
...V....L...... 
13%(1) 
...........S... 
13%(1) 
......... 77%(14) 
.K..V.... 11%(2) 
.K....... 5%(1) 
.......R. 5%(1) 
 
 
602 
  
 
ND 
  
 
ND 
...............     
100% (2994)   
..........  
100%(2355) 
...............  
100%(5569) 
......... 25%(1) 
C..P..RM. 25%(1) 
.......R. 25%(1) 
...D...R. 25%(1) 
 
2366 
......V..   
100%(4467) 
...R......  
100%(9501) 
...............  
100%(6566) 
.........    
100%(9652)  
...V..V.V...... 
97%(10757) 
...V....L...... 
3%(233) 
.........   
100%(15323) 
Amino acid sequence of HLA-B27 epitopes in acute HCV patients using NGS technology. Points indicate homologous residues  
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Figure 3-18:  Number of mapped reads to genotype 1a and 4d referenced at different time points in patient 28 
 
Patient 28 had a dual infection with two different HCV genotypes (1a and 4d). The graph shows the percentage of each genotype present at different timepoints based on NGS reads 
at the three different time points (T406, T602 and T2366). 
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Day HLA-B27 restricted epitope variation in patient P45 (progressor + HIV) 
 
 
P7 (780-788) 
GRWVPGAAY 
NS3 (1492-1501) 
GRGKPGIYRF 
NS5B (2571-2585) 
KGGRKPARLIVFPDL 
NS5B (2820-2828) 
ARHTPVNSW  
NS5B (2841-2849) 
TLWARMILMTHFFSV 
NS5B (2936-2944) 
GRAAICGKY  
108 ......V..  
100%(645839) 
..........   
100%(888356) 
...............      
100%(355099) 
.K.......   
100%(1204550) 
...............    
100%(1293207) 
.........   
100%(524161)  
265     ...............     
100%(28623) 
377 ...A..V..  
86%(4790) 
......V..  
14%(752) 
..........  
98%(8336) 
......T...  
2% (126) 
...............  
98%(7211) 
R..............  
2% (86) 
.K.......    
100%(10441) 
...............      
100%(11247)  
.........    
100%(7325)  
391 ...A..V..  
86%(50139) 
......V..  
14%(6360) 
..........  
97%(74045)  
......T...  
3%(1611) 
...............     
100%(58602)  
.K.......   
100%(137508) 
...............     
100%(152042) 
.........    
100%(98327) 
440 ...A..V..  
91%(8237) 
......V..  
9%(752) 
..........  
98%(11640)  
......T...   
2%(205) 
...............    
100%(16366) 
.K.......   
100%(24126) 
 
...............     
100%(26382)  
.........    
100%(20360) 
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Table 3-15 Mutations observed over time within HLA-B27 restricted epitopes in patient 45  
Table 3-16: Mutations observed over time within HLA-B27 restricted epitopes in patient 113  
Day HLA-B27 restricted epitope variation in patient 113 (progressor + HIV) 
 
P7 (780-788) 
GRWVPGAAY 
NS3(1492-1501) 
GRGKPGIYRF 
NS5B (2571-2585) 
KGGRKPARLIVFPDL 
NS5B (2820-2828) 
ARHTPVNSW  
NS5B(2841-2849) 
TLWARMILMTHFFSV 
NS5B (2936-2944) 
GRAAICGKY  
19 
.........  
100%(257044)  
..........   
100%(326285)  
...............  
100%(431124) 
.....I...    
100%(699421) 
A..V.V......   
100%(749410)  
.........   
100%(1384609)  
56 
.........  
98%(25888) 
......V..  
2%(528) 
.......... 
100%(61720) 
 ............... 
 100%(41182)  
.....I...   
98%(56549) 
.K.......   
2%(969) 
 
A..V.V......  
100%(78300) 
.........  
93%(34093) 
.......R.   
7%(2436) 
Amino acid sequence of HLA-B27 epitopes, HCV sequence found in acute HCV patinets using NGS technology. Points indicate homologous residues.  
 
Amino acid sequence of HLA-B27 epitopes, HCV sequence found in acute HCV patinets using NGS technology. Points indicate homologous residues.  
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Table 3-17: Mutations detected within the HLA-B27-restricted HIV gag epitope in patient 49  
Day HLA-B27 restricted HIV epitope in patient 49 
 p24 Gag (263-272) 
KRWIILGLNK 
 
    60 
 
..........  100%(4) 
 
         Amino acid sequence of HLA-B27 epitopes, sequence found in co-infected patients (HIV/HCV) using NGS technology. Points indicate homologous residues.  
 
 
 
 
 
 150 | P a g e  
Table 3-18: Mutations detected within HLA-B27 HIV epitope in patient 28 (P28) 
Day HLA-B27 restricted HIV epitope variation in patient 28 
 p24 Gag (263-272) 
KRWIILGLNK 
    
    406 
.....M....  
91%(8929) 
.......H..  
3%(273) 
.....M..H.  
1%(114) 
        Amino acid sequence of HLA-B27 epitopes, sequence found in co-infected patients (HIV/HCV) using NGS technology. Points indicate homologous residues. 
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Table 3-19: Mutations detect within HLA-B27 epitope in patient 45 (P45). 
Day HLA-B27 restricted HIV epitope in patient 45 
 p24 Gag (263-272)  
KRWIILGLNK 
 
   108 
 
..........   100%(2264) 
 
   391 
..........    91%(50) 
....M.....    2%(1) 
..C.......    2%(1) 
...M......    2%(1) 
.....QE.K.    2%(1) 
Amino acid sequence of HLA-B27 epitopes, sequence found in co-infected patients (HIV/HCV) using NGS technology. Points indicate homologous residues. 
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Table 3-20 Summary of the median number of mutations within different epitopes in spontaneous clearer and progressor patients.  
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3.1.12  Structural analysis  
 Predicted structure 3.1.12.1
The predicted structure of NS5B2841-2849 was carried out using Phyre 2 software 
and Pymol software was used to construct the predicted structure of the NS5B 
epitope, with and without the common mutations obseved in the NGS, using 
amino acid sequences and the known crystal structure of genotype 1a NS5B from 
the protein data bank at www.rcsb.org. 
Mutations detected within the immunodominant HLA-B27-restricted 2841 epitope 
using NGS were used to assess the impact on the predicted structure of NS5B 
using Pymol software. 
Figure 3-19: Single mutation (VRMILMTHF) compared to wild type sequence  
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicates the 
mutation.  
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Figure 3-20: Two mutations (VRVILMTHF) compared to wild type sequence  
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicates the 
mutations. 
 
 
Figure 3-21: Three mutations (VRVVLMTHF) compared to wild type sequence  
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicates the 
mutations.  
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Figure 3-22: Single mutation (AVMILMTHF) compared to wild type sequence 
 
 
 
Gray colour show the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicates the 
mutation.  
 
 
Figure 3-23: Four mutations (VRTVLVTHF) compared to wild type sequence  
 
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour 
indicates the mutations. 
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Figure 3-24: Single mutation (ARMILTTHF) compared to wild type sequence 
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicates the 
mutation.  
 
 
Figure 3-25: Single mutation (ARMILVTHF) compared to wild type sequence  
 
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicates the 
mutation.  
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Figure 3-26: Three mutations (VRMVLVTHF) compared to wild type sequence  
 
 
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicate the 
mutation.  
 
Figure 3-27: Single mutation (AVMILMTHF) compared to wild type sequence 
 
 
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicate the 
mutation.  
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Figure 3-28: Three mutations (ALWVRVILMTHFFSH) including a substitution 
outwith the epitope compared to wild type sequence  
 
 
Gray colour shows the NS5B, HLA-B27 restricted epitope highlighted in blue and the red colour indicate the 
mutation. 
  
3.1.13 Selection pressure across the HCV genome. 
Selection pressure across the entire HCV genome was calculated using dN-dS 
ratios using Hyphy within MEGA 6.0. The relationship between non-synonymous 
substitutions per non-synonymous site (dN) and synonymous substitutions per 
synonymous site (dS) used to measure selective pressure in different regions of 
the HCV genome. Codon-based selection analysis dN-dS was calculated by group.  
 Initially, selection pressure was calculated between HLA-B27+ and HLA-B27-
patients and then in HLA-B27+ spontaneous clearers HCV and progressors. Each 
region of the HCV genome was assessed for negative or positive selection 
pressure using Hyphy software. After aligning the sequences, codon-based 
selection pressure was assessed across the whole HCV genome.  
 Spontaneous clearer patients displayed largely negative selection pressure 
with no evidence of significant positive selection (Figure 3-29).This maybe 
attributed to the absence of a specific strong T cell immune repsonse although 
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small study numbers may limit the strength of the interpretation of these 
findings.  
Surprisingly, patients who progressed to chronicity also showed no evidence of 
significant positive selection pressure using dN-dS ratios (Figure 3-30). Two 
patients (P28 and P45) were assessed individually over time for the likelihood of 
amino acid changing substitutions across the whole genome (these patients were 
selected because sequence data was available at multiple timepoints) but no 
significant positive selection pressure was detected (Figure 3-31 and Figure 3-32 
This lack of statistical significance is likely to reflect the small sample size and 
clearer data may emerge following study of larger numbers of patients.   
  Finally, HLA-B27+ and HLA-B27- patients were compared. HLA-B27+ 
patients had evidence of higher positive selection pressure within codon 169 
within the core region (labelled according to the H77 reference) (Figure 3-33) 
than HLA-B27- (negative) patients (Figure 3-34).  
 In conclusion, positive selection pressure was detected in HLA B27+ 
patients at a site previously undescribed as being associated with positive 
selection in HLA B27+ patients. Surprisingly, statistically significantly selected 
codons were not detected – this may be due to small numbers in the final 
analysis. 
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Figure 3-29: dN-dS ratio in  HLA-B27+ spontaneous clearer patients  
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Figure 3-30: dN-dS ratio in HCV progressor patients 
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Figure 3-31: dN-dS ratio within progressor patient 28   
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Figure 3-32: dN-dS ratio within the progressor patient 45  
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Figure 3-33: dN-dS ratio in all HLA-B27+ patients 
 
dN-dS ratios indicate positive selection on codon 169 (leucine) within core (labelled according to H77 sequence) 
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Figure 3-34: dN-dS ratio in all HLA-B27 negative patients 
 
-25	
-20	
-15	
-10	
-5	
0	
5	
10	
1	 11
5	
22
9	
34
3	
45
7	
57
1	
68
5	
79
9	
91
3	
10
27
	
11
41
	
12
55
	
13
69
	
14
83
	
15
97
	
17
11
	
18
25
	
19
39
	
20
53
	
21
67
	
22
81
	
23
95
	
25
09
	
26
23
	
27
37
	
28
51
	
dN-dS	
dN-dS	
 166 | P a g e  
3.2 Functional analyses 
3.2.1 Design of a genotype 1a replicon containing a luciferase reporter 
gene 
 Introduction of adaptive mutations and a luciferase reporter gene 3.2.1.1
into the genotype 1a replicon 
A genotype 1a sub-genomic replicon (APP238 PH/SG-neo (L-I)), kindly donated by 
C. Rice (Figure 3-35) was adapted by introducing two mutations within NS4A 
(K1691R) and NS4B (E1726G) using site directed mutagenesis and cloning. An 
intermediate universal vector pEGFP-C1 (Figure 3-38) was used as a backbone 
plasmid to introduce the firefly luciferase gene that was ligated into the 
genotype 1a sub-genomic replicon. 
Figure 3-35: Original sub-genomic replicon HCV-1a 
 
Original genotype 1a sub-genomic replicon (APP238 pH/SG-Neo (L+I) containing the neomycin gene. shows 
the locations of two single-cutter restriction sites. The restriction enzymes AgeI and KpnI were used to cut 
the replicon and introduce the luciferase gene. 
 167 | P a g e  
3.2.2 Strategy for the construction of a replication-competent genotype 
1a sub-genomic replicon.  
The original genotype 1a sub-genomic replicon (App238 pH/SG-Neo (L+I)) was 
modified as follows. New adaptive mutations were introduced into the NS4A and 
NS4B (K1691R and E1726G) respectively, as well a firefly luciferase gene. This 
modification was carried out using site-directed mutagenesis and a standard 
cloning procedure. An intermediate plasmid pEGFP-C1 used to introduce the 
luciferase gene prior to transfer into the genotype 1a sub-genomic replicon 
(Figure 3-35). The genotype 1a replicon was used as backbone to introduce the 
mutations (A2841V, R2842V, M2843V, I2844V and T2838A) within the NS5B region 
to test the replicative capacity of a replicon containing mutations observed in 
the HLA B27+ cohort.   
3.2.3 Introduction of a luciferase reporter gene into the genotype 1a 
sub-genomic replicon  
To construct a genotype 1a sub-genomic replicon (APP238 pH/SG-Neo (L+I)) 
containing the firefly luciferase gene, a fragment composed of the firefly 
luciferase gene was amplified from pSGR-JFH1 using forward and reverse primers 
5`-ApaLI-luc : Gtgcac c ATG GAA GAC GCC AAA AAC, 3- luc(stop)-AscI:  “ GGC 
GGA AAG ATC GCC GTG TAA gGcgcgcc“, to produce a DNA fragment with two 
restriction sites ApaLI and AscI, located within the 5` and 3`termini 
respectively. The length of this DNA fragment about 1.65 KB. These primers was 
designed using CLC genomic® work-bench version 6.5.1(CLC Bio-Qiagen, Aarhus, 
Denmark).  
 The genotype 1a sub-genomic replicon (APP238 pH/SG-Neo (L+I)) was 
digested using two restriction enzymes AgeI and KpnI. The new DNA fragment 
from this diagestion was ligated into intermediate plasmids (pEGFP-C1), this step 
allow to introduce the firelfly luciferase gene from pSGR-JFH1 into the DNA 
fragment as the new DNA fragment composed the sites of two restriction 
enzymes ApaLI and AscI.  
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Following introduction of the firelfy luciferase gene into the DNA fragment, the 
DNA was digested with the AgeI-KpnI again, and re-ligated into the original 
genotype 1a sub-genomic replicon. Next, genotype 1a sub-genomic replicon was 
used to transform 10-Beta E.coli cells. Successfully transformed colonies were 
then sequenced using Sanger sequencing, to confirm the successful ligation of 
firefly luciferase gene into the genotype 1a sub-genomic replicon.   
 The new two adaptive mutations within NS4A and NS4B (K1691R and 
E1726G) were introduced into the genotype 1a sub-genomic replicon using site-
directed mutagenesis. Two restrictions enzymes was used to digest the genotype 
1a sub-genomic replicon (NsiI and Bsu36I) (Figure 3-39), DNA fragment was 
sequenced using Sanger sequencing to confirm the successful introduction of 
these two adaptive mutations (Figure 3-40 and Figure 3-41).  
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Figure 3-36: Proceedue used to introduce mutations into the genotype 1a replicon 
  
 
 
 
 
 
 
 
 
A) pEGFP –C1-Luc used to introduced the lucifersase gene prior to transfer into an intermediate genotype 1a sub-genomic replicon. B) The original genotype 1a sub-genomic replicon 
C) The final construction of genotype 1a sub-genomic replicon containing the luciferase gene.  
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Shorter plasmids obtained from genotype 1a sub-genomic replicon were created 
by digesting the sub-genomic replicon with two restriction enzymes AgeI and 
PmlI resulting in a new plasmid (8.4 Kb). This new shorter genotype 1a sub-
genomic replicon was used to introduce the mutations within the HLA-B27 
restricted epitope within the NS5B region (A2841V, R2842V, M2843V, I2844V and 
T2838A). The shorter plasmids were used as the chance of error rate is lower 
during the sub-cloning steps. 
Figure 3-37: Final Genotype 1a sub-genomic replicon  
 
     
The figure shows the sub-genomic replicon containing the luciferase gene.  Two restriction sites are 
highlighted that were used to cut genotype 1a sub-genomic replicon in order to create a smaller plasmid 
(8.4 Kb) that was used to introduce required  mutations within the NS5B2841-2849 restricted epitope. The 
smaller plasmid was then re-ligated into the main genotype 1a sub-genomic replcion. 
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3.2.4 Introduction of mutations within the NS5B2841-2849 restricted 
epitope  
After constructing the genotype 1a sub-genomic replicon, several mutations 
within the NS5B2841-2849 restricted epitope were introduced either single or 
sequentially, based on NGS detection of mutations from patients using site-
direct mutagenesis. 
Figure 3-38: Plasmid pGF-C1+Luc containing firefly luciferase gene 
 
 
 
The pEGFP-C1+Luc plasmid (6.2 Kb) was used to introduce the firefly luciferase gene that used to measure 
luciferase signal to measure replication capacity in the genotype-1a sub-genomic replicon. 
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Figure 3-39: Genotype 1a sub-genomic replicon digested using BSu36I  and NsiI 
 
To introduce the two adaptive mutations within the NS4A and NS4B two restriction enzymes used to shorten 
the plasmid and introduce the mutations successfully.  
 173 | P a g e  
Figure 3-40:  Adaptive mutations within NS4A 
 
E1726R mutation illustrating the substitution of GAG to GGG 
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Figure 3-41:  Adaptive mutation within NS4B 
 
K1691R mutation illustrating the substitution of GAG to GGG  
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Figure 3-42: Final construction of the genotype 1a sub-genomic replicon  
 
 
 
 
Genotype 1a sub-genomic replicon (12 Kb) containing mutations within the NS5B2841-2849 restricted epitope.  
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3.2.5 Assessing the replication assay 
To assess replication capacity following the introduction of specific mutations 
within the NS5B2841-2849 epitope in the genotype 1a sub-genomic replicon, a 
transient replication assay was used. In this assay, sub-genomic replicon RNA was 
introduced into human hepatoma cells 7.5 (Huh-7.5) and replication was 
evaluated based on luciferase detection.   
 During the transient assay the number of Huh-7.5 cells was adjusted to 
150,000 cells in each of the 24 wells. This standardisation was carried out to 
avoid cell confluence during incubation that could affect the outcome of the 
replication assay, particularly during later time points. For the genotype -1a sub-
genomic replicon, luciferase activity initially decreased after the first time point 
but increased 48 hours following transfection. The luciferase signal from a 
genotype-2a pSGR-Luc-JFH1 was higher than the genotype 1a sub-genomic 
replicon by about 100 fold, as expected from previous reports in the literature. 
A pSGR-Luc-JFH1/GND replicon was used as a negative control.  
 In order to optimise the assay using the genotype 1a sub-genomic replicon, 
Huh 7.5 cells were transfected with varying concentrations of sub-genomic 
replicon-1a RNA (1, 2.5, 5 and 10 ug). Post-transfection, luciferase activity was 
measured within 72 hours to study the correlation between the amount of sub-
genomic replicon-1a RNA inoculated and luciferase signal levels. Generally, 
within the first time point (4 h) the luciferase activity was higher as the amount 
of RNA inoculated increased. However, luciferase activity was the same at the 
end of the experiment regardless of the amount of RNA initially inoculated into 
the Huh-7.5 cells. Luciferase activity of the original sub-genomic replicon APP 
238 pH/SG-Neo (L+I) was low and identical to the sub-genomic negative control 
encoding the GND mutation (SG-Luc-1a-GND). 
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3.2.6  Replicative fitness of mutations within the NS5B 2841-2849 
restricted epitope 
Mutations were introduced into the new sub-genomic replicon containing the 
luciferase gene in order to measure replication and to assess the effect of 
mutations that occur in vivo within patients from the acute HCV cohort. These 
mutations were introduced either as a single mutation such as A2841V and 
R2842V or sequentially such as A2841V/M2843V, A2841V/M2843V/I2844V and 
A2841V/M2843V/T2838A (Figure 3-43). During all the experiments undertaken, 
new controls for sub-genomic replicon luc-JFH1 and luc-JFH1-GND were included 
to validate the experiments.  
Figure 3-43: Figures illustrating mutations introduced using site-directed 
mutagenesis. 
 
 
 
Mutations within the ARMILMTHF NS5B2841-2849 epitope selected during progression to chroncity were 
introduced into genotype 1a replicon system. 
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3.2.7 The effect of single and multiple clustered mutations on 
replication  
Using results from next generation sequencing, mutations observed in vivo from 
patients who either spontaneously cleared HCV or progressed to chronicity 
within the highly conserved HLA-B27 epitope (NS5B 2841-2849) were introduced to 
the replicon system.  
 The impact of each mutation on viral replication (fitness cost) was assessed 
using the genotype 1a sub-genomic replicon as described above. The 
introduction of the commonly observed A2841V mutation resulted in a 7-fold 
reduction in replication (Figure 3-44). The R2842V mutation (an HLA B27 anchor 
site) also showed a 7-fold decline in luciferase activity compared to the sub-
genomic replicon (Figure 3-45). 
 Next, double mutations were tested; the A2841V/M2843V replicon resulted 
in nine fold lower replication compared to the wild-type (WT) sub-genomic 
replicon (Figure 3-46).  
 Patients with triple mutations at position I2844V or outside the HLA-B27 
epitope T2838A showed a different response based on the mutation location. 
Triple mutations were introduced sequentially in addition to the other two 
mutations, for example, A2841V/M2843V/I2844V. Luciferase activity was 
measured and the replication capacity was increased compared with single or 
double mutation variants – at around 3-fold lower than WT replicon (Figure 
3-47). A mutation (T2838A) commonly found outside the HLA-B27 epitope, was 
found to restore replication capacity to a similar level compared to the genotype 
1a sub-genomic replicon (Figure 3-48).  
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Figure 3-44: A2841V mutation introduced into the genotype 1a sub-genomic replicon.  
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A) A single mutation (A2841V) was successfully introduced and is highlighted with a black rectangle. B) The A2841V mutation had minimal effect on predicted NS5B structure. C) RNA 
from the genotype 1a sub-genomic replicon containing a single mutation (A2841V) was electroporated into Huh7.5 cells. Huh7.5 were lysed at 6 time points (4, 24, 48, 72, 96 and 120 
h). Post-electroporation the luciferase signal activity was measured. All assays were done in triplicate and the average value is shown. D) p value calculated using the  Mann Whitney 
U test. 
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Figure 3-45: R2842V mutation introduced into the genotype 1a sub-genomic replicon. 
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A) Single mutation (R2842V) successfully introduced and highlighted with a black rectangle. B) The R2842V mutation appeared to cause a substantial change in NS5B structure due to 
the substitution of arginine with a large side chain structure to valine. C) RNA from the genotype 1a sub-genomic replicon containing a single mutation (R2842V) was electroporated 
into Huh7.5 cells. Huh7.5 were lysed at 6 time points (4, 24, 48, 72, 96 and 120 h). Post-electroporation the luciferase signa activity was measured. All assays were done in triplicate 
and the average value is shown. D) p value was calculated using the Mann Whitney U test. 
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Figure 3-46: A2841V/M2843V mutations introduced into the genotype 1a sub-genomic replicon.  
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A) Double mutations (A2841V/M2843V) were successfully introduced and highlighted with a black rectangle. B) The A2841V/M2843Vmutation appeared to significantly affect NS5B 
structure. C) RNA from the genotype 1a sub-genomic replicon containing the double mutation (A2841V/M2843V) was electroporated into Huh7.5 cells. Huh7.5 were lysed at 6 time 
points (4, 24, 48, 72, 96 and 120 h). Post-electroporation luciferase signal activity was measured. All assays were done in triplicate and the average value is shown. D) p values were 
calculated using the Mann Whitney U test.  
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Figure 3-47: A2841V, M2843V and I2844V mutations introduced into the genotype 1a sub-genomic replicon.  
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A) A triple mutation (A2841V/M2843V/I2844V) was successfully introduced and is highlighted with a black rectangle.  B) Effect of A2841V/M2843V/I2843V mutations on NS5B 
structure; the triple mutation appeared to have only a minimal effect on predicted structure. C) RNA from the genotype 1a sub-genomic replicon containing multiple mutations 
(A2841V/M2843V/I414V) was electroporated into Huh7.5 cells. Huh7.5 were lysed at 6 time points (4, 24, 48, 72, 96 and 120 h). Post-electroporation the luciferase signal activity was 
measured. All assays were done in triplicate and the average value is shown. D) p values were calculated using the Mann Whitney U test. 
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Figure 3-48: A2841V, M2843V and T418V mutations introduced into the genotype 1a sub-genomic replicon.  
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A) The triple mutation A2841V/M2843V/T418V was successfully introduced and highlighted with a black rectangle. B) The A2841V/M2843V/T2838A mutation appeared to have only a 
minimal effect on predicted NS5B structure. C)  RNA from the genotype 1a sub-genomic replicon containing multiple mutations (A2841V/M2843V/T2838A) was electroporated into 
Huh7.5 cells. Huh7.5 were lysed at 6 time points (4, 24, 48, 72, 96 and 120 h). Post-electroporation the luciferase signal activity was measured. All assays were done in triplicate and 
the average value is shown. D) p values were calculated using the Mann Whitney U test. 
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In summary, the predicted structure of the triple mutants observed in patients 
that progressed to chronicity appeared to have been restored to be close to 
wild-type NS5B – this was associated with restoration of replication.
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3.3 Detecting Virus Specific CD8+ T-cell responses using 
ELISpot 
3.3.1 Subject characteristics 
Fourteen patients were tested in this study using ELISpot assay technology. The 
cohort was divided into several groups based on their characteristics; HLA-B27+ 
patients who cleared HCV spontaneously (n=5) and HLA-B27+ patients who 
progressed to chronicity (n=4). A comparison was also made between HLA-B27+ 
patients (n=9) and HLA-B27- patients (n=5) and between co-infected patients 
(HIV/HCV) (n=9) and mono-infected patients (HCV) (n=5). Finally HLA-B27+ 
patients co-infected (HIV/HCV) (n=7) and HLA-B27+ mono-infected (HCV) (n=2) 
responses were compared. To determine the presence of specific T cell 
response, PBMCs were isolated, and cells were stimulated using HCV peptide 
pools spanning the whole HCV genome. Responses were compared using a Mann 
Whitney U test;  data with p values less than or equal to 0.05 were considered to 
be statistically significant. A “broad” T cell response was defined as a response 
to 3 or more peptide pools while a “strong” response was considered to be a 
response of greater than 20 SFU/106 cells.  
To determine the presence of specific T cell response, PBMCs were isolated, and 
cells were stimulated using HCV peptide pools spanning the whole HCV genome. 
 Measuring production of IFN-γ in HLA-B27+ spontaneous clearers 3.3.1.1
and progressors  
IFN-γ ELISPot assays were used to determine the production of IFN-γ-following 
stimulation of PBMCs with peptide pools supplied by BEI Resources and those 
designed in-house, based on prediction algorithm.  
Responses were compared in HLA-B27+ patients who spontaneously cleared the 
HCV infection or progressed to chronicity. Significantly higher responses were 
found in spontaneous clearers than progressors (p=0.001).  Multiple HCV peptide 
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pools were significantly selected indicating a broad multi-specific response in 
spontaneous clearers (Figure 3-49). 
 T cell responses in HLA-B27+ and HLA-B27- patients. 3.3.1.2
IFN-γ ELISpot production was higher in HLA-B27+ versus HLA B27- patients. 
Analysis of using the predicted peptide panel showed no significant difference in 
responses between groups (Figure 3-50). 
Figure 3-49: IFN-γ production in HLA-B27+ spontaneous clearers and progressors 
     
  
A) Total T cell responses was stronger in HLA-B27+ spontaneous clearers versus progressors (p=0.001) B) 
Total T cell responses to individual peptide pools.  
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Figure 3-50: IFN-γ production in HLA B27+ versus HLA B27- patients 
  
   
 
A) Total T cell response using total peptide pools. B) Total T cell response to different individual peptide 
pools. C) Total T cell response between HLA-B27+ and HLA-B27- patients using predicted peptides designed 
in-house. 
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3.3.2 T- cell response in HIV/HCV co-infected and HCV mono-infected 
patients  
IFN-γ measurement was carried out in patients (including HLA B27- control 
patients) with co-infection (HIV/HCV) and with monoinfection (HCV). Patients 
with monoinfection had higher specific T-cell responses than patients with co-
infection (p=0.0015)(Figure 3-51).  
 The same comparison was made between co-infected and mono-infected 
HLA B27+ groups with acute HCV infection. Patients with monoinfection had 
higher responses (p=0.0014) (Figure 3-52).  
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Figure 3-51: Total responses in HIV/HCV co-infected and HCV mono-infected 
patients  
  
Individual peptide pool responses in HIV/HCV co-infected and HCV mono-infected 
patients 
  
 IFN-γ responses measured by ELISpot in co-infected and mono-infected patients are shown A) Reponses in 
HLA-B27+ patients. B)  Responses measured using different peptides pools for each protein  
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Figure 3-52: Responses in HLA-B27+ co-infected and mono-infected patients 
  
  
IFN-γ responses measured by ELISpot in HLA B27+ co-infected and mono-infected patients A) Responses in 
HLA-B27+ co-infected and mono-infected patients. B)  Responses measured using different peptides pools 
for each protein  
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3.3.3 Individual patient responses 
Individual responses in all HLA-B27+ patients were tested are shown below. 
Figure 3-53: IFN-γ responses measured by ELISpot in G5 (clearer) 
 
 
 
 
 
 
 
  
Figure 3-54: IFN-γ responses measured by ELISpot in G17 (clearer) 
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Figure 3-55: IFN-γ responses measured by ELISpot in G18 (clearer) 
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Figure 3-56: IFN-γ responses measured by ELISpot in P49 (clearer) 
 
Figure 3-57: IFN-γ responses measured by ELISpot in P113 (progressor) 
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Figure 3-58: IFN-γ responses measured by ELISpot in P28 (progressor) 
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Figure 3-59: IFN-γ responses measured by ELISpot in P45 at different time points 
(progressor) 
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3.3.4 Flow cytometry  
Flow cytometry was carried out in order to examine the phenotype of the T cell 
response in representative patients with either spontaneous clearance or 
progression to chronicity. We used CCR7 and CD45RA expression to divide cells 
into memory (effector and central), naive and effector populations.  Sufficient 
cells to carry out flow cytometry experiments were available from single 
representative patients only. Samples from P28 (progressor) and G5 (clearer) 
were used to examine differences in phenotype in these patients. Samples were 
gated by lymphocyte population, CD3+ cells and CD4+ or CD8+ populations 
(Figure 3-60) 
Figure 3-60: Gating CD3+ cells into CD4+ and CD8+ sub-populations 
 
 
Qdot and PerCP-Cy5.5 antibodies were used to separate CD4 and CD8+ cells respectively. 
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No clear difference in secretion of CD4+ or CD8+ IL2, IFN or TNF was observed 
between these representative patients and the phenotype of CD8+ cells was 
similar, although a larger proportion of effector CD8+ cells was observed in the 
clearer patient (G5) than the progressor (P28); Figure 3-61.  
Figure 3-61: CD8+ cell populations in G5 (clearer) and P28 (progressor) 
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We nexct used pentamer staining to examine the phenotype of the HCV specific 
response directed against the NS5B2841 epitope. We examined the activation 
markers HLA-DR, CD38 and inhibition marker PD-1. No clear difference in the 
proportion of cells with NS5B2841 pentamer staining was seen in each patient 
and the pentamer positive cells in both patients showed an activated phenotype 
(CD38+) although HLA DR expression was higher in G5; Figure 3-62. Additionally, 
expression of PD-1 was higher in P28. 
Figure 3-62: Activation and inhibition markers in patients G5 (clearer) and P28 
(progressor). 
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While the proportion of pentamer + CD8+ cells was similar in each patient, the 
proportion of granzyme A, B and perforin staining in pentamer stained cells was 
higher in the clearer than the progressor, suggesting a difference in functionality 
in cells recognising the NS5B2841 epitope (Figure 3-63). 
Finally, we looked for evidence of degranulation using granzyme A and B and 
perforin staining in the same patients. 
Figure 3-63: Granzyme A and B and perforin staining in G5 (clearer) and P28 
(progressor) 
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In the clearer patient (G5), higher secretion of granzymes A and B and 
perforin was seen, when compared with the progressor patient (P28). 
A summary table is shown below outlining evidence of selection and T cell 
responses in the patients studied Table 3-21. A trend towards a larger number 
of mutations within NS5B2841 was seen but did not reach statistical 
significance (the median number of mutations in clearers was 0 and 3 in the 
progressor group; p=0.08; Mann Whitney test). Clearance occurred in both 
HIV negative patients while progression occurred in 80% of coinfected 
patients (p=0.13; Fishers exact test). 
 
Table 3-21: Summary of the immune response in the HLA B27+ cohort  
 
Patie
nt 
Pattern Selection within 
NS5B2841-2849 
Highest  
(SFU) 
 T cell 
response 
(ELISpot) 
HIV 
P49 Clearer WT 16  Weak Yes 
G5 Clearer WT 95  Strong Yes 
G18 Clearer 1 mutation 815  Strong No 
G17 Clearer NA   Strong No 
P110 Progressor* 
(2 episodes) 
3 mutations 23   NA Yes 
P45 Progressor WT   Weak Yes 
P28 Progressor 3 mutations 5  Weak Yes 
P10 Progressor 3 mutations NA  NA Yes 
P113 Progressor 2 mutations 14  Weak Yes 
P3 Progressor NA   NA Yes 
*P110 was initially classified as a spontaneous clearer as he had 2 episodes of infection, both of which 
resolved with an intervening period between viraemic episodes of >6 months. However, the phylogeny 
showed a highly similar virus indicating the presence of fluctuating viraemia and progression rather 
than 2 episodes of clearance. The presence on relapse of 3 escape mutations within NS5B2841 is also in 
keeping with progression.  
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Chapter 4: Discussion 
Several studies have shown that host immune responses against HCV play a 
crucial role in controlling the infection. HCV clearance is linked to strong 
specific adaptive immune responses (CD4+ and CD8+ T cells), which are 
known to increase and accumulate in the infected liver (Ascione et al., 2007, 
Jacobson et al., 2010, Lechner et al., 2000c, Thimme et al., 2001a). In 
addition, the role of specific CD8+ T cells has been shown in an animal model 
(chimpanzee);depletion of these cells was associated with progression of 
infection (Shoukry et al., 2003a). Failure of specific CD8+ T cells responses in 
most HCV patients and persistence and progress to chronicity is still not very 
well understood (Simmonds, 2013, Neumann-Haefelin et al., 2005). More than 
one mechanism may  lead to immune failure including the inability to make 
new T cells, exhaustion of CD8+ T cells functionality, or the  appearance of 
escape mutations (Thimme et al., 2012, Sievert et al., 2011, Neumann-
Haefelin et al., 2005, Rehermann and Nascimbeni, 2005). Growing evidence 
suggests that escape mutations from T cell responses emerge early during the 
acute phase of HCV infection and continue to appear in the circulation for 
many years (Weiner et al., 1995). Nevertheless, the evaluation of viral escape 
mutations during the infection with HCV is not always present . For instance, 
viral resolution can occur with minimum variation in the epitope before 
resolution. Several studies carried out on humans and chimpanzees show that 
not all epitopes restricted by human leukocytes class I (HLA class I) require  
multiple variations to produce escape mutations (Yahia, 2011, Chang et al., 
2007, Erickson et al., 2001).   
As the  CD8+ T cells response against specific epitopes is restricted by several 
HLA class I alleles, it is clear that HLA plays a crucial role in the outcome of 
infection. A study that was carried out on women who were infected with 
HCV from the same single source showed that the HLA class I alleles A03, B27 
and Cw01 were found more in patients who cleared the HCV infection 
compared with patients who progressed to chronicity. Significantly, HLA-B27 
has been observed as the strongest allele that is associated with viral 
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clearance (Tester et al., 2005). HLA-B27 has also been found to play a 
significant role in HIV as it is slows disease progression, for instance, in 
delaying the decline of CD4 T cells and onset of symptoms and lowering the 
HIV viral load (Trachtenberg et al., 2003, Scherer et al., 2004). In agreement 
with this finding, an immunodominant HLA-B27 restricted HIV-specific CD8+ T 
cell epitope has been studied (Nixon et al., 1988b), and the onset of viral 
escape mutations within this epitope has a high impact on the HIV outcome 
by progression toward AIDS (Goulder et al., 1997). 
4.1 The T cell mediated immune response to acute HCV 
In this study, the central aim was to investigate the T cell response to acute 
HCV infection in patients with the HLA B27 allele who were infected or 
uninfected with HIV. A next generation sequencing approach was used to 
sequence the whole genome of HCV to look for evidence of positive selection 
within HLA B27-restricted epitopes, a replicon system was used to investigate 
the impact of mutations within the immunodominant NS5B2841-2849 epitope and 
ELISpot assays and flow cytometry were employed to determine the 
phenotype and function of the T cell response.  
The HLA B27 allele is known to be associated strongly with spontaneous 
clearance of HCV (around 80% of such patients spontaneously clear HCV; a 
reversal of the likelihood of clearance in other individuals). Within the Acute 
HCV UK cohort, we noted that patients with HIV had a lower likelihood of 
spontaneous clearance (37.5% versus 100%) and aimed to identify if this was 
due to disruption of the T cell response in these patients. 
4.2 Failure of the T cell response in acute HCV infection  
During progression to chronic infection, the CD8+ T cell responses may fail 
due to a weak directed response (T cell exhaustion) or a misdirected response 
due to immune escape. Studies carried out in humans and chimpanzees 
within the acute phase show that in some patients CD8+ T cells are weak or 
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become exhausted during the early stages of infection (Cooper et al., 1999b, 
Thimme et al., 2002, Thimme et al., 2001b). In chimpanzees, specific T cells 
may be found in the liver and in the periphery, but they do not have the 
ability to clear the infection (Walker, 2010). In humans, the failure of specific 
CD4+ T cells and CD8+ T cells against HCV infection needs to be investigated 
more (this has been under-studied due to a lack of patient cohorts identified 
in the acute phase).  
Impaired priming of specific CD8+ T cells against HCV may also occur due to a 
low number of functional antigen presenting cells (Walker, 2010).  
4.3 Viral escape 
As HCV is an RNA virus with a high replication rate of an average 1012 virions 
per day (Neumann et al., 1998), changes within the genome (occurring as a 
result of lack of proof-reading function of the RNA polymerase) can result in 
rapid escape from virus-specific CD8+ T cell responses. The first descriptions 
of virus escape from the immune system came from chronically infected 
patients (Chang et al., 1997) and from a chimpanzee that was infected 
experimentally (Weiner et al., 1994, Erickson et al., 2001). Importantly, HCV 
escape mutations have more recently been found to become established 
within early phase of infection (acute phase) and are significantly associated 
with proceeding to chronicity (Erickson et al., 2001). 
 In various studies of patients with early HCV infection, viral escape from 
specific CD8+ T cell responses was not detected within patients who 
subsequently spontaneously cleared the infection but was detected within 
patients who progressed to the chronic phase (Timm et al., 2004b, Cox et al., 
2005a, Cox et al., 2005b). During chronicity, mutations within CD8+ T cell 
epitopes were found to revert to the original sequence as T cell responses 
regressed (Cox et al., 2005b). In patients with dissimilar HLA types, reversion 
within HLA-restricted epitopes can be seen following transmission of the 
virus; transmission of an HLA-B8-restricted epitope to a non-HLA-B8 patient 
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resulted in rapid reversion of this mutation (Timm et al., 2004a).  
 In another study of Irish rhesus negative women infected acutely with 
immunoglobulin therapy, changes in amino acid sequences in HLA-restricted 
epitopes were seen with reversion in other women who did not carry a similar 
allele (Ray et al., 2005a).  This phenomenon may be explained by the viral 
fitness cost concept, where viral escape mutations have an impact on 
reducing viral replication capacity (Bowen and Walker, 2005a).  
Thus, immuno-dominant CD8+ T-cell responses may leave footprints in the 
viral sequence within the viral genome. If this does not occur at a fitness cost 
to the virus, such immune escape footprints may become fixed at the 
population level. A study carried by Thimme and colleagues in 2007 showed a 
particularly strong association between particular sequence variations driven 
by the CD8+ response in HLA-B27+ patients. A single immuno-dominant CD8+ 
epitope at position 421 of the NS5B protein was found in this study to be 
associated with a protective CD8+ response (Timm et al., 2007b, Neumann-
Haefelin et al., 2006). This finding fits strongly with the hypothesis that CD8+ 
T-cells mediate immune pressure during acute HCV infection. 
 Mutations within such immuno-dominant epitopes can result in viral 
escape from HCV-specific CD8+ T-cell responses. Mutations within the anchor 
binding sites (usually positions 2 and 9 of a peptide epitope sequence) and 
the C-terminal amino acid can weaken peptide binding to the HLA class I 
molecule (such as HLA B27). Mutations located in the centre of the HLA 
molecule reduce the interaction with T cell receptors (TCR) (Soderholm et 
al., 2006). Mutations within flanking regions of the epitope may also have an 
impact by inhibiting proteasomal processing of the protein precursor (Seifert 
et al., 2004, Timm et al., 2004a, Kimura et al., 2005).  
 In experimentally infected chimpanzees, an impaired CD4+ T-cell 
response has been associated with escape from the CD8+ T-cell response and 
progression to chronicity (Grakoui et al., 2003b). This suggests that viral 
escape within specific CD8+ T-cell epitopes may occur in part as the result of 
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weak help from CD4+ T-cells. Another study carried out by Meyer et al. in 
2004 showed that low diversity within the TCR repertoire could play a role in 
viral escape (Meyer-Olson et al., 2004). Viral escape (Boettler et al., 2005) 
has been shown to be strongly associated with escape from immuno-dominant 
HLA-restricted CD8+ responses; indicating that such class I HLA alleles have a 
substantial impact on the immune response (Schmidt et al., 2011).  
 A major limitation on viral escape is virus fitness cost, which reduces 
the likelihood of persistence of a specific escape mutation. An epitope within 
an essential area for function of a particular viral protein increases the 
likelihood of a protective CD8+ T cell responses; this has been shown within 
specific HLA-B27 and HLA-A3-restricted epitopes (Dazert et al., 2009, 
Fitzmaurice et al., 2011). 
 The HLA B27-restricted NS5B2841-2849  epitope, situated adjacent to the 
active site of NS5B is particularly well-described. Mutations accrued 
sequentially within this epitope (cluster mutations) can diminish the HCV 
fitness cost by restoring viral replication. In one study, all HLA-B27+ patients 
infected chronically with HCV genotype 1 had clustered mutations within a 
single immune-dominant epitope that were strongly associated with HCV T 
cell escape (Dazert et al., 2009).  As multiple viral immune escape mutations 
may take a long time to emerge within patients who have the HLA-B27 allele, 
the immune system gains time to react to cognate epitopes.  
 This observation is in line with another study of the protective HLA-A*03 
allele; this allele was found to be protective in Irish women infected with 
HCV genotype 1b (McKiernan et al., 2004). Two separate studies carried out 
by Merani et al and the Klenerman et al showed that there is a strong 
association between this HLA class I allele and cluster mutations; these 
mutations were clearly observed within an HLA-A*03 restricted epitope within 
the NS3 protease protein.    
 Viral escape mutations can be found in MHC class II-restricted epitopes 
as well,  but such mutations are far less frequently found than escape within 
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CD8+ MHC-class I-restricted epitopes in both humans and chimpanzees 
(Fleming et al., 2010).  Other factors, such as impaired CD4+ T-cell function, 
are very likely to play a role in CD8+ epitope viral escape. Data from one 
study suggested that 50-70% of HCV immune escape occurs within targeted 
CD8+ T-cell epitopes (Neumann-Haefelin et al., 2008).   
   
4.4 CD8+ T-cell dysfunction  
Several studies have shown that viral escape is not the only reason for failure 
of the immune response to HCV infection; dysfunction of CD8+ T-cells also 
plays a significant role in progression to chronicity. Examples of T cell 
dysfunction include lack of production of antiviral cytokines (e.g. IFN-γ) or 
lack of proliferation occurring despite contact with cognate antigen 
(Nakamoto et al., 2009a).  
 A dysfunction pattern is commonly observed in HCV patients within the 
chronic phase and in patients within the acute phase who subsequently 
progress to chronicity. Such T cell dysfunction occurs in association increasing 
expression of inhibitory receptors such as PD-1 on CD8+ cells (Golden-Mason 
et al., 2007, Radziewicz et al., 2007a) and a decrease in expression of CD127 
(Bengsch et al., 2007).  
CD8+ T-cells within the liver that have high PD-1 expression have been found 
to be prone to apoptosis (Radziewicz et al., 2008). Blocking antibodies 
targeting PD-1 can increase proliferation of both CD127+ and PD-1+ HCV-
specific CD8 T-cells (Radziewicz et al., 2007a). Another study showed that an 
increase in T-cells function could be elicited by blocking another inhibitory 
receptor (CTLA-4) (Nakamoto et al., 2009a).  
 This suggests that such T-cells are exhausted due to the activation of 
inhibitory receptor pathways (Kasprowicz et al., 2008). Several other factors 
may contribute to or be associated with impairment of the CD8+ T-cell 
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responses such a lack of CD4+ T-cell helper cell support or upregulation of T 
regulatory cells. 
4.5 Lack of CD4+ help  
CD8+ T-cells are the main effector cells against HCV infection. Strong CD8+ 
responses require significant contributions from CD4+ T helper cells. Studies 
of the mouse LCMV model have clearly shown how a significant contribution 
from CD4+ T-cells helps to support an effective cytotoxic CD8 T-response 
(Matloubian et al., 1994).  Patients with chronic HCV infection commonly 
exhibit poor CD4+ T-cell responses that may lead to low functionality of CD8+ 
reponses (Semmo et al., 2005b).   
4.5.1 Importance of the HLA-B27 allele and the association with 
spontaneous clearance of HCV 
As discussed above, the HLA class I B27 allele has been associated with 
selection of a key HLA-B27-restricted epitope within NS5B (NS5B2841-2849) and 
more recently selection within several other B27-restricted HCV epitopes.  It 
also has an essential protective role in patients infected with HIV in 
association with recognition of a structurally unrelated epitope within HIV 
gag  (Goulder and Watkins, 2008, McKiernan et al., 2004).  
 In patients with HIV infection, viral escape from the HLA-B27 restricted 
gag epitope has an impact on viral replication by lowering viral load, 
prolonging the CD4+ T-cell decline and delaying the start of AIDS symptoms 
(Goulder and Watkins, 2008). As has already been described, for escape from 
the NS5B2841-2849 HCV epitope, escape from the B27-restricted HIV gag KK10 
epitope also requires a cluster of mutations to evade the acquired immune 
response.  A mutation noticed within this HLA-B27 restricted epitope (L268M) 
weakens recognition of the T cell response and this mutation can also  
negatively affect DC function (McMichael, 2007). Another mutation (R264K), 
at the main binding anchor site within the epitope, also leads to escape. This 
mutation often occurs in the later stages of HIV infection (McMichael, 2007).  
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 The R264K escape mutation has an impact on viral replication fitness 
when it is expressed alone and is often associated with another mutation, 
located 90 amino acids upstream of the HLA-B27 epitope (S173A), which 
works as a compensatory mutation (McMichael, 2007, Schneidewind et al., 
2008, Streeck et al., 2008). In summary, the HLA-B27 is associated with 
strong, significant, durable control of both HCV and HIV due to effective 
immune responses targeted against key B27-restricted epitopes. These 
responses may be partially abrogated by immune escape in association with 
compensatory mutations.                      
 The immuno-dominant HLA-B27-restricted HCV-specific CD8+ T-cell 
epitope NS5B2841-2849 of HCV (wild-type sequence ARMILMTHF) described above 
is present in patients infected with HCV genotype 1 (but not other HCV 
genotypes) and is associated with spontaneous resolution of HCV infection  
(McKiernan et al., 2004, Hraber et al., 2007). This HLA-B27 restricted immune 
response could help explain why other HCV genotypes are not cleared 
spontaneously as readily as other genotypes (Neumann‐Haefelin et al., 2010). 
HLA-B27+ patients that progress to the chronic phase classically display 
cluster mutations indicating a high level of selection pressure within this 
epitope (Neumann‐Haefelin et al., 2006).   
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Figure 4-1: Structure of NS5B 
A)                                                      B) 
 
                                                           
C) 
 
(A) NS5B (front) displayed and coloured according to individual domains using Pymol (red-fingers; blue-
palm; green-thumb). (B) NS5B (back). The HLA B27-restricted NS5B2841-2849 epitope (upper right and 
lower panels) is shown in pink. It is located at the thumb domain and close to the finger domain (C) 
Close-up of the epitope region with sequence positions. 
 
In this thesis, multiple mutations within the immunodominant NS5B2841-2849 
epitope were found to be present in HLA B27+ patients with genotype 1a 
acute HCV. In keeping with the studies described above, escape within this 
epitope was seen in patients with HCV that subsequently progressed to 
chronicity and interestingly in one patient (P110) that displayed spontaneous 
clearance of HCV on two occasions.  
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The predicted structure of the mutations observed in this patient was not 
hugely altered however, despite the presence of multiple clustered mutations 
(Figures 3-23 and 3-26) .  
 Mutations observed in vivo were introduced into a genotype 1a replicon 
system in order to assess viral fitness and to provide a model reflective of the 
genotype 1a sequence observed in patients in this cohort (previous studies 
have all employed a genotype 1b replicon system).  The majority of epitope 
mutations observed in this study were within TCR contact residues rather 
than anchor sites; this has been observed before in other studies. Although 
not observed in this study, mutations were introduced within HLA-B27 binding 
anchor sites in order to assess the impact this would have on viral replication 
(under the hypothesis that these do not persist due to poor replicative 
fitness). Such mutations were associated with reduced replication. 
 As in other studies, multiple clustered viral escape variants were 
observed in patients with progression to chronicity, highly suggestive of 
successful viral escape from the specific CD8+ T-cell response as observed in 
other studies  (Dazert et al., 2009). The accumulation of mutations appeared 
to occur sequentially during early infection. In theory, the HCV immune 
response could be primed by including this conserved region in a vaccine 
(Timm et al., 2007a). 
4.5.2 Mutations detected within HLA-B27 epitopes using NGS 
Deep sequencing generates a vast amount of sequence data, with more than 
10 million nucleotides of the viral genome produced in each sequencing run. 
Low-frequency mutations may be visualised with higher depth than ever 
before and variants that enable escape from T-cell immune pressure can be 
identified (Bull et al., 2011a, Plauzolles et al., 2013). In this study, we aimed 
to investigate the role of HLA-B27 in defining outcomes in early HCV infection 
in a cohort of individuals with or without HIV co-infection (Thomson et al., 
2010).  
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Advances in next-generation sequencing techniques allowed us to sequence 
full HCV genomes in the majority of patients, even those with low viral loads 
at the time of sampling (one genome was obtained from a patient with a viral 
load of 50 IU/ml). Two approaches were used; metagenomic and target-
enrichment-based sequencing.  
 Target enrichment was found to be a more efficient and sensitive 
method than metagenomic sequencing and genomes detected using both 
methods were found to be identical, indicating that the purification of HCV 
with target probes did not result in biased sampling. 
 Known HLA-B27 restricted CD8+ T-cell epitopes within the HCV genome 
were examined to investigate the natural history of accumulation of 
mutations within these epitopes and variation across the entire genome was 
also studied using measurement of pairwise distance and dN/dS ratios. In the 
majority of patients, a gradual accumulation of mutations over time occurred 
within a well-described immuno-dominant HLA-B27-restricted epitope 
(NS5B2841-2849) in evolving progressors, showing allele-specific selection 
pressure (Neumann‐Haefelin et al., 2006, Timm et al., 2007a). Such 
mutations are associated with CD8+ T-cell viral escape and have been 
described in HLA B27+ patients with chronic HCV, although accumulation of 
these mutations and their early accumulation in acutely infected patients has 
not been previously described.  
 We examined other mutations recently described to occur in HLA B27+ 
patients but did not find significant immune selection within these in evolving 
progressor patients or spontaneous clearers.  
 We next aimed to identify novel epitopes using a bioinformatic method 
based on known binding of the HLA B27+ molecule to amino acid sequences 
and the presence or absence of essential contact sites e.g. to metal ions or 
other amino acids using structural pdb data (in collaboration with Dr Sreenu 
Vattipally).  
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Although the NS5B2841-2849)  epitope was correctly identified using this method, 
other predicted epitopes did not result in functional T cell responses by 
ELISpot analysis. However, the presence of another HLA B27-restricted 
epitope was implicated by a significant dN/dS signal within the core of HCV. 
Peptide mapping would help to narrow down the location of this epitope but 
would require a large number of cells – further studies to examine this finding 
further in similar patients are indicated.  
 Immunological analysis using class I pentameric complexes has shown 
that a single mutation in the NS5B2841-2849 epitope slightly decreases T-cell 
binding and the release of interferon gamma (IFNγ) but that multiple (more 
than one mutation) clustered mutations result in the elimination of T-cell 
recognition (Dazert et al., 2009). 
 We used Illumina deep sequencing to identify variation within these 
HLA-B27 epitopes over time during acute HCV infection in order to associate 
these with spontaneous clearance or progression to chronicity. NGS identified 
one patient with mixed infection with other genotypes; P28 had mixed 
infection with genotypes 1a and 4d. In this patient, mixed infection did not 
substantially affect the number of mutations detected identified but 
variation in replication of co-dominant strains could in theory affect viral 
escape in other patients.       
 The majority of patients from the progressor group developed mutations 
within the NS5B2841 epitope over time; we hypothesized that this was due to 
the effect of HIV and an impaired CD8+ T-cell response against HCV and 
aimed to investigate this further by measuring T cell function using IFN 
ELISpot assays. 
 The majority of patients with spontaneous clearance of HCV had 0-1 
mutations within all previously described HLA-B27 epitopes. One patient who 
had a late spontaneous clearance of HCV more than a year after infection 
(P110) showed evidence of clustered mutations within a single epitope 
(NS5B2841-2849). However, this patient later develop recurrence of infection 
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and was reclassified as a progressor patient. 
 Viral persistence in the absence of T-cell escape may reflect a failure of 
the CD8+ T-cell response. As discussed above, this may occur as a result of an 
insufficient CD4+ T-helper cell response (especially in the context of co-
infection with HIV) or of upregulation of inhibitory markers such as PD-1 
expression that are associated with T-cell exhaustion (Dazert et al., 2009). 
We aimed to investigate the mechanism of persistence in those patients with 
no evidence of positive selection in known or unknown epitopes using ELISpot 
and flow cytometry when sample availability allowed. 
 Multiple clustered mutations of (two or more) amino-acids were found 
to be associated with markedly reduced viral replication. This supports our 
observation that wild-type variants (and variants with single amino acid 
substitutions) decline and are replaced by fitter triple mutants as the virus 
establishes persistence. These mutations may not emerge in patients who do 
not raise an effective T-cell mediated immune response; this may indeed be 
more likely in patients co-infected with HIV as the CD4+ T-helper cell 
response may be compromised (Grakoui et al., 2003a, Tester et al., 2005, 
Timm et al., 2004b).  
 Stratifying patients by HLA type has not been previously possible in most 
studies as HCV patients during the acute phase are usually asymptomatic, so 
most studies have been of 10-20 patients at a time and HLA-B27 only occurs 
with a percentage frequency of approximately 8%. Furthermore, HCV is only 
persistent in around 30% of HLA-B27+ patients (Gonzalez-Galarza et al., 
2011); thus a follow-up of this group of patients during their evolving 
progression has never been reported until now. We found in this study that 
while both HLA B27+ HIV uninfected patients spontaneously cleared infection 
in keeping with other studies, the majority of HIV-infected patients exhibited 
persistence. A previous study showed no variations in the HLA-B27-restricted 
NS5B epitope in patients that had acute but resolving HCV infection. This 
supports the concept that the absence of viral escape can help to protect 
patients. We generally observed single mutations in the epitope in patients 
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during spontaneous clearance – this was likely to have been insufficient to 
result in immune escape and may additionally have been detrimental to viral 
replication.   
 Adaptation to T-cell immune pressure is characteristic of infection with 
HCV. However, while HCV has a high mutation rate, the viral genome appears 
to show restricted plasticity, as evidenced in certain regions by an 
accumulation of silent synonymous (rather than non-synonymous) changes. 
While inaccurate replication has advantages, the possibility of error 
catastrophe is ever-present and may result in the production of non-viable or 
replication-deficient viral strains. In this study, the majority of sites studied 
using dN/dS ratios showed evidence of purifying (negative) selection although 
a single significantly positively selected codon was identified in HLA B27+ 
patients. 
 It is likely that the CD8+ T-cell immune pressure that arises in HLA-B27 
patients in reaction to a single NS5B epitope is sufficient to clear the virus in 
most patients infected with HCV before multiple mutations can occur in TCR 
residues. However, unlike the majority of HIV-uninfected patients, most of 
the patients in our HIV-positive cohort proceeded to chronic infection. The 
mechanism for failure of the immune response in these patients was most 
likely to be the immune escape from the CD8+ T-cell response (as evidenced 
by the gradual accumulation of mutations within the NS5B2841-2849  epitope). 
This is likely to have been worsened by a dysfunctional CD4+ T-cell response 
due to HIV co-infection. Flow cytometry in representative patients revealed 
that CD8+ cells that stained with the NS5B2841-2849 epitope (pentamer positive 
cells) had higher HLA-DR and lower PD-1 expression in a spontaneous clearer 
patient than a progressor indicating an activated profile. In addition, the 
spontaneous clearer had higher expression of functional CD8+ proteins 
granzymes A and B and perforin. Thus although the epitope was recognised by 
CD8+ cells in the progressor patient, these had a less activated phenotype. 
 221 | P a g e  
4.5.3 Functional analysis of observed mutations in the NS5B2841-2849  
epitope  
In this series of experiments, we aimed to study whether single or clustered 
mutations observed in vivo within or outwith the highly conserved NS5B2841-
2849 epitope (Figure 3-43) have an impact on viral replication (fitness cost). 
Mutations observed in vivo were introduced into a subgenomic replicon 
(Figure 3-42).  
The replication kinetics of mutant variants were compared with wild-type 
HCV genotype 1a replicon (WT 1a), a wild-type genotype 1a replicon 
containing GND (1a GND; this is a replication-deficient subgenomic replicon 
incorporating a GDD to GND mutation within NS5B), the genotype 2a JFH-1 
subgenomic replicon (pSGR-luc-JFH1) and the JFH-1 subgenomic replicon 
containing GND (pSGR-luc-JHF1-GND).  
 Single mutations 4.5.3.1
A g1a replicon mutant containing the single mutation A2841V replicated 
poorly, with a reduction in replication that was seven-fold lower than WT 
(1a). Previous studies utilising site-directed mutagenesis of a genotype 1b 
HCV replicon showed that a single mutation led to replication at a similar 
level to the wild type. Additionally, a single R2842V mutation (an HLA B27 
anchor site) showed a 7-fold decline in luciferase activity compared to the 
sub-genomic replicon indicating that changes at this site are associated with 
a significant viral fitness cost. 
 Our results differ from previous work; this may reflect the use of a 
different replicon model based on genotype 1a rather than 1b. Moreover, we 
selected mutants that were observed in vivo while other studies were based 
on hypothetical sequential mutations during evolving progression to 
chronicity during the acute phase, which had not been previously examined.  
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 Multiple mutations 4.5.3.2
Next, double mutations were tested; the A2841V/M2843V replicon resulted in 
a nine-fold lower replication compared to wild-type replicon. Patients with 
triple mutations or double mutants with an additional variant site outside the 
HLA-B27 epitope (T2838A) showed restored replication. Triple mutations 
were introduced sequentially in addition to the other two variations, such as, 
A2841V/M2843V/I2844V. Replication capacity based on luciferase activity was 
increased compared with single or double mutation variants –around 3-fold 
lower than WT replicon.  
A mutation (T2838A), commonly found outside the HLA-B27 epitope in HLA 
B27+ evolving progressor patients, was found to restore the replication 
capacity to a similar level compared to the genotype 1a sub-genomic 
replicon.  
 In patients infected with HIV, multiple mutations within the HLA-B27 
NS5B2841-2849 epitope occurred frequently and were associated with 
progression to chronicity. These mutations emerged late and may indicate 
that immunosuppression associated with HIV may result in impaired CD8+ 
responses (in particular lack of CD4+ support as evidenced by lack of IL-2 
production in such patients).  
 In the B27+-directed HIV immune response, escape from immuno-
dominant responses also requires clustered mutations (Flicek and Birney, 
2009, Grüner et al., 2000, Metzker, 2010). Mutations occuring within anchor 
binding sites within the dominant HCV epitope can result in immune escape 
but may be associated with a fitness cost that is too high.  
 Previous work has shown that escape can occur quickly when the second 
position arginine that first within the HLA B pocket is mutated (Dohm et al., 
2008, Fishman and Branch, 2009, Hillier et al., 2008a). Our data suggest that 
the acquisition of mutations results in immune escape occurring as a result of 
reduced T-cell receptor binding rather than of HLA binding, likely due to the 
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impaired fitness cost of a mutation within this anchor position (Table 3-13). 
 
 The potential impact of variations within the NS5B region can be further 
analysed by considering the structural features within the HLA-B27 restricted 
epitope (Figure 4-1). The distinctive shape of the Hepatitis C virus NS5B RNA-
dependent RNA polymerase results from an extended interaction between the 
two subdomains (the fingers and thumb). This link between these two 
subdomains is facilitated by an insertion inside the fingers subdomain. The 
insertion inside the fingers subdomains form two loops that pack against the 
thumb subdomain. Residues located between two motifs (motif A and B) 
create two amphipathic α-helices, which are packaged in an antiparallel 
arrangement next to a B helix. The third subdomain of the NS5B (thumb) 
includes residues from 371-528; these residues form seven different α-helices 
and a β-loop (Lesburg et al., 1999).The NS5B2841-2849 epitope is positioned 
within the helix Q of NS5B. This helix is functionally critical for the 
interaction of the two subdomains, the thumb and fingers of NS5B, and flanks 
the two pockets that contain the NNI binding sites A and B. Some of the HLA-
B27-restricted epitope residues such as A2841, I2844, and M2846 are 
completely enclosed within the thumb domain in the hydrophobic core. 
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Figure 4-2: Model illustrating presentation of class I epitopes to CD8+ cells  
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These amino-acids can be exchanged with other amino-acids that have an 
equal type and size (hydrophobic amino-acids) within the hydrophobic core 
without resulting in a major structural impact, which explains the 
observation that these substitutions appear to have only a slight effect on 
viral fitness. 
 In contrast, substitutions of residues R2842, M2843, H2848, and F2849, 
which line pockets A and B at the thumb surface, would have a much more 
marked structural effect; this may explain the stronger effect on viral 
replication and the high degree of conservation at these sites. One residue 
has considerable impact (T2847), as it is also located within the thumb 
domain in the hydrophobic core; this amino acid reported as being an 
essential amino acid in the stabilization of this region. Substitution of this 
amino acid with another amino acid would be highly likely to have an impact 
on the rearrangement of this critical region (NS5B) (Dazert et al., 2009). 
4.5.4 CD8+ T-cell responses in evolving spontaneous clearance 
and progression to chronicity. 
This is the first study examining HLA B27+ restricted T-cell responses during 
acute HCV infection within an HIV-HCV co-infected cohort. Our results show 
that patients who cleared HCV spontaneously have a strong T-cell response as 
evidenced by ELISpot. In contrast, patients with evolving progression to 
chronicity display weaker T cell responses and this was significantly more 
likely in patients with HIV. 
 We measured the immune response in both evolving spontaneous 
clearance and progression to chronicity using ELISpot assays following 
stimulation with overlapping peptide pools spanning the whole HCV genome. 
Patients who cleared HCV had significantly stronger IFN-γ responses; in 
keeping with findings from other studies (Heim, 2013, Neumann-Haefelin and 
Thimme, 2011) whereas patients who progressed to chronicity showed weak 
responses.  Core, NS3, and NS5B peptide pools elicited the highest IFN-γ 
responses.  
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Peptides predicted to elicit protective immune responses in HLA B27+ 
patients were also tested. While peptides spanning the HCV genome were 
found to be significantly stronger in HLA-B27+ patients versus HLA-B27- ones, 
the predicted peptide set showed no significant difference between groups. 
Our study showed the importance of this epitope in stimulation of T-cell 
immune response in acute HCV infection. Clearly, a specific definition of 
immunodominant HCV epitope across HCV genotypes is essential, and more 
work needs to be carried to develop a new vaccine. This epitope in addition 
to other epitopes across the HCV genome might be used to prevent the 
disease, or in infected patients can be used as prophylactic and a therapeutic 
hepatitis C virus vaccine to stimulate the adaptive immune response and 
eliminate the HCV infection. 
 This study is limited by two major restrictions; firstly the number of patients 
available to study the impact of the adaptive immune response in acute HCV 
and secondly, the number of samples available from patients at different 
time points. These restrictions have occurred because acute HCV infection is 
asymptomatic and not usually noticed by the patient and because patients 
with acute HCV are in vulnerable groups such as PWID who do not attend 
follow-up regularly.  While the sample size is small, this is the largest acute 
HCV cohort ever studied for immune response targeting HLA-B27 restricted 
epitopes. This sample size may affect the statistical significance of the 
results; the conclusions of this study need to be considered as a precursor for 
further study of the same cohort with larger number of patients. Study also 
of other protective alleles such as HLA B57 may further strengthen the 
findings. The next generation sequencing work would have been strengthened 
by carrying out sequencing in duplicate or even triplicate. However such an 
approach would be extremely expensive and was not possible due to the 
amount of sample available for each timepoint. During the course opf the 
thesis, the laboratory has improved methods available for analysis and 
limitation of cross-contamination – currently, known RNA/DNA sequences are 
being put into each well during all stages of sample preparation; this allows 
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for detection of low-level contamination. Further work with this cohort, 
would benefit from this approach. The T cell work in this study was based on 
the use of heterologous peptides; the use of autologous peptides might have 
increasd detection of strong T cell responses but this approach is also 
expensive.  
 
4.5.5 Conclusions and future work 
In summary, in this study, patients with the HLA-B27 allele had a high rate of 
spontaneous clearance of HCV infection as observed in other studies 
(McKiernan et al., 2004). However, HIV-infected individuals had a lower than 
expected clearance rate with evidence of slow evolution of escape mutations 
within a previously described immuno-dominant epitope NS5B2841-2849 or of 
weak T cell responses associated with no evidence of positive selection.  
 Other HLA-B27 restricted epitopes within the NS5B, p7 and NS3 proteins 
were not strongly associated with immune escape. Variation within the HLA-
B27 epitope was associated with a stronger T-cell response. Our results 
therefore indicate that an HLA-B27 restricted CD8+ T-cell response in HIV 
infected individuals may be defective, most likely by impaired CD4 help for 
CD8+ cells.  
 Earlier studies indicate that protective responses may be sustained. In 
chimpanzee and human subjects, responses can be detected for as long as 
seven years following HCV recovery (Lechner et al., 2000b, Cooper et al., 
1999b, Shoukry et al., 2003b, Cox et al., 2005a, Lauer et al., 2002).  One 
study has shown that specific CD8+ T-cell responses can persist for decades 
following clearance of HCV (Takaki et al., 2000). 
 Variation also occurred (to a lesser extent) in other HLA-B27 restricted 
epitopes within the HCV genome (p7, NS3, and NS5B) suggesting escape in 
these epitopes also. Two patients (P28 and P45) showed clustered mutations 
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within an HLA-B27 restricted p7 epitope while no variations occurred within 
NS5B2841-2849 epitope. One patient (P113) had mutations within the NS5B2820-2828  
epitope and one mutation within the p7780-788 epitope. This data is in 
accordance with other published data showing that escape mutations from 
CD8+ T-cell responses happen as a result of clustered mutations within 
restricted immuno-dominant epitopes (Timm et al., 2004b).  
 Associations between the expression of other alleles (HLA-B7, HLA-B8 
HLA-B25, and HLA-B37) and mutations within restricted epitopes which are 
presented by these alleles have also been described (Timm et al., 2004a, Ray 
et al., 2005b). Such associations highlight  the importance of HLA- restricted 
T cell selection pressure and how it is associated with HCV evolution within 
hosts and at a population level. It is likely that the main factor determining 
the outcome of infection is whether variation in an epitope can result in a 
reduction in virus fitness; for instance, mutations within the genome 
affecting certain conserved amino-acids can lead to a loss of viral enzymatic 
functions and even change virus structure (Altman and Feinberg, 2004).  
 Interestingly, the NS5B protein is generally conserved among HLA-B27 
negative patients. Other immunological factors can play a significant role in 
the disease outcome and in viral escape from CD8+ T-cell responses such as 
diversity within the TCR (Meyer-Olson et al., 2004) and a lack of strong CD4+ 
T-cell help. Chimpanzee models show an inadequate control of HCV 
replication via memory CD8+ T cells in the absence of strong support from 
CD4+ T-cells, resulting in viral escape from specific CD8+ T-cell responses 
(Grakoui et al., 2003a).  
 The HLA-B27 protective role in varied virus infections (both HIV and 
HCV) is not fully understood. Various mechanisms have been proposed, 
including the molecular characteristics of  peptides presented by HLA-B27, 
differences in binding capacity of different forms of HLA-B27 (including heavy 
chain homodimers with variable tertiary structure), the failure of KIR3DL1 as 
a B27 ligand, resulting in increased NK cell stimulation or linkage 
disequilibrium with other immune gene responses (López de Castro, 2005, 
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Stewart‐Jones et al., 2005).   
  
To sum up, our results confirm an association between HLA-B27 restricted 
CD8+ T-cell responses and resolution of HCV infection in acutely infected 
patients. In addition, our results indicate that this association is reduced in 
patients with HIV co-infection in association with weaker T cell responses and 
escape within HLA-B27 restricted epitopes even in a cohort of patients with 
relatively preserved total CD4 cell counts. An accumulation of multiple 
clustered mutations within HLA-B27 restricted epitopes is required for viral 
escape from the CD8+ T-response. A summary of our findings is shown in 
Table 3-21. 
 A new compensatory mutation was observed outwith the previously 
described HLA-B27 restricted NS5B2841-2849  epitope that restores viral 
replication. Additionally, a positively selected codon within core may form 
part of a previously undescribed epitope and further functional work is 
indicated to confirm this. All these data provide evidence that the outcome 
of HCV infection is controlled by highly specific CD8+ T-cell responses that 
are restricted by protective MHC class I alleles such as the HLA-B27 molecule. 
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